<SEC-DOCUMENT>0001213900-24-041030.txt : 20240509
<SEC-HEADER>0001213900-24-041030.hdr.sgml : 20240509
<ACCEPTANCE-DATETIME>20240509080028
ACCESSION NUMBER:		0001213900-24-041030
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20240507
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240509
DATE AS OF CHANGE:		20240509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			180 Life Sciences Corp.
		CENTRAL INDEX KEY:			0001690080
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				813832378
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38105
		FILM NUMBER:		24928668

	BUSINESS ADDRESS:	
		STREET 1:		3000 EL CAMINO REAL
		STREET 2:		BLDG 4, STE 200
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94306
		BUSINESS PHONE:		650-507-0669

	MAIL ADDRESS:	
		STREET 1:		3000 EL CAMINO REAL
		STREET 2:		BLDG 4, STE 200
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94306

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KBL MERGER CORP. IV
		DATE OF NAME CHANGE:	20161115
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0205589-8k_180lifesci.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:ATNF="http://180lifesciences.com/20240507">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03A_ATNF_180lifesciences.com_20240507 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20240507_20240507 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0001690080 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-05-07" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-05-07" id="Fact000004" name="dei:EntityCentralIndexKey">0001690080</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="atnf-20240507.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-05-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-07</xbrli:startDate>
        <xbrli:endDate>2024-05-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-072024-05-07_custom_CommonStockParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-07</xbrli:startDate>
        <xbrli:endDate>2024-05-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-072024-05-07_custom_WarrantsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-07</xbrli:startDate>
        <xbrli:endDate>2024-05-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>SECURITIES AND EXCHANGE
COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>FORM&#160;<span id="xdx_902_edei--DocumentType_c20240507__20240507_zWBN9ODt9wRg"><ix:nonNumeric contextRef="AsOf2024-05-07" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>PURSUANT TO SECTION
13 OR 15(d) OF THE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>SECURITIES EXCHANGE
ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Date of Report (Date of
earliest event reported):&#160;<span id="xdx_905_edei--DocumentPeriodEndDate_c20240507__20240507_zIi1MzZGHOhk"><ix:nonNumeric contextRef="AsOf2024-05-07" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">May 7, 2024</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b><span style="text-decoration: underline"><span id="xdx_904_edei--EntityRegistrantName_c20240507__20240507_zyVgYIrjJFoj"><ix:nonNumeric contextRef="AsOf2024-05-07" id="Fact000011" name="dei:EntityRegistrantName">180 LIFE SCIENCES
CORP.</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">(Exact Name of Registrant
as Specified in Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20240507__20240507_zZjbEaIKpNq8"><ix:nonNumeric contextRef="AsOf2024-05-07" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_900_edei--EntityFileNumber_c20240507__20240507_zidiambsjqYb"><ix:nonNumeric contextRef="AsOf2024-05-07" id="Fact000013" name="dei:EntityFileNumber">001-38105</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90D_edei--EntityTaxIdentificationNumber_c20240507__20240507_zDP3RXbw9VMa"><ix:nonNumeric contextRef="AsOf2024-05-07" id="Fact000014" name="dei:EntityTaxIdentificationNumber">90-1890354</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(State or Other Jurisdiction<br/>
of Incorporation)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Commission File Number)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(IRS Employer<br/>
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 49%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span id="xdx_905_edei--EntityAddressAddressLine1_c20240507__20240507_zhikViCm4tj3"><ix:nonNumeric contextRef="AsOf2024-05-07" id="Fact000015" name="dei:EntityAddressAddressLine1">3000 El Camino Real</ix:nonNumeric></span>,<span id="xdx_90C_edei--EntityAddressAddressLine2_c20240507__20240507_zf7zGOoEINUi"><ix:nonNumeric contextRef="AsOf2024-05-07" id="Fact000016" name="dei:EntityAddressAddressLine2">&#160;Bldg. 4</ix:nonNumeric></span>,<span id="xdx_909_edei--EntityAddressAddressLine3_c20240507__20240507_zGEuLfl8R5Eb"><ix:nonNumeric contextRef="AsOf2024-05-07" id="Fact000017" name="dei:EntityAddressAddressLine3">&#160;Suite
    200</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_903_edei--EntityAddressCityOrTown_c20240507__20240507_zpqPfJ2oHJy5"><ix:nonNumeric contextRef="AsOf2024-05-07" id="Fact000018" name="dei:EntityAddressCityOrTown">Palo
    Alto</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressStateOrProvince_c20240507__20240507_zWf9gkjWEdmi"><ix:nonNumeric contextRef="AsOf2024-05-07" id="Fact000019" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span></b></p></td>
    <td style="vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_909_edei--EntityAddressPostalZipCode_c20240507__20240507_zxnMdCvgyQD8"><ix:nonNumeric contextRef="AsOf2024-05-07" id="Fact000020" name="dei:EntityAddressPostalZipCode">94306</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Address of Principal Executive Offices)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Registrant&#8217;s telephone
number, including area code:&#160;<b><span style="text-decoration: underline">(<span id="xdx_90F_edei--CityAreaCode_c20240507__20240507_zjjNH7eTxaJ1"><ix:nonNumeric contextRef="AsOf2024-05-07" id="Fact000021" name="dei:CityAreaCode">650</ix:nonNumeric></span>)&#160;<span id="xdx_90A_edei--LocalPhoneNumber_c20240507__20240507_zVaX3SgGpp87"><ix:nonNumeric contextRef="AsOf2024-05-07" id="Fact000022" name="dei:LocalPhoneNumber">507-0669</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Check the appropriate&#160;box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (<i>see&#160;</i>General Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15pt; text-align: justify; text-indent: -0.15pt; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--WrittenCommunications_c20240507__20240507_zgs4ZcRC6Pfd"><ix:nonNumeric contextRef="AsOf2024-05-07" format="ixt:booleanfalse" id="Fact000023" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--SolicitingMaterial_c20240507__20240507_zI9vduMKXcq6"><ix:nonNumeric contextRef="AsOf2024-05-07" format="ixt:booleanfalse" id="Fact000024" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--PreCommencementTenderOffer_c20240507__20240507_z2BSG63M2pwg"><ix:nonNumeric contextRef="AsOf2024-05-07" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--PreCommencementIssuerTenderOffer_c20240507__20240507_znCtXMsvyMs3"><ix:nonNumeric contextRef="AsOf2024-05-07" format="ixt:booleanfalse" id="Fact000026" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e 4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Securities registered
pursuant to Section 12(b)&#160;of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_901_edei--Security12bTitle_c20240507__20240507__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zZWYsZYV0205"><ix:nonNumeric contextRef="From2024-05-072024-05-07_custom_CommonStockParValue0.0001PerShareMember" id="Fact000027" name="dei:Security12bTitle">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_907_edei--TradingSymbol_c20240507__20240507__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zHG0Y7Df0dAi"><ix:nonNumeric contextRef="From2024-05-072024-05-07_custom_CommonStockParValue0.0001PerShareMember" id="Fact000028" name="dei:TradingSymbol">ATNF</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">The <span id="xdx_90E_edei--SecurityExchangeName_c20240507__20240507__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zPsiRwPXGpCi"><ix:nonNumeric contextRef="From2024-05-072024-05-07_custom_CommonStockParValue0.0001PerShareMember" format="ixt-sec:exchnameen" id="Fact000029" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span>&#160;Stock Market LLC</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90D_edei--Security12bTitle_c20240507__20240507__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zTwllvnOG7z1"><ix:nonNumeric contextRef="From2024-05-072024-05-07_custom_WarrantsToPurchaseSharesOfCommonStockMember" id="Fact000030" name="dei:Security12bTitle">Warrants to purchase shares of Common Stock</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_905_edei--TradingSymbol_c20240507__20240507__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_z8jqCtj6atQ5"><ix:nonNumeric contextRef="From2024-05-072024-05-07_custom_WarrantsToPurchaseSharesOfCommonStockMember" id="Fact000031" name="dei:TradingSymbol">ATNFW</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">The <span id="xdx_900_edei--SecurityExchangeName_c20240507__20240507__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_z52PST2Itukk"><ix:nonNumeric contextRef="From2024-05-072024-05-07_custom_WarrantsToPurchaseSharesOfCommonStockMember" format="ixt-sec:exchnameen" id="Fact000032" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span>&#160;Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter)&#160;or
Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Emerging growth company&#160;<span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_edei--EntityEmergingGrowthCompany_c20240507__20240507_zhhkjRsWnVBe"><ix:nonNumeric contextRef="AsOf2024-05-07" format="ixt:booleanfalse" id="Fact000033" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a)&#160;of the Exchange Act.&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01 Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information and description
of the Woody Separation Agreement, Rothbard Separation Agreement, Rothbard Consulting Agreement and Jordan Consulting Agreement in <span style="text-decoration: underline">Item
5.02</span> below is incorporated by reference into this <span style="text-decoration: underline">Item 1.01</span> in their entirety.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.02 Termination of a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information and description
of the Woody Separation Agreement and Rothbard Separation Agreement in <span style="text-decoration: underline">Item 5.02</span> below is incorporated by reference into this <span style="text-decoration: underline">Item
1.01</span> in their entirety. No material early termination penalties were incurred in connection with the termination of Dr. Rothbard&#8217;s
Employment Agreement and the termination fees associated with the termination of Dr. Woody&#8217;s Employment Agreement as discussed in
<span style="text-decoration: underline">Item 5.02</span>, below, and incorporated by reference in this <span style="text-decoration: underline">Item 1.02</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 7, 2024, Dr. James
N. Woody resigned as Chief Executive Officer (Principal Executive Officer), and as a member of the Board of Directors, of 180 Life Sciences
Corp. (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;, &#8220;<span style="text-decoration: underline">we</span>&#8221; and &#8220;<span style="text-decoration: underline">us</span>&#8221;) effective the same date, and entered into
a Separation and Release Agreement with the Company (the &#8220;<span style="text-decoration: underline">Woody Separation Agreement</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Woody Separation
Agreement, the Company agreed to (a) pay Dr. Woody $50,000 in cash, less all applicable withholdings and required deductions (the &#8220;<span style="text-decoration: underline">Severance
Cash</span>&#8221;); (b) issue Dr. Woody 25,000 fully-vested shares of the Company&#8217;s common stock; and (c) provide Dr. Woody the right
to earn the Future Contingent Payment (as defined below). The amounts above (except for the amounts payable pursuant to (c), which shall
be paid by the 15th day following the date such payment is due as discussed below), are required to be paid within 15 days of the date
of Dr. Woody&#8217;s resignation (the &#8220;<span style="text-decoration: underline">Payment Date</span>&#8221;). We also agreed to pay Dr. Woody a bonus of $50,000 (the &#8220;<span style="text-decoration: underline">Future
Contingent Payment</span>&#8221;), [A] if we, within the 24 months following the date of Dr. Woody&#8217;s resignation, complete any corporate
transaction, including but not limited to any merger, reverse merger, acquisition, disposal, joint-venture and/or investment involving
the Company (a &#8220;<span style="text-decoration: underline">Corporate Transaction</span>&#8221;), which results in a Change of Control (a &#8220;<span style="text-decoration: underline">Change of Control</span>&#8221;
means any Corporate Transaction pursuant to which the ownership of an aggregate of 50.1% or more of the outstanding shares of the Company
is held by one or more parties after completing the Corporate Transaction); or [B] if we raise at least $5 million from any source within
12 months from Dr. Woody&#8217;s resignation date. The Future Contingent Payment is to be forfeited from Dr. Woody in the event that we
are required to restate any financial statements of the Company for periods prior to Dr. Woody&#8217;s resignation date, if Dr. Woody
was Chief Executive Officer of the Company during such period(s), or any disclosure made the Company in any report or filing with the
Securities and Exchange Commission, is found by the Company to be materially incorrect or misleading, as determined by the reasonable
discretion of the Board of Directors of the Company (each a &#8220;<span style="text-decoration: underline">Forfeiture Trigger</span>&#8221;). In the event a Forfeiture Trigger
occurs or is deemed to have occurred, Dr. Woody is also required to promptly repay in full the Severance Cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Woody Separation
Agreement, Dr. Woody agreed to provide a customary general release to the Company, waived any severance pay that would have been due pursuant
to the terms of his employment agreement, agreed to the termination of his employment agreement, and also agreed to certain confidentiality,
non-disclosure, non-solicitation, non-disparagement, and cooperation covenants in favor of the Company. The 25,000 fully-vested shares
of the Company&#8217;s common stock due to Dr. Woody will be issued under the Company&#8217;s Second Amended and Restated 2022 Omnibus
Incentive Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 7, 2024, Dr. Jonathan
Rothbard resigned as Chief Scientific Officer of the Company effective the same date, and entered into a Separation and Release Agreement
with the Company (the &#8220;<span style="text-decoration: underline">Rothbard Separation Agreement</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Rothbard Separation
Agreement, the Company agreed to pay Dr. Rothbard $200 in cash, less all applicable withholdings and required deductions. Under the Rothbard
Separation Agreement, Dr. Rothbard agreed to provide a customary general release to the Company, waived any severance pay that would have
been due pursuant to the terms of his employment agreement, agreed to the termination of his employment agreement, and also agreed to
certain confidentiality, non-disclosure, non-solicitation, non-disparagement, and cooperation covenants in favor of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective on May 7, 2024,
the Company entered into a Consulting Agreement with Dr. Rothbard pursuant to which he agreed to provide general consulting services to
the Company for a term of six months, for $150 per hour (the &#8220;<span style="text-decoration: underline">Rothbard Consulting Agreement</span>&#8221;). The agreement contains
standard and customary confidentiality requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 7, 2024, the Company
entered into a Fourth Amendment to Consulting Agreement with Dr. Lawrence Steinman, the then Executive Chairman of the Board (the &#8220;<span style="text-decoration: underline">Fourth
Amendment</span>&#8221;). Pursuant to the Fourth Amendment, Dr. Steinman waived and forgave all amounts accrued and owed to him under the
Consulting Agreement through such date, and agreed that compensation payable to him under the Consulting Agreement moving forward would
be $0, provided that as long as Dr. Steinman remains a member of the Board of Company, he is to receive the same compensation payable
to other non-executive members of the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Steinman also agreed to
step down as Executive Chairman of the Board of Directors and will instead just serve as a member of the Board of Directors, provided
that on May 7, 2024, Dr. Steinman was appointed as a member of the Strategy and Alternatives Committee of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Also effective on May 7, 2024,
effective immediately after the resignation of Dr. Woody, the Board of Directors appointed Mr. Blair Jordan, a then member of the Board
of Directors of the Company, as Interim Chief Executive Officer and Principal Executive Officer of the Company, to fill the vacancy left
by Dr. Woody&#8217;s resignation. Upon such appointment, Mr. Jordan ceased being the Lead Independent director of the Company (which position
is currently vacant), and ceased being a member of the Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee,
and Strategy and Alternatives Committee of the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 7, 2024, the Company
entered into an Executive Consulting Agreement with Mr. Jordan and Blair Jordan Strategy and Finance Consulting Inc. (an entity owned
by Mr. Jordan)(&#8220;<span style="text-decoration: underline">Jordan Consulting</span>&#8221; and the &#8220;<span style="text-decoration: underline">Jordan Consulting Agreement</span>&#8221;). Pursuant to the Jordan
Consulting Agreement, the Company agreed to engage Jordan Consulting to provide the services of Mr. Jordan to the Company as Interim Chief
Executive Officer of the Company. The Jordan Consulting Agreement has a term through April 30, 2025, unless otherwise terminated pursuant
to the terms of the agreement (discussed below) and provides for Mr. Jordan to act as Interim Chief Executive Officer of the Company,
and to be paid $216,000 per year in consideration for services rendered to the Company, plus a $250,000 bonus in the event that the Company
completes a Corporate Transaction which results in a Change of Control. Notwithstanding the above, the Board of Directors, with the recommendation
of the Compensation Committee, may grant Mr. Jordan bonuses from time to time in its discretion, in cash or equity. The Jordan Consulting
Agreement includes customary confidentiality, non-disclosure and proprietary right requirements of Jordan Consulting and Mr. Jordan, and
a prohibition on Jordan Consulting and Mr. Jordan competing against us during the term of the agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Jordan Consulting Agreement
terminates automatically upon the completion of a Corporate Transaction (provided we pay the transaction bonus discussed above). We have
the right to terminate the Jordan Consulting Agreement at any time, provided that if we terminate the agreement after 60 days and prior
to completion of a Corporate Transaction, then we agreed to pay Jordan Consulting $75,000 in connection with such termination, within
60 days of such termination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also able to terminate
the Jordan Consulting Agreement at any time, without notice upon: (a) the death or physical or mental incapacity of Mr. Jordan if as a
result of which Mr. Jordan is unable to perform services for a period in excess of 60 days; (b) in the event Mr. Jordan or a related party
to Mr. Jordan ceases to own or control 100% of Jordan Consulting; (c) the Board terminating the Jordan Consulting Agreement for just cause
where &#8220;<span style="text-decoration: underline">just cause</span>&#8221; means any of the following events: (i) any material or persistent breach by Jordan Consulting or
Mr. Jordan of the terms of the agreement; (ii) the conviction of Jordan Consulting or Mr. Jordan of a felony offence, or the equivalent
in a non-American jurisdiction, or of any crime involving moral turpitude, fraud or misrepresentation, or misappropriation of money or
property of the Company or any affiliate of the Company; (iii) a willful failure or refusal by Jordan Consulting or Mr. Jordan to satisfy
its respective obligations to the Company under the agreement including without limitation, specific lawful directives, reasonably consistent
with the agreement, or requests of the Board; (iv) any negligent or willful conduct or omissions of Jordan Consulting or Mr. Jordan that
directly results in substantial loss or injury to the Company; (v) fraud or embezzlement of funds or property, or misappropriation involving
the Company&#8217;s assets, business, customers, suppliers, or employees; (vi) any failure to comply with any of the Company&#8217;s written
policies and procedures, including, but not limited to, the Company&#8217;s Corporate Code of Ethics and Insider Trading Policy, provided
that subject to certain limited exceptions, we must first give written notice to Jordan Consulting and Mr. Jordan, as applicable, advising
them of the acts or omissions that constitute failure or refusal to perform their obligations and that failure or refusal continues after
Jordan Consulting and Mr. Jordan, as applicable, has had thirty (30) days to correct the acts or omissions as set out in the notice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Company terminates
the Jordan Consulting Agreement for just cause, we are required to pay Jordan Consulting any unpaid fees and/or unpaid and unreimbursed
expenses accrued but unpaid prior to the effective termination date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Jordan&#8217;s biographical
information is included in the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on <a href="http://www.sec.gov/Archives/edgar/data/1690080/000121390023013822/ea174095-8k_180lifesci.htm">February 29, 2023</a>, and is incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Jordan is not party to
any material plan, contract or arrangement (whether or not written) with the Company, except for the Jordan Consulting Agreement (discussed
and described below), and there are no arrangements or understandings between Mr. Jordan and any other person pursuant to which Mr. Jordan
was selected to serve as a director or officer of the Company, nor is Mr. Jordan a participant in any related party transaction required
to be reported pursuant to Item 404(a) of Regulation S-K. There are no family relationships between any director or executive officer
of the Company, including Mr. Jordan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 7, 2024, the Company
entered into Indemnity Agreements (each an &#8220;<span style="text-decoration: underline">Indemnification Agreement</span>&#8221;) with each of its then directors and officers
(i.e., each remaining officer and director after the resignations described above) other than Mr. Ozan Pamir, the Chief Financial Officer
of the Company who was already party to an Indemnity Agreement with the Company (each an &#8220;<span style="text-decoration: underline">Indemnitee</span>&#8221;), to provide
for indemnification to the officers and directors under Delaware law. Among other things, consistent with the Company&#8217;s Bylaws,
each Indemnification Agreement generally requires that the Company (i) indemnify the Indemnitee from and against all expenses and liabilities
with respect to proceedings to which Indemnitee may be subject by reason of the Indemnitee&#8217;s service to the Company to the fullest
extent authorized or permitted by Delaware law and (ii) advance all expenses incurred by the Indemnitee in connection with the investigation,
defense, settlement or appeal of any proceeding, and in connection with any proceeding to enforce the Indemnitee&#8217;s rights under
the Indemnification Agreement. The Indemnification Agreement also establishes various related procedures and processes and generally requires
the Company to maintain directors and officers&#8217; liability insurance coverage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing summary of the
Woody Separation Agreement, Rothbard Separation Agreement, Rothbard Consulting Agreement, Fourth Amendment, Jordan Consulting Agreement,
and Indemnification Agreement are a summary only and are qualified in their entirety by reference to the Woody Separation Agreement, Rothbard
Separation Agreement, Rothbard Consulting Agreement, Fourth Amendment, Jordan Consulting Agreement, and Indemnification Agreement, copies
of which are attached hereto as <span style="text-decoration: underline">Exhibit 10.1</span> through <span style="text-decoration: underline">10.6</span>, respectively and are incorporated into this&#160;<span style="text-decoration: underline">Item 5.02</span>&#160;by
reference in its entirety.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 8.01 Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective on May 7, 2024,
the Board of Directors set the compensation payable to non-executive members of the Board of Directors for services on the Board of Directors,
at (a) $50,000 per year for service on the Board; (b) $15,000 for each Chairperson of a committee of the Board of Directors (provided
that only one additional $15,000 payment shall be made even if the Director chairs multiple committees); and $25,000 additional for each
member of the Strategy and Alternatives Committee of the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>Item 9.01 Financial Statements
and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 9%"><span style="font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 90%; text-align: center"><span style="font-size: 10pt"><b>Description of Exhibit</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCECFF">
    <td><span style="font-size: 10pt">10.1*</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ea020558901ex10-1_180lifesci.htm"><span style="font-size: 10pt">Separation and Release Agreement dated May 7, 2024, by and between 180 Life Sciences Corp. and Dr. James N. Woody</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.2*</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ea020558901ex10-2_180lifesci.htm"><span style="font-size: 10pt">Separation and Release Agreement dated May 7, 2024, by and between 180 Life Sciences Corp. and Dr. Jonathan Rothbard</span></a></td></tr>
  <tr style="vertical-align: top; background-color: #CCECFF">
    <td><span style="font-size: 10pt">10.3*</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ea020558901ex10-3_180lifesci.htm"><span style="font-size: 10pt">Consulting Agreement dated May 7, 2024, by and between 180 Life Sciences Corp. and Dr. Jonathan Rothbard</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.4*</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ea020558901ex10-4_180lifesci.htm"><span style="font-size: 10pt">Fourth Amendment to Consulting Agreement dated May 7, 2024, by and between 180 Life Sciences Corp. and Dr. Lawrence Steinman</span></a></td></tr>
  <tr style="vertical-align: top; background-color: #CCECFF">
    <td><span style="font-size: 10pt">10.5*</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ea020558901ex10-5_180lifesci.htm"><span style="font-size: 10pt">Executive Consulting Agreement dated May 7, 2024, by and between 180 Life Sciences Corp. , Blair Jordan and Blair Jordan Strategy and Finance Consulting Inc.</span></a></td></tr>
  <tr>
    <td><span style="font-size: 10pt">10.6*</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="ea020558901ex10-6_180lifesci.htm"><span style="font-size: 10pt">Form of 180 Life Sciences Corp. Indemnity Agreement</span></a></td></tr>
  <tr style="background-color: #CCECFF">
    <td><span style="font-size: 10pt">104</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL documents).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Date: May 9, 2024</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="3"><span style="font-size: 10pt"><b>180 LIFE SCIENCES CORP.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><i>/s/ Blair Jordan</i></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">Name:&#160;</span></td>
    <td style="width: 31%"><span style="font-size: 10pt">Blair Jordan</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Title:</span></td>
    <td><span style="font-size: 10pt">Interim Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; background-color: white">5</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJx1kdFOwjAUhp+AdzhZvCTQVUjM7nRBYgRdgKC3dZxJw9aznHYTHsm3tOsgcqFNk7Y55/v//6RRNIzm9KhLZHh/WC1gg1VdKoewwgIZTY6+I316TsCfK/zU1rEyLjwvYEqeQc9MR1IqXwitrba4S0BMx+JuLCf+kkxuIVtGg66ekin0Do3TqgRldpAx1azRKT71Cht1JEPVKVhtka0mk0A8En35G6SIJbxQq76IDxYWizQaDMMaRHOmpvZds6ND05EwK7Hydranf3dIkzfWUZW8Ke6GsxvKGs73yuJ6rxjta+FHrMisHeWHJVYfyB6KhZSxuD/nubDgCOozDTbgQAX0AhAU/nC+0s8Ub1XZoBgJIeIMOWT4x/Vadgi1Ymg7Fm56Gmr/PSHExfMHby+WBw== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ea020558901ex10-1_180lifesci.htm
<DESCRIPTION>SEPARATION AND RELEASE AGREEMENT DATED MAY 7, 2024, BY AND BETWEEN 180 LIFE SCIENCES CORP. AND DR. JAMES N. WOODY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SEPARATION AND RELEASE AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
Separation and Release Agreement (this &ldquo;<B><U>Agreement and Release</U></B>&rdquo; or &ldquo;<B><U>Agreement</U></B>&rdquo;)&nbsp;dated
May [ ], 2024, is made by and between James N. Woody, an individual (&ldquo;<B><U>Woody</U></B>&rdquo;)&nbsp;and 180 Life Sciences Corp.,
a Delaware corporation (&ldquo;<B><U>180 Life</U></B>&rdquo;)&nbsp;(collectively referred to as the &ldquo;<B><U>Parties</U></B>&rdquo;
or individually referred to as a &ldquo;<B><U>Party</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, Woody currently
serves as Chief Executive Officer and as a member of the Board of Directors of 180 Life;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, 180 Life and
Woody previously entered into an amended and restated employment agreement dated February 24, 2021 and effective November 6, 2020 (as
amended to date, the &ldquo;<B><U>Employment Agreement</U></B>&rdquo;), pursuant to which Woody agreed to serve as an employee (Chief
Executive Officer)&nbsp;of 180 Life;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, Woody&rsquo;s
Employment Agreement was amended on January 1, 2024, to provide for the reduction and accrual of a portion of Woody&rsquo;s base salary;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, after discussion
among the Parties, the Parties believe that it is in the best interest of Woody and 180 Life to terminate the Employment Agreement and
mutually terminate Woody&rsquo;s employment with 180 Life, and for Woody to resign as a member of the Board of Directors of 180 Life;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, Woody&rsquo;s
Employment Agreement and Woody&rsquo;s employment with 180 Life is hereby terminated effective May [ ], 2024 (the &ldquo;<B><U>Separation&nbsp;Date</U></B>&rdquo;);
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Parties
wish to resolve any and all disputes, claims, complaints, grievances, charges, actions, petitions, and demands that Woody may have against
180 Life and any of the Released Parties as defined below, including, but not limited to, any and all claims arising out of or in any
way related to Woody&rsquo;s employment with or separation from 180 Life, each pursuant to the terms and conditions of this Agreement
set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in
consideration of the mutual promises made herein and the Severance Payment (defined below), the receipt and sufficiency of which is acknowledge
and confirmed, Woody and 180 Life hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;<U>Severance Payment</U>.
Subject to Woody&rsquo;s compliance with the terms and conditions of this Agreement and Release, 180 Life agrees to (a)&nbsp;pay Woody
$50,000 in cash, less all applicable withholdings and required deductions (the &ldquo;<B><U>Severance Cash</U></B>&rdquo;); (b)&nbsp;issue
Woody 25,000 fully-vested shares of 180 Life&rsquo;s common stock; and (c)&nbsp;provide Woody the right to earn the Future Contingent
Payment (as defined below)(collectively, (a), (b)&nbsp;and (c), the &ldquo;<B><U>Severance Payment</U></B>&rdquo;). The Severance Payment
(except for the amounts payable pursuant to (c), which shall be paid by the 15<SUP>th</SUP>&nbsp;day following the date such payment is
due as discussed below), shall be paid within 15 days of the Separation Date (the &ldquo;<B><U>Payment Date</U></B>&rdquo;). Woody agrees
that the Severance Payment to be paid under this Agreement and Release is due solely from 180 Life and represents consideration which
would not otherwise be due to Woody. 180 Life shall pay Woody a bonus of $50,000 (the &ldquo;<B><U>Future Contingent Payment</U></B>&rdquo;),
<B><U>[A]</U></B> if 180 Life, within the 24 months following the Separation Date, completes any corporate transaction, including but
not limited to any merger, reverse merger, acquisition, disposal, joint-venture and/or investment involving 180 Life, which results in
a Change of Control of 180 Life (each a &ldquo;<B><U>Corporate Transaction</U></B>&rdquo;); or <B><U>[B]</U></B> if 180 Life raises at
least $5 million from any source within 12 months from the Separation Date. For the purpose of this Agreement and Release, &ldquo;<B><U>Change
of Control</U></B>&rdquo; means any Corporate Transaction pursuant to which the ownership of an aggregate of 50.1% or more of the outstanding
shares of 180 Life is held by one or more parties after completing the Corporate Transaction. For greater certainty, the parties to this
Agreement and Release acknowledge that a Corporate Transaction may involve one or more entities, acting separately or in concert. The
Future Contingent Payment shall be forfeited in the event that 180 Life shall be required to restate any financial statements of 180 Life
for periods prior to the Separation Date if Woody was Chief Executive Officer of 180 Life during such period(s), or any disclosure made
180 Life in any report or filing with the Securities and Exchange Commission, is found by 180 Life to be materially incorrect or misleading,
as determined by the reasonable discretion of the Board of Directors of 180 Life (each a &ldquo;<B><U>Forfeiture Trigger</U></B>&rdquo;).
In the event a Forfeiture Trigger occurs or is deemed to have occurred, Woody shall also promptly repay in full the Severance Cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Separation and Release Agreement<BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> of 10</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;<U>Release of Further
Payments</U>. The consideration set forth in&nbsp;<U>Paragraph&nbsp;1</U>&nbsp;is inclusive of any and all amounts, including but not
limited to attorneys&rsquo; fees, that may be claimed by Woody or on Woody&rsquo;s behalf against 180 Life. In furtherance of the above,
and without limiting any other term or condition of this Agreement and Release, Woody agrees to release any rights he may have to, and
to waive all rights of 180 Life to pay, other than as set forth in&nbsp;<U>Paragraph 1</U>, any severance fees set forth in the Employment
Agreement, any bonus, accrued compensation, reimbursement for unused vacation days, sick days or other benefits, in connection with severance
pay or otherwise, any stock or option compensation, and further acknowledges that he is not owed any funds from 180 Life in connection
with unreimbursed business expenses as of the date of this Agreement and Release and/or any other amounts due under the Employment Agreement.
Woody further agrees that he is owed by 180 Life, those amounts set forth in&nbsp;<U>Paragraph 1</U>, for any vacation time, sick time,
paid time off or paid leave of absence, or in connection with any severance or deferred compensation plan, if eligible, and that he has
been given all time off or is being paid for all time off to which he was entitled under any policy or law, including but not limited
to leave under the Family and Medical Leave Act. Notwithstanding any other term or condition of this Agreement and Release, Woody may
elect to continue health insurance coverage, following the Separation Date, in accordance with the provisions of COBRA regardless of whether
180 Life enters into this Agreement and Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;<U>No Further Payments</U>.
Except as described in&nbsp;<U>Paragraph&nbsp;1</U>, Woody acknowledges and agrees that he is not entitled to any other compensation,
severance, benefits, stock compensation, options, severance pay, or other payments in connection with his engagement by, or employment
or positions with, 180 Life or the termination thereof, or pursuant to the Employment Agreement or the termination thereof or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&nbsp;<U>Woody Acknowledgements</U>.
By entering into this Agreement and Release, Woody confirms and acknowledges the Separation Date and that Woody shall be deemed to have
voluntarily resigned from employment with 180 Life as of the Separation Date. Woody further acknowledges and confirms that Woody has been
paid or is being paid for any salary, wages, incentives, bonuses, commissions and any other type of compensation due to Woody, for work
performed through and including the Separation Date. Woody further acknowledges that, as of the date of Woody&rsquo;s signing of this
Agreement and Release, Woody has sustained no injury or illness related in any way to Woody&rsquo;s employment with 180 Life for which
a worker&rsquo;s compensation claim has not already been filed. Concurrently with Woody&rsquo;s entry into this Agreement Woody shall
provide a written resignation, resigning as an officer and director of 180 Life. Woody represents that he does not have any pending lawsuits,
claims, or actions against 180 Life and has fully disclosed all lawsuits, claims, or actions to 180 Life prior to executing this Agreement
and Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Separation and Release Agreement<BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 10</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&nbsp;<U>Woody&rsquo;s General
Release.</U>&nbsp;In return for 180 Life&rsquo;s agreement to provide Woody with the Severance Payment referred to in&nbsp;<U>Paragraph&nbsp;1</U>,
Woody agrees to the following, in addition to the other terms and conditions of this Agreement and Release:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a.&nbsp;<I><U>General
Release</U></I>. Woody, for Woody and Woody&rsquo;s heirs, beneficiaries, devisees, privies, executors, administrators, attorneys, representatives,
and agents, and Woody&rsquo;s and his assigns, successors and predecessors, hereby releases and forever discharges 180 Life, and its subsidiaries
and affiliates, and each of their officers, directors, employees, members, agents, attorneys, predecessors, successors and assigns of
each of the foregoing entities (collectively, the &ldquo;<B><U>Released Parties</U></B>&rdquo;), from any and all actions, causes of action,
suits, debts, claims, complaints, charges, contracts, controversies, agreements, promises, damages, counterclaims, cross-claims, claims
for costs and/or attorneys&rsquo; fees, judgments and demands whatsoever, in law or equity, known or unknown, Woody ever had, now has,
or may have against the Released Parties as of the date of Woody&rsquo;s signing of this Agreement and Release. This release includes,
but is not limited to, any claims for severance pay, restricted stock, restricted stock units, stock or option compensation, any claims
alleging breach of express or implied contract, wrongful discharge, constructive discharge, breach of an implied covenant of good faith
and fair dealing, negligent or intentional infliction of emotional distress, negligent supervision or retention, violation of the Age
Discrimination in Employment Act, the Older Workers Benefit Protection Act, Older Workers Benefit Protection Act of 1990, the Workers
Adjustment and Retraining Notification Act, the Rehabilitation Act of 1973, the Civil Rights Act of 1866, Title VII of the Civil Rights
Act of 1964, the Civil Rights Act of 1991, the Americans with Disabilities Act, Sections 1981 through 1988 of Title 42 of the United States
Code, as amended, the Employee Retirement Income Security Act of 1974, the Immigration Reform and Control Act, the Equal Pay Act of 1963,
the Family and Medical Leave Act of 1993, the Fair Labor Standards Act of 1938, the Older Workers Benefit Protection Act of 1990, the
Occupational Safety and Health Act of 1970, the Worker Adjustment and Retraining Notification Act of 1989, the Genetic Information Nondiscrimination
Act of 2008, California Family Rights Act &ndash; Cal. Gov&rsquo;t Code &sect; 12945.2, California Fair Employment and Housing Act &ndash;
Cal. Gov&rsquo;t Code &sect; 12900 et seq., California Unruh Civil Rights Act &ndash; Cal. Civ. Code &sect; 51 et seq., Statutory Provisions
Regarding the Confidentiality of AIDS Information &ndash; Cal. Health &amp; Safety Code &sect; 120775 et seq., California Confidentiality
of Medical Information Act &ndash; Cal. Civ. Code &sect; 56 et seq., California Parental Leave Law &ndash; Cal. Lab. Code &sect; 230.7
et seq., California Military Personnel Bias Law &ndash; Cal. Mil. &amp; Vet. Code &sect; 394, the California Occupational Safety and Health
Act, as amended, and any applicable regulations thereunder, the California Consumer Credit Reporting Agencies Act &ndash; Cal. Civ. Code
&sect; 1785 et seq., California Investigative Consumer Reporting Agencies Act &ndash; Cal. Civ. Code &sect; 1786 et seq., those provisions
of the California Labor Code that lawfully may be released, the Sarbanes-Oxley Act of 2002, claims pursuant to any other federal, state
or local law regarding discrimination, harassment or retaliation based on age, race, sex, religion, national origin, marital status, disability,
sexual orientation or any other unlawful basis or protected status or activity, and claims for alleged violation of any other local, state
or federal law, regulation, ordinance, public policy or common-law duty having any bearing whatsoever upon the terms and conditions of,
and/or the cessation of Woody&rsquo;s employment with and by 180 Life and/or the termination of the Employment Agreement or relating to
180 Life or his employment with 180 Life in general, each to the extent allowed pursuant to applicable law. Along with such release, all
benefits to Woody from 180 Life (i.e., health insurance coverage, 401(k)&nbsp;plans and life insurance (if any))&nbsp;will be terminated.
The Released Parties can seek attorneys&rsquo; fees, costs, or other damages arising from Woody for Woody&rsquo;s breach of the release.
Woody agrees that, if any portion of this release is found to be unenforceable, the remainder of the release will remain enforceable.
This release does not include claims that may not be released under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b.&nbsp;<I><U>Unknown
Claims</U></I>. Woody understands and agrees that the release set forth in Section 5.a above, extends to all claims of every nature, known
or unknown, suspected or unsuspected, past or present, and that any and all rights granted to Woody under Section 1542 of the California
Civil Code or any analogous federal law or regulation are hereby expressly waived. Said Section 1542 of the California Civil Code reads
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><I>&ldquo;A general release does not extend
to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release
and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Woody hereby specifically
acknowledges and agrees that (i)&nbsp;Woody&rsquo;s waiver of known and unknown claims and of California Civil Code &sect; 1542 is knowing
and voluntary; (ii)&nbsp;the Severance Payment is in addition to anything of value to which Woody already is entitled; and (iii)&nbsp;but
for this Agreement, Woody would not be entitled to the Severance Payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Separation and Release Agreement<BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 10</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c.&nbsp;<I><U>Specific
Release</U></I><U>.</U>&nbsp;Woody agrees not only to release and discharge the Released Parties from any and all claims against the Released
Parties that Woody could make on Woody&rsquo;s own behalf, but also those which may have been or may be made by any other person or organization
on Woody&rsquo;s behalf. Woody specifically waives any right to become, and promises not to become, a member of any class in a case in
which any claim or claims are asserted against any of the Released Parties based on any acts or omissions occurring on or before the date
of Woody&rsquo;s signing of this Agreement and Release. If Woody is asserted to be a member of a class in a case against any of the Released
Parties based on any acts or omissions occurring on or before the date of Woody&rsquo;s signing of this Agreement and Release, Woody shall
immediately withdraw with prejudice in writing from said class, if permitted by law to do so. Woody agrees that Woody will not encourage
or assist any person in filing or pursuing any proceeding, action, charge, complaint, or claim against the Released Parties, except as
required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.&nbsp;<U>Nonwaivable Claims</U>.
This Agreement and Release is not intended to interfere with Woody&rsquo;s exercise of any protected, nonwaivable right, including Woody&rsquo;s
right to file a charge with the Equal Employment Opportunity Commission or other government agency. By entering into this Agreement and
Release, however, Woody acknowledges that the Severance Payment set forth herein is in addition to amounts 180 Life owes Woody under the
Employment Agreement, that 180 Life would not have agreed to pay such amounts to Woody if not for Woody agreeing to the terms of this
Agreement, such amount is in full satisfaction of any amounts to which Woody might be entitled and Woody is forever discharging the Released
Parties from any liability to Woody for any acts or omissions occurring on or before the date of Woody&rsquo;s signing of this Agreement
and Release. This Agreement and Release is also not intended to diminish any right of indemnity that Woody may enjoy in respect of his
actions or inactions during his tenure as an employee of 180 Life Sciences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.&nbsp;<U>Claims Not Released</U>.
Woody is not waiving any rights hereunder that Woody may have to: (i)&nbsp;Woody&rsquo;s vested 180 Life equity grants or any other vested
accrued employee benefits under any of 180 Life&rsquo;s health, welfare, or retirement benefit plans as of the Separation Date or unemployment
claims (which 180 Life agrees not to contest); (ii)&nbsp;any rights or claims Woody may have for indemnification, and/or contribution,
advancement or payment of related expenses pursuant to any Indemnification Agreement entered into with 180 Life (&ldquo;<B><U>Indemnification
Agreement</U></B>&rdquo;), or any other written agreement with 180 Life, 180 Life&rsquo;s Bylaws or other organizing documents, and/or
under applicable law; (iii)&nbsp;benefits or rights to seek benefits under applicable workers&rsquo; compensation (except as to claims
under Labor Code sections 132a and 4553), unemployment insurance or indemnification statutes or pursue claims which by law cannot be waived
by signing this Agreement; (iv)&nbsp;enforce or challenge the validity of this Agreement; (v)&nbsp;coverage under any directors and officers
liability insurance, other insurance policies of 180 Life, COBRA or any similar state law; (vi)&nbsp;as a shareholder of 180 Life, if
applicable; and (vii)&nbsp;any claims arising after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.&nbsp;<U>No Admission</U>.
Neither this Agreement and Release, nor anything contained herein, shall be construed as an admission by the Released Parties of any liability
or unlawful conduct whatsoever. The Parties hereto agree and understand that the consideration set forth in&nbsp;<U>Paragraph&nbsp;1</U>&nbsp;is
in excess of that which 180 Life is obligated to provide to Woody, and that it is provided solely in consideration of Woody&rsquo;s execution
of this Agreement and Release. 180 Life and Woody agree that the consideration set forth in&nbsp;<U>Paragraph&nbsp;1</U>&nbsp;is sufficient
consideration for the release being given by Woody in&nbsp;<U>Paragraph&nbsp;5</U>, and for Woody&rsquo;s other promises herein, including,
but not limited to in&nbsp;<U>Paragraphs 9</U>&nbsp;and&nbsp;<U>10</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.&nbsp;<U>Confirmation of
No 180 Life Property</U>. Woody&rsquo;s signature below constitutes Woody&rsquo;s agreement that he doesn&rsquo;t have any original or
copies of any files, notes, programs, correspondence (whether electronic or hard copy), intellectual property, documents, slides, computer
disks, printouts, reports, lists of 180 Life&rsquo;s clients or leads or referrals to prospective clients, nor does he have any other
media or property in his possession or control which contain or pertain to Confidential Information (as defined below)&nbsp;or any other
items provided to Woody by 180 Life, developed or obtained by Woody in connection with Woody&rsquo;s employment with 180 Life, or otherwise
belonging to 180 Life.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Separation and Release Agreement<BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 10</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.&nbsp;<U>Restrictive Covenants</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a.&nbsp;<U>Confidential
Information</U>. Woody understands and agrees that Woody may have learned or had access to, or assisted in the development of, highly
confidential and sensitive information and trade secrets about 180 Life, its operations and its clients, and that providing its clients
with appropriate assurances that their confidences will be protected is crucial to 180 Life&rsquo;s ability to obtain clients, maintain
good client relations, and conform to contractual obligations. &ldquo;<B><U>Confidential Information</U></B>&rdquo; means any non-public
information that relates to the actual or anticipated business or research and development of 180 Life, technical data, trade secrets
or know-how, and includes, but is not limited to: (i)&nbsp;financial and business information related to 180 Life, such as strategies
and plans for future business, new business, product or other development, potential acquisitions or divestitures, and new marketing ideas;
(ii)&nbsp;product and technical information related to 180 Life, such as product formulations, methods, intellectual property, patented
technology, patent pending technology, and technology which may be patented in the future, new and innovative product ideas, methods,
procedures, devices, equipment, machines, data processing programs, software, software codes, source codes, computer models, and research
and development projects; (iii)&nbsp;client and supplier information, such as the identity of 180 Life&rsquo;s clients and suppliers,
the names of representatives of 180 Life&rsquo;s clients and suppliers responsible for entering into contracts with 180 Life, the amounts
paid by such clients and suppliers to 180 Life, specific client needs and requirements, and leads and referrals to prospective clients
and suppliers; (iv)&nbsp;personnel information, such as the identity and number of 180 Life&rsquo;s other employees, their salaries, bonuses,
benefits, skills, qualifications, and abilities; (v)&nbsp;any and all information in whatever form relating to any client or client of
180 Life, including but not limited to its business, employees, operations, systems, assets, liabilities, finances, products, and marketing,
selling, and operating practices; (vi)&nbsp;any information not included in (i)&nbsp;or (ii)&nbsp;above which Woody knows or should know
is subject to a restriction on disclosure or which Woody knows or should know is considered by 180 Life or 180 Life&rsquo;s clients or
suppliers or prospective clients or suppliers to be confidential, sensitive, proprietary, or a trade secret or is not readily available
to the public; (vii)&nbsp;intellectual property, including inventions and copyrightable works and (viii)&nbsp;any information related
to any governmental investigations. Confidential Information is not generally known or available to the general public, but has been developed,
compiled or acquired by 180 Life at its great effort and expense. Confidential Information can be in any form: oral, written, or machine
readable, including electronic files.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b.&nbsp;<U>Confidentiality
Requirements</U>. Woody acknowledges and agrees that 180 Life is engaged in a highly competitive business and that its competitive position
depends upon its ability to maintain the confidentiality of the Confidential Information, which was developed, compiled and acquired by
180 Life at its great effort and expense. Woody further acknowledges and agrees that any disclosing, divulging, revealing or using of
any of the Confidential Information, other than as specifically authorized by 180 Life, will be highly detrimental to 180 Life and will
cause it to suffer serious loss of business and pecuniary damage. Accordingly, Woody agrees that Woody will not, for any purpose whatsoever,
directly or indirectly use, disseminate, or disclose to any person, organization, or entity Confidential Information, except as expressly
authorized by the highest executive officer of 180 Life or by order of a court of competent jurisdiction after providing 180 Life with
sufficient notice to contest such order (the &ldquo;<B><U>Confidentiality Requirements</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c.&nbsp;<U>Non-Use
of Confidential Information</U>. Woody agrees not to use, disclose to others, or permit anyone access to any of 180 Life&rsquo;s trade
secrets or confidential or proprietary information without 180 Life&rsquo;s express consent, and to return immediately to 180 Life all
of 180 Life&rsquo;s property, including all files related to 180 Life, upon termination of Woody&rsquo;s employment. Woody shall not retain
any copy or other reproduction whatsoever of any 180 Life property after the termination of Woody&rsquo;s employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Separation and Release Agreement<BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 10</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d.&nbsp;<U>Mutual
Non-Disparagement</U>. 180 Life, Woody and Released Parties agree not to say, write or cause to be said, disseminated, published, issued,
communicated or written, any statement that may be considered defamatory, derogatory, or disparaging of each other&nbsp;<FONT STYLE="background-color: white">concerning
Woody, 180 Life or any Released Party, Woody&rsquo;s employment with 180 Life, acts occurring before the signing of this Agreement and
Release, before the Separation Date or relating to this Agreement and Release and the matters covered hereby, or any other matter whatsoever,
provided that nothing shall prohibit Woody from communicating any concerns about potential violations of law, rule or regulation to the
Securities and Exchange Commission, Occupational Safety and Health Administration or any other government authority or self-regulatory
agency (collectively, &ldquo;<B><U>Agencies</U></B>&rdquo;), or prohibit Woody from discussing any such matters with any Agency</FONT>&nbsp;(collectively,
the &ldquo;<B><U>Non-Disparagement Requirements</U></B>&rdquo;). Nothing in this agreement prevents Woody from discussing or disclosing
information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that Woody has reason to believe
is unlawful. Nothing in this Agreement prevents or restricts Woody from disclosing factual information relating to claims of harassment,
discrimination, or retaliation under the Fair Employment and Housing Act (FEHA), the Equal Employment Opportunity Commission, or a state
or local commission on human rights, or any self-regulatory organization regarding possible violations of law, including claims based
on race, sexual orientation, religion, color, national origin, ancestry, disability, medical condition, and age. Further, nothing in this
Agreement or any other agreement by and between 180 Life and Woody shall prohibit or restrict Woody from (i)&nbsp;voluntarily communicating
with an attorney retained by Woody, (ii)&nbsp;initiating, testifying, assisting, complying with a subpoena from, or participating in any
manner with an investigation conducted by any Agencies, (iii)&nbsp;recovering a Securities and Exchange Commission whistleblower award
as provided under Section 21F of the Securities Exchange Act of 1934, (iv)&nbsp;disclosing any confidential information to a court or
other administrative or legislative body in response to a subpoena, provided that Woody first promptly notifies and provides 180 Life
with the opportunity to seek, and join in its efforts at the sole expense of 180 Life, to challenge the subpoena or obtain a protective
order limiting its disclosure, or other appropriate remedy, or (v)&nbsp;filing or disclosing any facts necessary to receive unemployment
insurance, Medicaid or other public benefits to which Woody is entitled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e.&nbsp;<FONT STYLE="background-color: white"><U>Non-Interference</U>.
For a period of one (1)&nbsp;year from the Separation Date (the &ldquo;<B><U>Non-Solicitation Period</U></B>&rdquo;),&nbsp;</FONT>Woody
agrees to n<FONT STYLE="background-color: white">ot interfere with 180 Life&rsquo;s and any of its affiliates&rsquo; business relationships
with their employees, consultants, representatives, customers, researchers or suppliers by directly and actively soliciting, recruiting
or encouraging same for employment with Woody or any future employer of Woody or to leave the service of 180 Life or its affiliate(s).
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f.&nbsp;<U>Reasonableness</U>.
Woody acknowledges and agrees that the restrictions set forth in this&nbsp;<U>Paragraph&nbsp;10</U>&nbsp; are critical and necessary to
protect 180 Life&rsquo;s legitimate business interests (including the protection of its Confidential Information); are reasonably drawn
to this end with respect to duration, scope, and otherwise; are not unduly burdensome; are not injurious to the public interest; and are
supported by adequate consideration. Woody also acknowledges and agrees that 180 Life would be irreparably damaged if Woody were to breach
the covenants set forth in this&nbsp;<U>Paragraph&nbsp;10</U>&nbsp; <FONT STYLE="background-color: white">and in the event that Woody
breaches any of the provisions in&nbsp;<U>Paragraph&nbsp;10</U>, 180 Life will be entitled to injunctive relief, in addition to any other
damages to which it may be entitled as well as the costs and reasonable attorneys&rsquo; fees it incurs in enforcing its rights under
this section. Woody further acknowledges that any breach or claimed breach of the provisions set forth in this Agreement will not be a
defense to enforcement of the restrictions set forth in this&nbsp;<U>Paragraph&nbsp;10</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g.&nbsp;<FONT STYLE="background-color: white"><U>Invalid
or Unenforceable Provisions</U>. Each word, phrase, sentence, Paragraph&nbsp;or provision (each a
&ldquo;<B><U>Provision</U></B>&rdquo;)&nbsp;of this&nbsp;<U>Paragraph&nbsp;10</U>&nbsp;is severable. If any Provision of
this&nbsp;<U>Paragraph&nbsp;10&nbsp;</U>is invalid or unenforceable, such invalidity or unenforceability shall not affect the
validity or enforceability of the remaining Provisions of this Agreement and Release or this&nbsp;<U>Paragraph&nbsp;10</U>. If any
Provision is deemed invalid or unenforceable for any reason, it is the Parties&rsquo; intention that such covenants be equitably
reformed, stricken or modified to the extent necessary to render them valid and enforceable in all respects. In the event that the
time period and/or geographic scope referenced above is deemed unreasonable, overbroad, or otherwise invalid, it is the
Parties&rsquo; intention that the enforcing court reduce or modify the time period and/or geographic scope to the extent necessary
to render such covenants reasonable, valid, and enforceable in all respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.&nbsp;<U>Assistance Following
Termination</U>. Woody agrees that, following the Separation Date, he will cooperate fully with 180 Life upon request in all matters relating
to the completion of his pending work on behalf of 180 Life and in connection with the orderly transition of such work to such other employees
as 180 Life may designate. 180 Life will reimburse Woody for any reasonable out-of-pocket expenses incurred pursuant to his duties under
this&nbsp;<U>Paragraph&nbsp;11</U>, after the Separation Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Separation and Release Agreement<BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> of 10</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.&nbsp;<U>Cooperation in
Investigations and Litigation</U>. In connection with 180 Life&rsquo;s pending legal matters and in the event 180 Life becomes involved
in any future investigations or legal proceedings of any nature, related directly or indirectly to events which occurred during Woody&rsquo;s
employment and about which Woody has personal knowledge, Woody agrees that Woody will, at any future time, be available upon reasonable
notice from 180 Life, with or without subpoena, to answer discovery requests, give depositions, or testify, with respect to matters of
which Woody has or may have knowledge as a result of or in connection with Woody&rsquo;s employment relationship with 180 Life. In performing
Woody&rsquo;s obligations under this paragraph to testify or otherwise provide information, Woody agrees that Woody will truthfully, forthrightly,
and completely provide the information requested. Woody further agrees that Woody will not be compensated in any way by 180 Life for Woody&rsquo;s
cooperation with 180 Life in connection with any litigation or other activity covered by this paragraph, except that Woody shall be reimbursed
as permitted by law for any reasonable expenses that Woody incurs in providing testimony or other assistance to 180 Life under this paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.&nbsp;<U>Requests for References</U>.
180 Life will confirm Woody&rsquo;s job title, dates of employment and, with written authorization from Woody, Woody&rsquo;s salary in
connection with any requests for references for Woody&rsquo;s potential future employers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.&nbsp;<U>Costs and Fees
Incurred</U>. Each Party shall bear its own costs and attorneys&rsquo; fees, if any, incurred in connection with this Agreement and Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.&nbsp;<U>Modifications</U>.
This Agreement and Release contains the full agreement of the Parties and may not be modified, altered, changed or terminated except upon
the express prior written consent of Woody and 180 Life or their authorized agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.&nbsp;<U>Acknowledgements</U>.
Woody acknowledges and agrees that: (a)&nbsp;no promise or inducement for this Agreement and Release has been made except as set forth
in this Agreement and Release; (b)&nbsp;this Agreement and Release is executed by Woody of his own free will and volition, without reliance
upon any statement or representation by 180 Life except as set forth herein; (c)&nbsp;Woody is legally competent to execute this Agreement
and Release and to accept full responsibility therefor; (d)&nbsp;Woody has been given twenty-one (21)&nbsp;days within which to consider
this Agreement and Release; (e)&nbsp;Woody has used all or as much of that twenty-one (21)&nbsp;day period as Woody deemed necessary to
consider fully this Agreement and Release and, if Woody has not used the entire twenty-one (21)&nbsp;day period, Woody waives that period
not used; (f)&nbsp;Woody has read and fully understands the meaning of each provision of this Agreement and Release; (g)&nbsp;180 Life
has advised Woody to consult with an attorney concerning this Agreement and Release and has provided Woody notice and an opportunity to
retain an attorney; (h)&nbsp;Woody knowingly, freely and voluntarily enters into this Agreement and Release; and (i)&nbsp;no fact, evidence,
event, or transaction currently unknown to Woody but which may hereafter become known to Woody shall affect in any manner the final and
unconditional nature of the release stated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.&nbsp;<U>Effective Date</U>.
This Agreement and Release shall become effective and enforceable on the eighth (8<SUP>th</SUP>)&nbsp;day following execution hereof by
Woody unless Woody revokes it by so advising 180 Life in writing before the end of the seventh (7<SUP>th</SUP>)&nbsp;day after its execution
by Woody (the &ldquo;<B><U>Effective Date</U></B>&rdquo;). In the event this Agreement is revoked prior to the Effective Date, Woody shall
immediately repay/return the Severance Payment (if paid prior to such date), and shall forfeit such Severance Payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.&nbsp;<U>[Intentionally
Removed].</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.&nbsp;<U>Termination of
Unvested Options</U>. Woody agrees and acknowledges that any unvested options to purchase shares of common stock of 180 Life held by him
as of the Separation Date shall be deemed forfeited and terminated and any vested options held by him as of the Separation Date shall
be exercisable, pursuant to their terms, for three (3)&nbsp;months following the Separation Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">20.&nbsp;<U>Governing Law</U>.
This Agreement and Release shall be governed by and construed in accordance with the laws of the State of California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Separation and Release Agreement<BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> of 10</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">21.&nbsp;<U>Notices</U>. Any
notice or communication required or permitted to be given hereunder shall be in writing and deemed duly served on and given (i)&nbsp;when
delivered personally; (ii)&nbsp;three (3)&nbsp;business days after having been sent by priority or certified mail, return receipt requested,
postage prepaid; (iii)&nbsp;upon delivery by fax with written facsimile confirmation and electronically by email with written delivery
receipt; or (iv)&nbsp;one (1)&nbsp;business day after deposit with a commercial overnight carrier, with written verification of receipt.
Such notices shall be in writing and delivered to the address set forth below or to such other notice address as the other Party has provided
by written notice:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 39%"><FONT STYLE="font-size: 10pt"><I>If to Former Employer:</I></FONT></TD>
    <TD STYLE="width: 53%"><FONT STYLE="font-size: 10pt"><I>If to Former Employee:</I></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">180 Life Sciences Corp.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">James N. Woody</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3000 El Camino Real, Bldg. 4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">_____________________</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Suite 200</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">_____________________</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Palo Alto, CA 94306</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Email: [_______________]</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Email: _____________________</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">22.&nbsp;<U>Waiver</U>. The
waiver by a Party of a breach of any provision herein shall not operate or be construed as a waiver of any subsequent breach by the other
Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">23.&nbsp;<U>Severability</U>.
The provisions of this Agreement and Release are severable. Should any provision herein be declared invalid by a court of competent jurisdiction,
the remainder of this Agreement and Release will continue in force, and the Parties agree to renegotiate the invalidated provision in
good faith to accomplish its objective to the extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">24.&nbsp;<U>No Benefit for
Others</U>. The Parties acknowledge that Woody&rsquo;s right to the Severance Pay described herein shall be determined exclusively under
the provisions stated herein, and this Agreement and Release is not intended to, and does not, create rights for the benefit of any other
employee or person except in connection with the rights of the Released Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">25.&nbsp;<U>No Wrongful Conduct</U>.
Woody represents, warrants and covenants to each of the Released Parties that at no time prior to or contemporaneous with its execution
of this Agreement and Release has he (i)&nbsp;knowingly engaged in any wrongful conduct against, on behalf of or as the representative
or agent of 180 Life; (ii)&nbsp;breached any provision of the Employment Agreement; or (iii)&nbsp;violated any state, federal, local or
other law, including any securities laws or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">26.&nbsp;<U>No Assignment
or Transfer</U>. Woody warrants and represents that Woody has not heretofore assigned or transferred to any person not a party to this
Agreement and Release any released matter or any part or portion thereof and he shall defend, indemnify and hold 180 Life and each Released
Party harmless from and against any claim (including the payment of attorneys&rsquo; fees and costs actually incurred whether or not litigation
is commenced)&nbsp;based on or in connection with or arising out of any such assignment or transfer made, purported or claimed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">27.&nbsp;<U>Not Assignable</U>.
This Agreement and Release is personal to Woody and shall not, without the prior written consent of 180 Life, be assignable by Woody.
This Agreement and Release shall inure to the benefit of and be binding upon 180 Life and its respective successors and assigns and any
such successor or assignee shall be deemed substituted for 180 Life under the terms of this Agreement and Release for all purposes. As
used herein, &ldquo;<B><U>successor</U></B>&rdquo; and &ldquo;<B><U>assignee</U></B>&rdquo; shall include any person, firm, corporation
or other business entity which at any time, whether by purchase, merger, acquisition of assets, or otherwise, directly or indirectly acquires
the ownership of 180 Life, acquires all or substantially all of 180 Life&rsquo;s assets, or to which 180 Life assigns this Agreement and
Release by operation of law or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">28.&nbsp;<U>Forfeiture of
Severance Payment</U>. Woody agrees that he will forfeit (and be forced to return)&nbsp;the Severance Payment payable by 180 Life pursuant
to this Agreement and Release&nbsp;if Woody challenges the validity of this Agreement and Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Separation and Release Agreement<BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> of 10</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.&nbsp;<U>Counterparts</U>.
This Agreement and Release may be signed in counterparts, and each counterpart shall be considered an original agreement for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">30.&nbsp;<U>Clawback</U>.
Woody agrees that, notwithstanding any other provisions in this Agreement to the contrary, any incentive-based compensation paid to Woody
under the Employment Agreement or any other agreement or arrangement with 180 Life which is subject to recovery under any law, government
regulation, or stock exchange listing requirement is be subject to such deductions and clawback pursuant to applicable law and 180 Life&rsquo;s
Policy for the Recovery of Erroneously Awarded Incentive-Based Compensation, as may be amended or modified from time to time. With respect
to any potential clawback or recovery effected or subject to a determination by the Board of Directors (the &ldquo;<B><U>Board</U></B>&rdquo;),
the Board will make its determination for clawback or recovery in good faith, upon advice of counsel, and in accordance with any applicable
law or regulation, and to the extent permitted by law, only after (i)&nbsp;providing Woody prior written notice of the deliberation of
such potential clawback or recovery and (ii)&nbsp;providing Woody (and his counsel)&nbsp;an opportunity to present to the Board all relevant
information related to such determination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">31.&nbsp;<U>Section 409A</U>.
It is intended that this Agreement comply with, or be exempt from, Internal Revenue Code Section 409A and the final regulations and official
guidance thereunder (&ldquo;<B><U>Section 409A</U></B>&rdquo;)&nbsp;and any ambiguities and ambiguous terms herein will be interpreted
to so comply and/or be exempt from Section 409A. Each payment and benefit to be paid or provided under this Agreement (including without
limitation any Severance Payment)&nbsp;is intended to constitute a series of separate payments for purposes of Section 1.409A-2(b)(2)&nbsp;of
the Treasury Regulations. Woody acknowledges that if any provision of this Agreement (or of any award of compensation or benefits)&nbsp;would
cause Woody to incur any additional tax or interest under Section 409A and accompanying Treasury regulations and other authoritative guidance,
such additional tax and interest shall solely be his responsibility. 180 Life and Woody will work together in good faith to consider either
(i)&nbsp;amendments to this Agreement; or (ii)&nbsp;revisions to this Agreement with respect to the payment of any awards, which are necessary
or appropriate to avoid imposition of any additional tax or income recognition prior to the actual payment to Woody under Section 409A.
In no event will the Released Parties have any obligation, liability or responsibility to reimburse, indemnify or hold harmless Woody
for any taxes imposed, or other costs incurred, as a result of Section 409A. The Separation Date is intended to constitute Woody&rsquo;s
&ldquo;separation from service&rdquo; within the meaning of Section 409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Remainder of page left intentionally blank. Signature
page follows.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Separation and Release Agreement<BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> of 10</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
the Parties have hereunto set their hands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>James N. Woody</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>180 Life Sciences Corp.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="width: 37%; border-bottom: black 1.5pt solid">/s/ James N. Woody</TD>
    <TD STYLE="width: 5%; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="width: 41%; border-bottom: black 1.5pt solid">/s/ Ozan Pamir </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>James N. Woody</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-size: 10pt">Printed Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid">Ozan Pamir</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid">CFO</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">5/6/2024</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">5/7/2024</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Date</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Date</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Separation and Release Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Page 10 of 10</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ea020558901ex10-2_180lifesci.htm
<DESCRIPTION>SEPARATION AND RELEASE AGREEMENT DATED MAY 7, 2024, BY AND BETWEEN 180 LIFE SCIENCES CORP. AND DR. JONATHAN ROTHBARD
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SEPARATION AND RELEASE AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
Separation and Release Agreement (this &ldquo;<B><U>Agreement and Release</U></B>&rdquo; or &ldquo;<B><U>Agreement</U></B>&rdquo;)&nbsp;dated
May [ ], 2024, is made by and between Jonathan Rothbard, an individual (&ldquo;<B><U>Rothbard</U></B>&rdquo;)&nbsp;and 180 Life Sciences
Corp., a Delaware corporation (&ldquo;<B><U>180 Life</U></B>&rdquo;)&nbsp;(collectively referred to as the &ldquo;<B><U>Parties</U></B>&rdquo;
or individually referred to as a &ldquo;<B><U>Party</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, Rothbard currently
serves as Chief Scientific Officer of 180 Life;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, 180 Life and
Rothbard previously entered into an employment agreement dated August 21, 2019, and effective November 6, 2020 (as amended to date, the
&ldquo;<B><U>Employment Agreement</U></B>&rdquo;), pursuant to which Rothbard agreed to serve as an employee (Chief Scientific Officer)&nbsp;of
180 Life;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, Rothbard&rsquo;s
Employment Agreement was amended on January 1, 2024, to provide for the reduction and accrual of a portion of Rothbard&rsquo;s base salary;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, after discussion
among the Parties, the Parties believe that it is in the best interest of Rothbard and 180 Life to terminate the Employment Agreement
and mutually terminate Rothbard&rsquo;s employment with 180 Life;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, Rothbard&rsquo;s
Employment Agreement and Rothbard&rsquo;s employment with 180 Life is hereby terminated effective May [ ], 2024 (the &ldquo;<B><U>Separation&nbsp;Date</U></B>&rdquo;);
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Parties
wish to resolve any and all disputes, claims, complaints, grievances, charges, actions, petitions, and demands that Rothbard may have
against 180 Life and any of the Released Parties as defined below, including, but not limited to, any and all claims arising out of or
in any way related to Rothbard&rsquo;s employment with or separation from 180 Life, each pursuant to the terms and conditions of this
Agreement set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in
consideration of the mutual promises made herein and the Severance Payment (defined below), the receipt and sufficiency of which is acknowledge
and confirmed, Rothbard and 180 Life hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;<U>Severance Payment</U>.
Subject to Rothbard&rsquo;s compliance with the terms and conditions of this Agreement and Release, 180 Life agrees (a) to pay Rothbard
$200 in cash, less all applicable withholdings and required deductions (the &ldquo;<B><U>Severance Payment</U></B>&rdquo;); and (b)&nbsp;enter
into a Consulting Agreement with Rothbard in the form of <B>Exhibit A</B> hereto (the &ldquo;<B><U>Consulting Agreement</U></B>&rdquo;).
The Severance Payment shall be paid within 15 days of the Separation Date (the &ldquo;<B><U>Payment Date</U></B>&rdquo;). Rothbard agrees
that the Severance Payment to be paid under this Agreement and Release is due solely from 180 Life and represents consideration which
would not otherwise be due to Rothbard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;<U>Release of Further
Payments</U>. The consideration set forth in&nbsp;<U>Paragraph&nbsp;1</U>&nbsp;is inclusive of any and all amounts, including but not
limited to attorneys&rsquo; fees, that may be claimed by Rothbard or on Rothbard&rsquo;s behalf against 180 Life. In furtherance of the
above, and without limiting any other term or condition of this Agreement and Release, Rothbard agrees to release any rights he may have
to, and to waive all rights of 180 Life to pay, other than as set forth in&nbsp;<U>Paragraph 1</U>, any severance fees set forth in the
Employment Agreement, any bonus, accrued compensation, reimbursement for unused vacation days, sick days or other benefits, in connection
with severance pay or otherwise, any stock or option compensation, and further acknowledges that he is not owed any funds from 180 Life
in connection with unreimbursed business expenses as of the date of this Agreement and Release and/or any other amounts due under the
Employment Agreement. Rothbard further agrees that he is owed by 180 Life, those amounts set forth in&nbsp;<U>Paragraph 1</U>, for any
vacation time, sick time, paid time off or paid leave of absence, or in connection with any severance or deferred compensation plan, if
eligible, and that he has been given all time off or is being paid for all time off to which he was entitled under any policy or law,
including but not limited to leave under the Family and Medical Leave Act. Notwithstanding any other term or condition of this Agreement
and Release, Rothbard may elect to continue health insurance coverage, following the Separation Date, in accordance with the provisions
of COBRA regardless of whether 180 Life enters into this Agreement and Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Separation and Release Agreement<BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> of 10</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;<U>No Further Payments</U>.
Except as described in&nbsp;<U>Paragraph&nbsp;1</U>, Rothbard acknowledges and agrees that he is not entitled to any other compensation,
severance, benefits, stock compensation, options, severance pay, or other payments in connection with his engagement by, or employment
or positions with, 180 Life or the termination thereof, or pursuant to the Employment Agreement or the termination thereof or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&nbsp;<U>Rothbard Acknowledgements</U>.
By entering into this Agreement and Release, Rothbard confirms and acknowledges the Separation Date and that Rothbard shall be deemed
to have voluntarily resigned from employment with 180 Life as of the Separation Date. Rothbard further acknowledges and confirms that
Rothbard has been paid or is being paid for any salary, wages, incentives, bonuses, commissions and any other type of compensation due
to Rothbard, for work performed through and including the Separation Date. Rothbard further acknowledges that, as of the date of Rothbard&rsquo;s
signing of this Agreement and Release, Rothbard has sustained no injury or illness related in any way to Rothbard&rsquo;s employment with
180 Life for which a worker&rsquo;s compensation claim has not already been filed. Concurrently with Rothbard&rsquo;s entry into this
Agreement Rothbard shall provide a written resignation, resigning as an officer of 180 Life. Rothbard represents that he does not have
any pending lawsuits, claims, or actions against 180 Life and has fully disclosed all lawsuits, claims, or actions to 180 Life prior to
executing this Agreement and Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&nbsp;<U>Rothbard&rsquo;s
General Release.</U>&nbsp;In return for 180 Life&rsquo;s agreement to provide Rothbard with the Severance Payment referred to in&nbsp;<U>Paragraph&nbsp;1</U>,
Rothbard agrees to the following, in addition to the other terms and conditions of this Agreement and Release:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a.&nbsp;<I><U>General
Release</U></I>. Rothbard, for Rothbard and Rothbard&rsquo;s heirs, beneficiaries, devisees, privies, executors, administrators, attorneys,
representatives, and agents, and Rothbard&rsquo;s and his assigns, successors and predecessors, hereby releases and forever discharges
180 Life, and its subsidiaries and affiliates, and each of their officers, directors, employees, members, agents, attorneys, predecessors,
successors and assigns of each of the foregoing entities (collectively, the &ldquo;<B><U>Released Parties</U></B>&rdquo;), from any and
all actions, causes of action, suits, debts, claims, complaints, charges, contracts, controversies, agreements, promises, damages, counterclaims,
cross-claims, claims for costs and/or attorneys&rsquo; fees, judgments and demands whatsoever, in law or equity, known or unknown, Rothbard
ever had, now has, or may have against the Released Parties as of the date of Rothbard&rsquo;s signing of this Agreement and Release.
This release includes, but is not limited to, any claims for severance pay, restricted stock, restricted stock units, stock or option
compensation, any claims alleging breach of express or implied contract, wrongful discharge, constructive discharge, breach of an implied
covenant of good faith and fair dealing, negligent or intentional infliction of emotional distress, negligent supervision or retention,
violation of the Age Discrimination in Employment Act, the Older Workers Benefit Protection Act, Older Workers Benefit Protection Act
of 1990, the Workers Adjustment and Retraining Notification Act, the Rehabilitation Act of 1973, the Civil Rights Act of 1866, Title VII
of the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Americans with Disabilities Act, Sections 1981 through 1988 of Title
42 of the United States Code, as amended, the Employee Retirement Income Security Act of 1974, the Immigration Reform and Control Act,
the Equal Pay Act of 1963, the Family and Medical Leave Act of 1993, the Fair Labor Standards Act of 1938, the Older Workers Benefit Protection
Act of 1990, the Occupational Safety and Health Act of 1970, the Worker Adjustment and Retraining Notification Act of 1989, the Genetic
Information Nondiscrimination Act of 2008, California Family Rights Act &ndash; Cal. Gov&rsquo;t Code &sect; 12945.2, California Fair
Employment and Housing Act &ndash; Cal. Gov&rsquo;t Code &sect; 12900 et seq., California Unruh Civil Rights Act &ndash; Cal. Civ. Code
&sect; 51 et seq., Statutory Provisions Regarding the Confidentiality of AIDS Information &ndash; Cal. Health &amp; Safety Code &sect;
120775 et seq., California Confidentiality of Medical Information Act &ndash; Cal. Civ. Code &sect; 56 et seq., California Parental Leave
Law &ndash; Cal. Lab. Code &sect; 230.7 et seq., California Military Personnel Bias Law &ndash; Cal. Mil. &amp; Vet. Code &sect; 394,
the California Occupational Safety and Health Act, as amended, and any applicable regulations thereunder, the California Consumer Credit
Reporting Agencies Act &ndash; Cal. Civ. Code &sect; 1785 et seq., California Investigative Consumer Reporting Agencies Act &ndash; Cal.
Civ. Code &sect; 1786 et seq., those provisions of the California Labor Code that lawfully may be released, the Sarbanes-Oxley Act of
2002, claims pursuant to any other federal, state or local law regarding discrimination, harassment or retaliation based on age, race,
sex, religion, national origin, marital status, disability, sexual orientation or any other unlawful basis or protected status or activity,
and claims for alleged violation of any other local, state or federal law, regulation, ordinance, public policy or common-law duty having
any bearing whatsoever upon the terms and conditions of, and/or the cessation of Rothbard&rsquo;s employment with and by 180 Life and/or
the termination of the Employment Agreement or relating to 180 Life or his employment with 180 Life in general, each to the extent allowed
pursuant to applicable law. Along with such release, all benefits to Rothbard from 180 Life (i.e., health insurance coverage, 401(k)&nbsp;plans
and life insurance (if any))&nbsp;will be terminated. The Released Parties can seek attorneys&rsquo; fees, costs, or other damages arising
from Rothbard for Rothbard&rsquo;s breach of the release. Rothbard agrees that, if any portion of this release is found to be unenforceable,
the remainder of the release will remain enforceable. This release does not include claims that may not be released under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Separation and Release Agreement<BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 10</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b.&nbsp;<I><U>Unknown
Claims</U></I>. Rothbard understands and agrees that the release set forth in Section 5.a above, extends to all claims of every nature,
known or unknown, suspected or unsuspected, past or present, and that any and all rights granted to Rothbard under Section 1542 of the
California Civil Code or any analogous federal law or regulation are hereby expressly waived. Said Section 1542 of the California Civil
Code reads as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><I>&ldquo;A general release does not extend
to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release
and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Rothbard hereby
specifically acknowledges and agrees that (i)&nbsp;Rothbard&rsquo;s waiver of known and unknown claims and of California Civil Code &sect;
1542 is knowing and voluntary; (ii)&nbsp;the Severance Payment is in addition to anything of value to which Rothbard already is entitled;
and (iii)&nbsp;but for this Agreement, Rothbard would not be entitled to the Severance Payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c.&nbsp;<I><U>Specific
Release</U></I><U>.</U>&nbsp;Rothbard agrees not only to release and discharge the Released Parties from any and all claims against the
Released Parties that Rothbard could make on Rothbard&rsquo;s own behalf, but also those which may have been or may be made by any other
person or organization on Rothbard&rsquo;s behalf. Rothbard specifically waives any right to become, and promises not to become, a member
of any class in a case in which any claim or claims are asserted against any of the Released Parties based on any acts or omissions occurring
on or before the date of Rothbard&rsquo;s signing of this Agreement and Release. If Rothbard is asserted to be a member of a class in
a case against any of the Released Parties based on any acts or omissions occurring on or before the date of Rothbard&rsquo;s signing
of this Agreement and Release, Rothbard shall immediately withdraw with prejudice in writing from said class, if permitted by law to do
so. Rothbard agrees that Rothbard will not encourage or assist any person in filing or pursuing any proceeding, action, charge, complaint,
or claim against the Released Parties, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.&nbsp;<U>Nonwaivable Claims</U>.
This Agreement and Release is not intended to interfere with Rothbard&rsquo;s exercise of any protected, nonwaivable right, including
Rothbard&rsquo;s right to file a charge with the Equal Employment Opportunity Commission or other government agency. By entering into
this Agreement and Release, however, Rothbard acknowledges that the Severance Payment set forth herein is in addition to amounts 180 Life
owes Rothbard under the Employment Agreement, that 180 Life would not have agreed to pay such amounts to Rothbard if not for Rothbard
agreeing to the terms of this Agreement, such amount is in full satisfaction of any amounts to which Rothbard might be entitled and Rothbard
is forever discharging the Released Parties from any liability to Rothbard for any acts or omissions occurring on or before the date of
Rothbard&rsquo;s signing of this Agreement and Release. This Agreement and Release is also not intended to diminish any right of indemnity
that Rothbard may enjoy in respect of his actions or inactions during his tenure as an employee of 180 Life Sciences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Separation and Release Agreement<BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 10</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.&nbsp;<U>Claims Not Released</U>.
Rothbard is not waiving any rights hereunder that Rothbard may have to: (i)&nbsp;Rothbard&rsquo;s vested 180 Life equity grants or any
other vested accrued employee benefits under any of 180 Life&rsquo;s health, welfare, or retirement benefit plans as of the Separation
Date or unemployment claims (which 180 Life agrees not to contest); (ii)&nbsp;any rights or claims Rothbard may have for indemnification,
and/or contribution, advancement or payment of related expenses pursuant to any Indemnification Agreement entered into with 180 Life (&ldquo;<B><U>Indemnification
Agreement</U></B>&rdquo;), or any other written agreement with 180 Life, 180 Life&rsquo;s Bylaws or other organizing documents, and/or
under applicable law; (iii)&nbsp;benefits or rights to seek benefits under applicable workers&rsquo; compensation (except as to claims
under Labor Code sections 132a and 4553), unemployment insurance or indemnification statutes or pursue claims which by law cannot be waived
by signing this Agreement; (iv)&nbsp;enforce or challenge the validity of this Agreement; (v)&nbsp;coverage under any directors and officers
liability insurance, other insurance policies of 180 Life, COBRA or any similar state law; (vi)&nbsp;as a shareholder of 180 Life, if
applicable; and (vii)&nbsp;any claims arising after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.&nbsp;<U>No Admission</U>.
Neither this Agreement and Release, nor anything contained herein, shall be construed as an admission by the Released Parties of any liability
or unlawful conduct whatsoever. The Parties hereto agree and understand that the consideration set forth in&nbsp;<U>Paragraph&nbsp;1</U>&nbsp;is
in excess of that which 180 Life is obligated to provide to Rothbard, and that it is provided solely in consideration of Rothbard&rsquo;s
execution of this Agreement and Release. 180 Life and Rothbard agree that the consideration set forth in&nbsp;<U>Paragraph&nbsp;1</U>&nbsp;is
sufficient consideration for the release being given by Rothbard in&nbsp;<U>Paragraph&nbsp;5</U>, and for Rothbard&rsquo;s other promises
herein, including, but not limited to in&nbsp;<U>Paragraphs 9</U>&nbsp;and&nbsp;<U>10</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.&nbsp;<U>Return of 180 Life&rsquo;s
Property</U>. Rothbard&rsquo;s signature below constitutes Rothbard&rsquo;s agreement to return any originals and all copies of all files,
notes, programs, intellectual property, documents, slides, computer disks, printouts, reports, lists of 180 Life&rsquo;s clients or leads
or referrals to prospective clients, and other media or property in Rothbard&rsquo;s possession or control which contain or pertain to
Confidential Information (as defined below)&nbsp;and other items provided to Rothbard by 180 Life, developed or obtained by Rothbard in
connection with Rothbard&rsquo;s employment with 180 Life, or otherwise belonging to 180 Life, including all property of 180 Life, such
as supplies, keys, access devices, books, identification cards, computers, cell phones, laptops, PDAs, telephones, and other equipment
within 10 days of the Separation Date, and that Rothbard has not supplied and shall not supply prior to the Separation Date, any such
Confidential Information to any person, except as was required to carry out Rothbard&rsquo;s duties as a former employee of 180 Life.
Furthermore, Rothbard has provided 180 Life all login ids and passwords relating to 180 Life and any websites, programs or software associated
with 180 Life or Rothbard&rsquo;s prior services performed on behalf of 180 Life. Rothbard shall immediately delete all files, programs,
source code, notes, documents, slides, computer disks, electronically stored information, physically stored information, printouts and
other media or property in Rothbard&rsquo;s possession or control which contain or pertain to Confidential Information, to the extent
not delivered as discussed above on or prior to the Separation Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.&nbsp;<U>Restrictive Covenants</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a.&nbsp;<U>Confidential
Information</U>. Rothbard understands and agrees that Rothbard may have learned or had access to, or assisted in the development of, highly
confidential and sensitive information and trade secrets about 180 Life, its operations and its clients, and that providing its clients
with appropriate assurances that their confidences will be protected is crucial to 180 Life&rsquo;s ability to obtain clients, maintain
good client relations, and conform to contractual obligations. &ldquo;<B><U>Confidential Information</U></B>&rdquo; means any non-public
information that relates to the actual or anticipated business or research and development of 180 Life, technical data, trade secrets
or know-how, and includes, but is not limited to: (i)&nbsp;financial and business information related to 180 Life, such as strategies
and plans for future business, new business, product or other development, potential acquisitions or divestitures, and new marketing ideas;
(ii)&nbsp;product and technical information related to 180 Life, such as product formulations, methods, intellectual property, patented
technology, patent pending technology, and technology which may be patented in the future, new and innovative product ideas, methods,
procedures, devices, equipment, machines, data processing programs, software, software codes, source codes, computer models, and research
and development projects; (iii)&nbsp;client and supplier information, such as the identity of 180 Life&rsquo;s clients and suppliers,
the names of representatives of 180 Life&rsquo;s clients and suppliers responsible for entering into contracts with 180 Life, the amounts
paid by such clients and suppliers to 180 Life, specific client needs and requirements, and leads and referrals to prospective clients
and suppliers; (iv)&nbsp;personnel information, such as the identity and number of 180 Life&rsquo;s other employees, their salaries, bonuses,
benefits, skills, qualifications, and abilities; (v)&nbsp;any and all information in whatever form relating to any client or client of
180 Life, including but not limited to its business, employees, operations, systems, assets, liabilities, finances, products, and marketing,
selling, and operating practices; (vi)&nbsp;any information not included in (i)&nbsp;or (ii)&nbsp;above which Rothbard knows or should
know is subject to a restriction on disclosure or which Rothbard knows or should know is considered by 180 Life or 180 Life&rsquo;s clients
or suppliers or prospective clients or suppliers to be confidential, sensitive, proprietary, or a trade secret or is not readily available
to the public; (vii)&nbsp;intellectual property, including inventions and copyrightable works and (viii)&nbsp;any information related
to any governmental investigations. Confidential Information is not generally known or available to the general public, but has been developed,
compiled or acquired by 180 Life at its great effort and expense. Confidential Information can be in any form: oral, written, or machine
readable, including electronic files.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Separation and Release Agreement<BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 10</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b.&nbsp;<U>Confidentiality
Requirements</U>. Rothbard acknowledges and agrees that 180 Life is engaged in a highly competitive business and that its competitive
position depends upon its ability to maintain the confidentiality of the Confidential Information, which was developed, compiled and acquired
by 180 Life at its great effort and expense. Rothbard further acknowledges and agrees that any disclosing, divulging, revealing or using
of any of the Confidential Information, other than as specifically authorized by 180 Life, will be highly detrimental to 180 Life and
will cause it to suffer serious loss of business and pecuniary damage. Accordingly, Rothbard agrees that Rothbard will not, for any purpose
whatsoever, directly or indirectly use, disseminate, or disclose to any person, organization, or entity Confidential Information, except
as expressly authorized by the highest executive officer of 180 Life or by order of a court of competent jurisdiction after providing
180 Life with sufficient notice to contest such order (the &ldquo;<B><U>Confidentiality Requirements</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c.&nbsp;<U>Non-Use
of Confidential Information</U>. Rothbard agrees not to use, disclose to others, or permit anyone access to any of 180 Life&rsquo;s trade
secrets or confidential or proprietary information without 180 Life&rsquo;s express consent, and to return immediately to 180 Life all
of 180 Life&rsquo;s property, including all files related to 180 Life, upon termination of Rothbard&rsquo;s employment. Rothbard shall
not retain any copy or other reproduction whatsoever of any 180 Life property after the termination of Rothbard&rsquo;s employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d.&nbsp;<U>Mutual
Non-Disparagement</U>. 180 Life, Rothbard and Released Parties agree not to say, write or cause to be said, disseminated, published, issued,
communicated or written, any statement that may be considered defamatory, derogatory, or disparaging of each other&nbsp;<FONT STYLE="background-color: white">concerning
Rothbard, 180 Life or any Released Party, Rothbard&rsquo;s employment with 180 Life, acts occurring before the signing of this Agreement
and Release, before the Separation Date or relating to this Agreement and Release and the matters covered hereby, or any other matter
whatsoever, provided that nothing shall prohibit Rothbard from communicating any concerns about potential violations of law, rule or regulation
to the Securities and Exchange Commission, Occupational Safety and Health Administration or any other government authority or self-regulatory
agency (collectively, &ldquo;<B><U>Agencies</U></B>&rdquo;), or prohibit Rothbard from discussing any such matters with any Agency</FONT>&nbsp;(collectively,
the &ldquo;<B><U>Non-Disparagement Requirements</U></B>&rdquo;). Nothing in this agreement prevents Rothbard from discussing or disclosing
information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that Rothbard has reason to
believe is unlawful. Nothing in this Agreement prevents or restricts Rothbard from disclosing factual information relating to claims of
harassment, discrimination, or retaliation under the Fair Employment and Housing Act (FEHA), the Equal Employment Opportunity Commission,
or a state or local commission on human rights, or any self-regulatory organization regarding possible violations of law, including claims
based on race, sexual orientation, religion, color, national origin, ancestry, disability, medical condition, and age. Further, nothing
in this Agreement or any other agreement by and between 180 Life and Rothbard shall prohibit or restrict Rothbard from (i)&nbsp;voluntarily
communicating with an attorney retained by Rothbard, (ii)&nbsp;initiating, testifying, assisting, complying with a subpoena from, or participating
in any manner with an investigation conducted by any Agencies, (iii)&nbsp;recovering a Securities and Exchange Commission whistleblower
award as provided under Section 21F of the Securities Exchange Act of 1934, (iv)&nbsp;disclosing any confidential information to a court
or other administrative or legislative body in response to a subpoena, provided that Rothbard first promptly notifies and provides 180
Life with the opportunity to seek, and join in its efforts at the sole expense of 180 Life, to challenge the subpoena or obtain a protective
order limiting its disclosure, or other appropriate remedy, or (v)&nbsp;filing or disclosing any facts necessary to receive unemployment
insurance, Medicaid or other public benefits to which Rothbard is entitled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Separation and Release Agreement<BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 10</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e.&nbsp;<FONT STYLE="background-color: white"><U>Non-Interference</U>.
For a period of one (1)&nbsp;year from the Separation Date (the &ldquo;<B><U>Non-Solicitation Period</U></B>&rdquo;),&nbsp;</FONT>Rothbard
agrees to n<FONT STYLE="background-color: white">ot interfere with 180 Life&rsquo;s and any of its affiliates&rsquo; business relationships
with their employees, consultants, representatives, customers, researchers or suppliers by directly and actively soliciting, recruiting
or encouraging same for employment with Rothbard or any future employer of Rothbard or to leave the service of 180 Life or its affiliate(s).
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f.&nbsp;<U>Reasonableness</U>.
Rothbard acknowledges and agrees that the restrictions set forth in this&nbsp;<U>Paragraph&nbsp;10</U>&nbsp; are critical and necessary
to protect 180 Life&rsquo;s legitimate business interests (including the protection of its Confidential Information); are reasonably drawn
to this end with respect to duration, scope, and otherwise; are not unduly burdensome; are not injurious to the public interest; and are
supported by adequate consideration. Rothbard also acknowledges and agrees that 180 Life would be irreparably damaged if Rothbard were
to breach the covenants set forth in this&nbsp;<U>Paragraph&nbsp;10</U>&nbsp; <FONT STYLE="background-color: white">and in the event that
Rothbard breaches any of the provisions in&nbsp;<U>Paragraph&nbsp;10</U>, 180 Life will be entitled to injunctive relief, in addition
to any other damages to which it may be entitled as well as the costs and reasonable attorneys&rsquo; fees it incurs in enforcing its
rights under this section. Rothbard further acknowledges that any breach or claimed breach of the provisions set forth in this Agreement
will not be a defense to enforcement of the restrictions set forth in this&nbsp;<U>Paragraph&nbsp;10</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g.&nbsp;<FONT STYLE="background-color: white"><U>Invalid
or Unenforceable Provisions</U>. Each word, phrase, sentence, Paragraph&nbsp;or provision (each a &ldquo;<B><U>Provision</U></B>&rdquo;)&nbsp;of
this&nbsp;<U>Paragraph&nbsp;10</U>&nbsp;is severable. If any Provision of this&nbsp;<U>Paragraph&nbsp;10&nbsp;</U>is invalid or unenforceable,
such invalidity or unenforceability shall not affect the validity or enforceability of the remaining Provisions of this Agreement and
Release or this&nbsp;<U>Paragraph&nbsp;10</U>. If any Provision is deemed invalid or unenforceable for any reason, it is the Parties&rsquo;
intention that such covenants be equitably reformed, stricken or modified to the extent necessary to render them valid and enforceable
in all respects. In the event that the time period and/or geographic scope referenced above is deemed unreasonable, overbroad, or otherwise
invalid, it is the Parties&rsquo; intention that the enforcing court reduce or modify the time period and/or geographic scope to the extent
necessary to render such covenants reasonable, valid, and enforceable in all respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.&nbsp;<U>Assistance Following
Termination</U>. Rothbard agrees that, following the Separation Date, he will cooperate fully with 180 Life upon request in all matters
relating to the completion of his pending work on behalf of 180 Life and in connection with the orderly transition of such work to such
other employees as 180 Life may designate. 180 Life will reimburse Rothbard for any reasonable out-of-pocket expenses incurred pursuant
to his duties under this&nbsp;<U>Paragraph&nbsp;11</U>, after the Separation Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.&nbsp;<U>Cooperation in
Investigations and Litigation</U>. In connection with 180 Life&rsquo;s pending legal matters and in the event 180 Life becomes involved
in any future investigations or legal proceedings of any nature, related directly or indirectly to events which occurred during Rothbard&rsquo;s
employment and about which Rothbard has personal knowledge, Rothbard agrees that Rothbard will, at any future time, be available upon
reasonable notice from 180 Life, with or without subpoena, to answer discovery requests, give depositions, or testify, with respect to
matters of which Rothbard has or may have knowledge as a result of or in connection with Rothbard&rsquo;s employment relationship with
180 Life. In performing Rothbard&rsquo;s obligations under this paragraph to testify or otherwise provide information, Rothbard agrees
that Rothbard will truthfully, forthrightly, and completely provide the information requested. Rothbard further agrees that Rothbard will
not be compensated in any way by 180 Life for Rothbard&rsquo;s cooperation with 180 Life in connection with any litigation or other activity
covered by this paragraph, except that Rothbard shall be reimbursed as permitted by law for any reasonable expenses that Rothbard incurs
in providing testimony or other assistance to 180 Life under this paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Separation and Release Agreement<BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> of 10</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.&nbsp;<U>Requests for References</U>.
180 Life will confirm Rothbard&rsquo;s job title, dates of employment and, with written authorization from Rothbard, Rothbard&rsquo;s
salary in connection with any requests for references for Rothbard&rsquo;s potential future employers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.&nbsp;<U>Costs and Fees
Incurred</U>. Each Party shall bear its own costs and attorneys&rsquo; fees, if any, incurred in connection with this Agreement and Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.&nbsp;<U>Modifications</U>.
This Agreement and Release contains the full agreement of the Parties and may not be modified, altered, changed or terminated except upon
the express prior written consent of Rothbard and 180 Life or their authorized agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.&nbsp;<U>Acknowledgements</U>.
Rothbard acknowledges and agrees that: (a)&nbsp;no promise or inducement for this Agreement and Release has been made except as set forth
in this Agreement and Release; (b)&nbsp;this Agreement and Release is executed by Rothbard of his own free will and volition, without
reliance upon any statement or representation by 180 Life except as set forth herein; (c)&nbsp;Rothbard is legally competent to execute
this Agreement and Release and to accept full responsibility therefor; (d)&nbsp;Rothbard has been given twenty-one (21)&nbsp;days within
which to consider this Agreement and Release; (e)&nbsp;Rothbard has used all or as much of that twenty-one (21)&nbsp;day period as Rothbard
deemed necessary to consider fully this Agreement and Release and, if Rothbard has not used the entire twenty-one (21)&nbsp;day period,
Rothbard waives that period not used; (f)&nbsp;Rothbard has read and fully understands the meaning of each provision of this Agreement
and Release; (g)&nbsp;180 Life has advised Rothbard to consult with an attorney concerning this Agreement and Release and has provided
Rothbard notice and an opportunity to retain an attorney; (h)&nbsp;Rothbard knowingly, freely and voluntarily enters into this Agreement
and Release; and (i)&nbsp;no fact, evidence, event, or transaction currently unknown to Rothbard but which may hereafter become known
to Rothbard shall affect in any manner the final and unconditional nature of the release stated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.&nbsp;<U>Effective Date</U>.
This Agreement and Release shall become effective and enforceable on the eighth (8<SUP>th</SUP>)&nbsp;day following execution hereof by
Rothbard unless Rothbard revokes it by so advising 180 Life in writing before the end of the seventh (7<SUP>th</SUP>)&nbsp;day after its
execution by Rothbard (the &ldquo;<B><U>Effective Date</U></B>&rdquo;). In the event this Agreement is revoked prior to the Effective
Date, Rothbard shall immediately repay/return the Severance Payment (if paid prior to such date), and shall forfeit such Severance Payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.&nbsp;<U>[Intentionally
Removed].</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.&nbsp;<U>Termination of
Unvested Options</U>. Rothbard agrees and acknowledges that any unvested options to purchase shares of common stock of 180 Life held by
him as of the Separation Date shall be deemed forfeited and terminated and any vested options held by him as of the Separation Date shall
be exercisable, pursuant to their terms, for three (3)&nbsp;months following the Separation Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">20.&nbsp;<U>Governing Law</U>.
This Agreement and Release shall be governed by and construed in accordance with the laws of the State of California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">21.&nbsp;<U>Notices</U>. Any
notice or communication required or permitted to be given hereunder shall be in writing and deemed duly served on and given (i)&nbsp;when
delivered personally; (ii)&nbsp;three (3)&nbsp;business days after having been sent by priority or certified mail, return receipt requested,
postage prepaid; (iii)&nbsp;upon delivery by fax with written facsimile confirmation and electronically by email with written delivery
receipt; or (iv)&nbsp;one (1)&nbsp;business day after deposit with a commercial overnight carrier, with written verification of receipt.
Such notices shall be in writing and delivered to the address set forth below or to such other notice address as the other Party has provided
by written notice:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt"><I>If to Former Employer:</I></FONT></TD>
    <TD STYLE="width: 53%"><FONT STYLE="font-size: 10pt"><I>If to Former Employee:</I></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">180 Life Sciences Corp.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Jonathan Rothbard</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3000 El Camino Real, Bldg. 4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">_____________________</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Suite 200</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">_____________________</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Palo Alto, CA 94306</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Email: [_______________]</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Email: _____________________</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Separation and Release Agreement<BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> of 10</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">22.&nbsp;<U>Waiver</U>. The
waiver by a Party of a breach of any provision herein shall not operate or be construed as a waiver of any subsequent breach by the other
Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">23.&nbsp;<U>Severability</U>.
The provisions of this Agreement and Release are severable. Should any provision herein be declared invalid by a court of competent jurisdiction,
the remainder of this Agreement and Release will continue in force, and the Parties agree to renegotiate the invalidated provision in
good faith to accomplish its objective to the extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">24.&nbsp;<U>No Benefit for
Others</U>. The Parties acknowledge that Rothbard&rsquo;s right to the Severance Pay described herein shall be determined exclusively
under the provisions stated herein, and this Agreement and Release is not intended to, and does not, create rights for the benefit of
any other employee or person except in connection with the rights of the Released Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">25.&nbsp;<U>No Wrongful Conduct</U>.
Rothbard represents, warrants and covenants to each of the Released Parties that at no time prior to or contemporaneous with its execution
of this Agreement and Release has he (i)&nbsp;knowingly engaged in any wrongful conduct against, on behalf of or as the representative
or agent of 180 Life; (ii)&nbsp;breached any provision of the Employment Agreement; or (iii)&nbsp;violated any state, federal, local or
other law, including any securities laws or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">26.&nbsp;<U>No Assignment
or Transfer</U>. Rothbard warrants and represents that Rothbard has not heretofore assigned or transferred to any person not a party to
this Agreement and Release any released matter or any part or portion thereof and he shall defend, indemnify and hold 180 Life and each
Released Party harmless from and against any claim (including the payment of attorneys&rsquo; fees and costs actually incurred whether
or not litigation is commenced)&nbsp;based on or in connection with or arising out of any such assignment or transfer made, purported
or claimed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">27.&nbsp;<U>Not Assignable</U>.
This Agreement and Release is personal to Rothbard and shall not, without the prior written consent of 180 Life, be assignable by Rothbard.
This Agreement and Release shall inure to the benefit of and be binding upon 180 Life and its respective successors and assigns and any
such successor or assignee shall be deemed substituted for 180 Life under the terms of this Agreement and Release for all purposes. As
used herein, &ldquo;<B><U>successor</U></B>&rdquo; and &ldquo;<B><U>assignee</U></B>&rdquo; shall include any person, firm, corporation
or other business entity which at any time, whether by purchase, merger, acquisition of assets, or otherwise, directly or indirectly acquires
the ownership of 180 Life, acquires all or substantially all of 180 Life&rsquo;s assets, or to which 180 Life assigns this Agreement and
Release by operation of law or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">28.&nbsp;<U>Forfeiture of
Severance Payment</U>. Rothbard agrees that he will forfeit (and be forced to return)&nbsp;the Severance Payment payable by 180 Life pursuant
to this Agreement and Release&nbsp;if Rothbard challenges the validity of this Agreement and Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Separation and Release Agreement<BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> of 10</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.&nbsp;<U>Counterparts</U>.
This Agreement and Release may be signed in counterparts, and each counterpart shall be considered an original agreement for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">30.&nbsp;<U>Clawback</U>.
Rothbard agrees that, notwithstanding any other provisions in this Agreement to the contrary, any incentive-based compensation paid to
Rothbard under the Employment Agreement or any other agreement or arrangement with 180 Life which is subject to recovery under any law,
government regulation, or stock exchange listing requirement is be subject to such deductions and clawback pursuant to applicable law
and 180 Life&rsquo;s Policy for the Recovery of Erroneously Awarded Incentive-Based Compensation, as may be amended or modified from time
to time. With respect to any potential clawback or recovery effected or subject to a determination by the Board of Directors (the &ldquo;<B><U>Board</U></B>&rdquo;),
the Board will make its determination for clawback or recovery in good faith, upon advice of counsel, and in accordance with any applicable
law or regulation, and to the extent permitted by law, only after (i)&nbsp;providing Rothbard prior written notice of the deliberation
of such potential clawback or recovery and (ii)&nbsp;providing Rothbard (and his counsel)&nbsp;an opportunity to present to the Board
all relevant information related to such determination.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">31.&nbsp;<U>Section 409A</U>.
It is intended that this Agreement comply with, or be exempt from, Internal Revenue Code Section 409A and the final regulations and official
guidance thereunder (&ldquo;<B><U>Section 409A</U></B>&rdquo;)&nbsp;and any ambiguities and ambiguous terms herein will be interpreted
to so comply and/or be exempt from Section 409A. Each payment and benefit to be paid or provided under this Agreement (including without
limitation any Severance Payment)&nbsp;is intended to constitute a series of separate payments for purposes of Section 1.409A-2(b)(2)&nbsp;of
the Treasury Regulations. Rothbard acknowledges that if any provision of this Agreement (or of any award of compensation or benefits)&nbsp;would
cause Rothbard to incur any additional tax or interest under Section 409A and accompanying Treasury regulations and other authoritative
guidance, such additional tax and interest shall solely be his responsibility. 180 Life and Rothbard will work together in good faith
to consider either (i)&nbsp;amendments to this Agreement; or (ii)&nbsp;revisions to this Agreement with respect to the payment of any
awards, which are necessary or appropriate to avoid imposition of any additional tax or income recognition prior to the actual payment
to Rothbard under Section 409A. In no event will the Released Parties have any obligation, liability or responsibility to reimburse, indemnify
or hold harmless Rothbard for any taxes imposed, or other costs incurred, as a result of Section 409A. The Separation Date is intended
to constitute Rothbard&rsquo;s &ldquo;separation from service&rdquo; within the meaning of Section 409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Remainder of page left intentionally blank. Signature
page follows.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Separation and Release Agreement<BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> of 10</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
the Parties have hereunto set their hands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>Jonathan Rothbard</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>180 Life Sciences Corp.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="width: 37%; border-bottom: black 1.5pt solid">/s/ Jonathan Rothbard</TD>
    <TD STYLE="width: 5%; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="width: 41%; border-bottom: black 1.5pt solid">/s/ Ozan Pamir </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Jonathan Rothbard</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-size: 10pt">Printed Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid">Ozan Pamir </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid">CFO</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">5/7/2024</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">5/7/2024</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Date</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Date</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Separation and Release Agreement</P>

<P STYLE="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt">Page 10 of 10</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>ea020558901ex10-3_180lifesci.htm
<DESCRIPTION>CONSULTING AGREEMENT DATED MAY 7, 2024, BY AND BETWEEN 180 LIFE SCIENCES CORP. AND DR. JONATHAN ROTHBARD
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.3</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSULTING AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THIS CONSULTING AGREEMENT</B>
(this &ldquo;<B><U>Agreement</U></B>&rdquo;)&nbsp;is made this 7th day of May 2024 (the &ldquo;<B><U>Effective Date</U></B>&rdquo;),
by and between 180 Life Sciences Corp., a Delaware corporation (the &ldquo;<B><U>Company</U></B>&rdquo;), and Jonathan Rothbard, an individual
(the &ldquo;<B><U>Consultant</U></B>&rdquo;)&nbsp;(each of the Company and Consultant is referred to herein as a &ldquo;<B><U>Party</U></B>&rdquo;,
and collectively referred to herein as the &ldquo;<B><U>Parties</U></B>&rdquo;).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">W I T N E S S E T H:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Company
desires to obtain the services of Consultant, and Consultant desires to provide consulting services to the Company upon the terms and
conditions hereinafter set forth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in
consideration of the premises, the agreements herein contained and other good and valuable consideration, receipt and sufficiency of which
is hereby acknowledged, the Parties hereto agree as of the Effective Date as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>CERTAIN TERMS USED BELOW
ARE DEFINED IN ARTICLE VII.</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
I.</FONT><BR>
ENGAGEMENT; TERM; SERVICES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.1. </FONT><U>Services</U>.
Pursuant to the terms and conditions hereinafter set forth, the Company hereby engages Consultant, and Consultant hereby accepts such
engagement, to provide services to the Company reasonably requested by the Company during the Term of this Agreement (collectively, the
&ldquo;<B><U>Services</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.2. </FONT><U>Term</U>.
Consultant shall begin providing Services hereunder on the Effective Date, and this Agreement shall remain in effect until the earlier
of (a) six months, or (b) terminated as provided in <B>ARTICLE </B>IV, below (the &ldquo;<B><U>Term</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.3. </FONT><U>Allocation
of Time and Energies</U>. The Consultant hereby promises to perform and discharge faithfully the Services which may be requested from
the Consultant from time to time by the Company and duly authorized representatives of the Company. The Consultant shall provide the Services
required hereunder in a diligent and professional manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.4. </FONT><U>Compliance
with Applicable Laws</U>. All services provided by the Consultant hereunder shall be in full compliance with all applicable laws and regulations.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
II.</FONT><BR>
CONSIDERATION; EXPENSES; INDEPENDENT CONTRACTOR; TAXES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.1. </FONT><U>Consideration</U>.
During the Term of this Agreement, for all Services rendered by Consultant hereunder and all covenants and conditions undertaken by the
Parties pursuant to this Agreement, the Company shall pay, and Consultant shall accept, as compensation, a fee of $150 per hour (the &ldquo;<B><U>Consulting
Fees</U></B>&rdquo;). Consultant shall provide the Company, on a monthly basis, documentation of all hours spent providing Services for
the Company during such calendar month, along with the date such Services were provided, the hours per day spent on Services, and a summary
of the work accomplished in connection with such Services (collectively, the &ldquo;<B><U>Billables</U></B>&rdquo;). The Company shall
pay the Consultant the Consulting Fees relating to the Billables within 10 business days of receipt of the Billables.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.2. </FONT><U>Expenses</U>.
The Company agrees to reimburse Consultant for his reasonable, documented out-of-pocket expenses associated with the Services (the &ldquo;<B><U>Expenses</U></B>&rdquo;),
subject to the Company&rsquo;s normal and usual reimbursement policies of its employees and consultants, provided that the Consultant
shall receive written authorization of any one-time Expense greater than $500 not included in a pre-approved budget for any study relating
to the Services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.3. </FONT><U>Independent
Contractor</U>. It is the express intention of the Company and Consultant that Consultant perform the Services as an independent contractor
to the Company. Nothing in this Agreement shall in any way be construed to constitute Consultant as an agent or employee of the Company.
Without limiting the generality of the foregoing, Consultant is not authorized to bind the Company to any liability or obligation or to
represent that Consultant has any such authority in connection with the Services. Consultant acknowledges and agrees that Consultant is
obligated to report as income all compensation received by Consultant pursuant to this Agreement. Consultant agrees to and acknowledges
the obligation to pay all self-employment and other taxes on such income. The Company and Consultant agree that Consultant will receive
no Company-sponsored benefits from the Company pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.4. </FONT><U>Taxes</U>.
The Company makes no representations or warranties with respect to the tax consequences of the payments and any other consideration provided
to Consultant under the terms of this Agreement. Consultant agrees and understands that it is responsible for payment, if any, of local,
state, and/or federal taxes on the payments and any other consideration provided hereunder by the Company and any penalties or assessments
thereon. Consultant agrees to indemnify and hold harmless the Company and its affiliates and their directors, officers and employees from
and against all taxes, losses, damages, liabilities, costs and expenses, including attorneys&rsquo; fees and other legal expenses, arising
from or in connection with (i)&nbsp;any obligation imposed on the Company to pay withholding taxes or similar items, or (ii)&nbsp;any
determination by a court or agency that the Consultant is not an independent contractor pursuant to this Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
III.</FONT><BR>
TERMINATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1. </FONT><U>Termination</U>.
This obligations under this Agreement shall begin on the Effective Date and continue to bind the Parties until the earlier of (a)&nbsp;the
end of the Term; (b) thirty (30)&nbsp;days after written notice to terminate this Agreement is provided by either the Company or the Consultant,
to the other Party hereto; and (c)&nbsp;the date this Agreement is mutually terminated by the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.2. </FONT><U>Rights
Upon Termination</U>. Upon termination of the Term, the Consultant shall be paid any and all Consulting Fees accrued and due through the
Termination Date, which shall represent the sole compensation and fees due to Consultant. The Consultant shall also continue to comply
with the terms of <B>ARTICLE V</B> hereof following the Termination Date.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Consulting Agreement</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 9</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
IV.</FONT><BR>
CONFIDENTIAL/TRADE SECRET INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AND RESTRICTIVE COVENANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.1.
</FONT><U>Confidential/Trade Secret Information</U>.<FONT STYLE="font-size: 10pt">&nbsp;</FONT>During the course of Consultant&rsquo;s
Services, Consultant will have access to Confidential/Trade Secret Information of the Company and information developed for the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.2.
</FONT><U>Non-Solicitation During the Term</U>.<FONT STYLE="font-size: 10pt">&nbsp;</FONT>During the Term and for twelve months after
the Termination Date, Consultant shall not: (a) interfere with the Company&rsquo;s business relationship with its customers or suppliers,
(b) solicit, directly or indirectly, or otherwise encourage any of the Company&rsquo;s customers or suppliers to terminate their business
relationship with the Company, or (c) solicit, directly or indirectly, or otherwise encourage any employees of the Company to leave the
employ of the Company, or solicit any of the Company&rsquo;s employees for employment outside the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Restriction on Use of
Confidential/Trade Secret Information</U>.<FONT STYLE="font-size: 10pt"> </FONT>Consultant agrees that his use of Confidential/Trade
Secret Information is subject to the following restrictions for an indefinite period of time so long as the Confidential/Trade
Secret Information does not become generally known to the public:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i) </FONT><FONT STYLE="font-size: 10pt"><U>Non-Disclosure</U>.
Consultant agrees that he will not publish or disclose, or allow to be published or disclosed, Confidential/Trade Secret Information to
any person without the prior written authorization of the Company unless pursuant to or in connection with Consultant&rsquo;s job duties
to the Company under this Agreement or as otherwise allowed pursuant to the terms of this Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii) </FONT>
<FONT STYLE="font-size: 10pt"><U>Surrender</U>. Consultant agrees that he shall surrender to the Company and/or destroy all documents
and materials in his possession or control which contain Confidential/Trade Secret Information and which are the property of the Company
upon the termination of his Services with the Company, and that he shall not thereafter retain any copies of any such materials except
as needed in any legal action to enforce the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.3. </FONT><U>Company
Property</U>. Upon termination of this Agreement, or on demand by the Company during the Term of this Agreement, Consultant will immediately
deliver to the Company, and will not keep in his possession, recreate or deliver to anyone else, any and all Company property, records,
data, notes, notebooks, reports, files, proposals, lists, correspondence, specifications, drawings blueprints, sketches, materials, photographs,
charts, all documents and property, and reproductions of any of the aforementioned items that were developed by Consultant pursuant to
the terms of this Agreement, obtained by Consultant in connection with the provision of the Services, or otherwise belonging to the Company
or its successors or assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.4.
</FONT><U>Prohibition Against Unfair Competition/Non-Solicitation of Customers</U>.<FONT STYLE="font-size: 10pt">&nbsp;</FONT>4.4.1 Consultant
agrees that at no time after the Termination Date will he engage in competition with the Company while making any use of the Confidential/Trade
Secret Information, or otherwise exploit or make use of the Confidential/Trade Secret Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.5.
</FONT><U>Third Party Information</U>.&nbsp;A. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consultant acknowledges
that the Company may have received and in the future may receive from third parties associated with the Company (including, but not limited
to, the Company&rsquo;s customers, suppliers, licensors, licensees, partners, or collaborators (&ldquo;<B><U>Associated Third Parties</U></B>&rdquo;))
confidential or proprietary information (&ldquo;<B><U>Associated Third Party Confidential Information</U></B>&rdquo;). By way of example,
Associated Third Party Confidential Information may include the habits or practices, technology, or requirements of Associated Third
Parties, or other information related to the business conducted between the Company and Associated Third Parties. Consultant agrees that
Associated Third Party Confidential Information is Confidential/Trade Secret Information, and at all times during the Term of this Agreement
and thereafter, Consultant agrees to hold in the strictest confidence, and not to use or to disclose to any Person any Associated Third-Party
Confidential Information, except as necessary in carrying out his work for the Company consistent with the Company&rsquo;s agreement
with such Associated Third Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Consulting Agreement</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 9</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.6.
</FONT><U>Reasonable Restrictions</U>.<FONT STYLE="font-size: 10pt">&nbsp;</FONT>The Parties acknowledge that the foregoing restrictions,
as well as the duration and the territorial scope thereof as set forth in this <B>ARTICLE V</B> are under all of the circumstances reasonable
and necessary for the protection of the Company and its business and are (i) reasonable given Consultant&rsquo;s role with the Company,
and are necessary to protect the interests of the Company and (ii) completely severable and independent agreements supported by good
and valuable consideration and, as such, shall survive the termination of this Agreement for any reason whatsoever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.7.
</FONT><U>Specific Performance</U>.<FONT STYLE="font-size: 10pt">&nbsp;</FONT>Consultant acknowledges and agrees that the Company&rsquo;s
remedies at law for a breach or threatened breach of any of the provisions of this <B>ARTICLE V</B> would be inadequate and, in recognition
of this fact, Consultant agrees that, in the event of such a breach or threatened breach, in addition to any remedies at law, the Company,
without posting any bond, shall be entitled to obtain equitable relief in the form of specific performance, temporary restraining order,
temporary or permanent injunction or any other equitable remedy which may then be available. Consultant further agrees that the restricted
period set forth in this <B>ARTICLE V</B> shall be tolled, and shall not run, during the period of any breach by Consultant of any of
the covenants contained this <B>ARTICLE V</B>. Finally, no other violation of law attributed to the Company, or change in the nature
or scope of Consultant&rsquo;s services or other relationship with the Company, shall operate to excuse Consultant from the performance
of his obligations under this <B>ARTICLE V</B>. The remedies under this Agreement are without prejudice to the Company&rsquo;s right
to seek any other remedy to which it may be entitled at law or in equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.8.
</FONT><U>Response to Legal Process; Allowable Disclosures</U>.<FONT STYLE="font-size: 10pt">&nbsp;</FONT>Notwithstanding any other term
of this Agreement (including this <B>ARTICLE V</B>), including any exhibit hereto, (a) the Consultant may respond to a lawful and valid
subpoena or other legal process relating to the Company or its business or operations; provided that the Consultant shall: (i) give the
Company the earliest possible notice thereof; (ii) as far in advance of the return date as possible, at the Company&rsquo;s sole cost
and expense, make available to the Company and its counsel the documents and other information sought; and (iii) at the Company&rsquo;s
sole cost and expense, assist such counsel in resisting or otherwise responding to such process, and (b) the Consultant&rsquo;s reporting
of possible violations of federal law or regulation to any governmental agency or entity in accordance with the provisions of and rules
promulgated under Section 21F of the Exchange Act, or any other whistleblower protection provisions of state or federal law or regulation
shall not violate or constitute a breach of this Agreement. Nothing contained in this Agreement (or any exhibit hereto) shall be construed
to prevent the Consultant from reporting any act or failure to act to the Securities and Exchange Commission or other governmental body
or prevent the Consultant from obtaining a fee as a &ldquo;<B><U>whistleblower</U></B>&rdquo; under Rule 21F-17(a) under the Exchange
Act or other rules or regulations implemented under the Dodd-Frank Wall Street Reform Act and Consumer Protection Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Consulting Agreement</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 9</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE V.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"><B>MUTUAL REPRESENTATIONS,
COVENANTS AND </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"><B>WARRANTIES OF
THE PARTIES; LIMITATION OF LIABILITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.1. </FONT><U>Power
and Authority</U>. The Parties have all requisite power and authority, corporate or otherwise, to execute and deliver this Agreement and
to consummate the transactions contemplated hereby and thereby. The Parties have duly and validly executed and delivered this Agreement
and will, on or prior to the consummation of the transactions contemplated herein, execute, such other documents as may be required hereunder
and, assuming the due authorization, execution and delivery of this Agreement by the Parties hereto and thereto, this Agreement constitutes,
the legal, valid and binding obligation of the Parties enforceable against each Party in accordance with its terms, except as such enforcement
may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the Parties rights generally
and general equitable principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.2. </FONT><U>Execution
and Delivery</U>. The execution and delivery by the Parties of this Agreement and the consummation of the transactions contemplated hereby
and thereby do not and shall not, by the lapse of time, the giving of notice or otherwise: (a)&nbsp;constitute a violation of any law;
or (b)&nbsp;constitute a breach or violation of any provision contained in the Certificate of Incorporation or Bylaws, or such other document(s)&nbsp;regarding
organization and/or management of the Parties, if applicable; or (c)&nbsp;constitute a breach of any provision contained in, or a default
under, any governmental approval, any writ, injunction, order, judgment or decree of any governmental authority or any contract to which
the Parties are bound or affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.3. </FONT><U>Authority
of Entities</U>. Any individual executing this Agreement on behalf of an entity has authority to act on behalf of such entity and has
been duly and properly authorized to sign this Agreement on behalf of such entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.4. </FONT><U>Limitation
of Liability</U>. In no event will either Party be liable to the other Party for any claim or cause of action requesting or claiming any
incidental, consequential, special, indirect, statutory, punitive or reliance damages. Any claim or cause of action requesting or claiming
such damages is specifically waived and barred, whether such damages were foreseeable or not or a Party was notified in advance of the
possibility of such damages. Damages prohibited under this Agreement will include, without limitation, damage or loss of property or equipment,
loss of profits, revenues or savings, cost of capital, cost of replacement services, opportunity costs and cover damages.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
VI.</FONT><BR>
DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.1. </FONT><U>Definitions</U>.
Unless otherwise required by the context in which a defined term appears, or otherwise set forth, the following terms shall have the meanings
specified in this <B>ARTICLE VII</B>. Terms that are defined in other Certificate shall have the meanings given to them in those Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.1.1 </FONT>&ldquo;<B><U>Confidential/Trade
Secret Information</U></B>&rdquo; is information that is not generally known to the public and, as a result, is of economic benefit to
the Company in the conduct of its business, and the business of the Company&rsquo;s subsidiaries, which includes, but is not limited to,
all proprietary information developed or obtained by the Company, including its affiliates, and predecessors, and comprising the following
items, whether or not such items have been reduced to tangible form (e.g., physical writing, computer hard drive, disk, tape, e-mail,
etc.): all methods, techniques, processes, ideas, research and development, product designs, engineering designs, plans, models, production
plans, business plans, add-on features, trade names, service marks, slogans, forms, pricing structures, business forms, marketing programs
and plans, layouts and designs, financial structures, operational methods and tactics, cost information, the identity of and/or contractual
arrangements with customers, partners, suppliers and/or vendors, accounting procedures, and any document, record or other information
of the Company relating to the above. Confidential/Trade Secret Information includes not only information directly belonging to the Company
which existed before the date of this Agreement, but also information developed by Consultant for the Company, including its Subsidiaries,
affiliates and predecessors, during the Term. Confidential/Trade Secret Information does not include any information which (a) was in
the lawful and unrestricted possession of Consultant prior to its disclosure to Consultant by the Company, its subsidiaries, affiliates
or predecessors, (b) is or becomes generally available to the public by lawful acts other than those of Consultant after receiving it,
or (c) has been received lawfully and in good faith by Consultant from a third party who is not and has never been an executive of the
Company, its subsidiaries, affiliates or predecessors, and who did not derive it from the Company, its subsidiaries, affiliates or predecessors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Consulting Agreement</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 9</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.1.2 </FONT>&ldquo;<B><U>Person</U></B>&rdquo;
(when capitalized) means any individual, corporation, partnership, joint venture, limited liability company, trust, unincorporated organization
or governmental entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.1.3 </FONT>&ldquo;<B><U>Subsidiary</U></B>&rdquo;
or &ldquo;<B><U>Subsidiaries</U></B>&rdquo; means any or all Persons of which the Company owns directly or indirectly through another
Person, a nominee arrangement or otherwise (a) at least a 20% of the outstanding capital stock (or other shares of beneficial interest)
entitled to vote generally or otherwise have the power to elect a majority of the board of directors or similar governing body or the
legal power to direct the business or policies of such Person or (b) at least 20% of the economic interests of such Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.1.4 </FONT>&ldquo;<B><U>Termination
Date</U></B>&rdquo; shall mean the date on which this Agreement is validly terminated as provided herein.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
VII.</FONT><BR>
MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.1. </FONT><U>Notices</U>.
All notices, approvals, consents, requests, and other communications hereunder shall be in writing and shall be delivered (i)&nbsp;by
personal delivery, or (ii)&nbsp;by national overnight courier service, or (iii)&nbsp;by certified or registered mail, return receipt requested,
or (iv)&nbsp;via facsimile transmission, with confirmed receipt or (v)&nbsp;via email. Notice shall be effective upon receipt except for
notice via fax (as discussed above)&nbsp;or email, which shall be effective only when the recipient, by return or reply email or notice
delivered by other method provided for in this <U>Section 8.1</U>, acknowledges having received that email (with an automatic &ldquo;<B><U>read
receipt</U></B>&rdquo; or similar notice not constituting an acknowledgement of an email receipt for purposes of this <U>Section 8.1</U>,
or which such recipient &lsquo;replies&rsquo; to such prior email). Such notices shall be sent to the applicable party or parties at the
address specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><U>If to the Company</U>:</FONT></TD>
    <TD STYLE="width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">180 Life Sciences Corp.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Attn: [__________________]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Email: [__________________]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt"><U>If to the Consultant:</U></FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Jonathan Rothbard</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Email: [__________________]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Consulting Agreement</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> of 9</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.2. </FONT><U>Binding
Effect; Assignment</U>. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal representatives,
heirs, successors and assigns. Consultant may not assign any of its rights or obligations under this Agreement. The Company may assign
its rights and obligations under this Agreement to any successor entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.3. </FONT><U>Severability</U>.
If any provision of this Agreement, or portion thereof, shall be held invalid or unenforceable by a court of competent jurisdiction, such
invalidity or unenforceability shall attach only to such provision or portion thereof, and shall not in any manner affect or render invalid
or unenforceable any other provision of this Agreement or portion thereof, and this Agreement shall be carried out as if any such invalid
or unenforceable provision or portion thereof were not contained herein. In addition, any such invalid or unenforceable provision or portion
thereof shall be deemed, without further action on the part of the Parties hereto, modified, amended or limited to the extent necessary
to render the same valid and enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.4. </FONT><U>Waiver</U>.
No waiver by a Party of a breach or default hereunder by the other Party shall be considered valid, unless expressed in a writing signed
by such first Party, and no such waiver shall be deemed a waiver of any subsequent breach or default of the same or any other nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.5. </FONT><U>Entire
Agreement</U>. This Agreement sets forth the entire agreement between the Parties with respect to the subject matter hereof, and supersedes
any and all prior agreements between the Company and Consultant, whether written or oral, relating to any or all matters covered by and
contained or otherwise dealt with in this Agreement. This Agreement does not constitute a commitment of the Company with regard to Consultant&rsquo;s
engagement, express or implied, other than to the extent expressly provided for herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.6. </FONT><U>Amendment</U>.
No modification, change or amendment of this Agreement or any of its provisions shall be valid, unless in a writing signed by the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.7. </FONT><U>Captions</U>.
The captions, headings and titles of the sections of this Agreement are inserted merely for convenience and ease of reference and shall
not affect or modify the meaning of any of the terms, covenants or conditions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.8. </FONT><U>Governing
Law</U>. This Agreement, and all of the rights and obligations of the Parties in connection with the relationship established hereby,
shall be governed by and construed in accordance with the substantive laws of the State of Delaware without giving effect to principles
relating to conflicts of law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.9. </FONT><U>Survival</U>.
The termination of Consultant&rsquo;s engagement with the Company pursuant to the provisions of this Agreement shall not affect Consultant&rsquo;s
obligations to the Company hereunder which by the nature thereof are intended to survive any such termination, including, without limitation,
Consultant&rsquo;s obligations under <B>ARTICLE V</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Consulting Agreement</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> of 9</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.10. </FONT><U>No
Presumption from Drafting</U>. This Agreement has been negotiated at arm&rsquo;s-length between persons knowledgeable in the matters set
forth within this Agreement. Accordingly, given that all Parties have had the opportunity to draft, review and/or edit the language of
this Agreement, no presumption for or against any Party arising out of drafting all or any part of this Agreement will be applied in any
action relating to, connected with or involving this Agreement. In particular, any rule of law, legal decisions, or common law principles
of similar effect that would require interpretation of any ambiguities in this Agreement against the Party that has drafted it, is of
no application and is hereby expressly waived. The provisions of this Agreement shall be interpreted in a reasonable manner to affect
the intentions of the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.11. </FONT><U>Review
and Construction of Documents</U>. Each Party herein expressly represents and warrants to all other Parties hereto that (a)&nbsp;before
executing this Agreement, said Party has fully informed itself of the terms, contents, conditions and effects of this Agreement; (b)&nbsp;said
Party has relied solely and completely upon its own judgment in executing this Agreement; (c)&nbsp;said Party has had the opportunity
to seek and has obtained the advice of its own legal, tax and business advisors before executing this Agreement; (d)&nbsp;said Party has
acted voluntarily and of its own free will in executing this Agreement; and (e)&nbsp;this Agreement is the result of arm&rsquo;s length
negotiations conducted by and among the Parties and their respective counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.12. </FONT><U>Interpretation</U>.
When used in this Agreement, unless a contrary intention appears: (i)&nbsp;a term has the meaning assigned to it; (ii)&nbsp;&ldquo;<B><U>or</U></B>&rdquo;
is not exclusive; (iii)&nbsp;&ldquo;<B><U>including</U></B>&rdquo; means including without limitation; (iv) words used herein regardless
of the number and gender specifically used, shall be deemed and construed to include any other number, singular or plural, and any other
gender, masculine, feminine or neuter, as the context requires; (v) any agreement, instrument or statute defined or referred to herein
or in any instrument or certificate delivered in connection herewith means such agreement, instrument or statute as from time to time
amended, modified or supplemented and includes (in the case of agreements or instruments)&nbsp;references to all attachments thereto and
instruments incorporated therein; (vi)&nbsp;the words &ldquo;<B><U>hereof</U></B>&rdquo;, &ldquo;<B><U>herein</U></B>&rdquo; and &ldquo;<B><U>hereunder</U></B>&rdquo;
and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision hereof;
(vii)&nbsp;references contained herein to Article, Section, Schedule and Exhibit, as applicable, are references to Articles, Sections,
Schedules and Exhibits in this Agreement unless otherwise specified; and (viii)&nbsp;references to &ldquo;<B><U>writing</U></B>&rdquo;
include printing, typing, lithography and other means of reproducing words in a visible form, including, but not limited to email.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.13. </FONT><U>Electronic
Signatures and Counterparts</U>. This Agreement and any signed agreement or instrument entered into in connection with this Agreement,
and any amendments hereto or thereto, may be executed in one or more counterparts, all of which shall constitute one and the same instrument.
Any such counterpart, to the extent delivered by means of a facsimile machine or by .pdf, .tif, .gif, .jpeg or similar attachment to electronic
mail (any such delivery, an &ldquo;<B><U>Electronic Delivery</U></B>&rdquo;)&nbsp;shall be treated in all manner and respects as an original
executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered
in person. At the request of any Party, each other Party shall re execute the original form of this Agreement and deliver such form to
all other Parties. No Party shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement
or instrument was transmitted or communicated through the use of Electronic Delivery as a defense to the formation of a contract, and
each such Party forever waives any such defense, except to the extent such defense relates to lack of authenticity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">[Remainder of page left intentionally
blank. Signature page follows.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Consulting Agreement</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> of 9</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the Parties hereto have
executed this Agreement as of the day and year first above written, to be effective as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-size: 10pt">&ldquo;<B><U>COMPANY</U></B>&rdquo;</FONT></TD>
  <TD COLSPAN="2"><B>180 Life Sciences Corp.</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>By:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Ozan Pamir</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 60%">&nbsp;</TD>
  <TD STYLE="width: 4%">Its:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">CFO</TD>
  </TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 60%">&nbsp;</TD>
  <TD STYLE="width: 12%">Printed&nbsp;Name:&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 28%">Ozan Pamir</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 60%"><FONT STYLE="font-size: 10pt">&ldquo;<B><U>CONSULTANT</U></B>&rdquo;</FONT></TD>
  <TD STYLE="width: 40%">&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Jonathan Rothbard</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Jonathan Rothbard</TD></TR>
</TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Consulting Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page 9 of 9</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>ea020558901ex10-4_180lifesci.htm
<DESCRIPTION>FOURTH AMENDMENT TO CONSULTING AGREEMENT DATED MAY 7, 2024, BY AND BETWEEN 180 LIFE SCIENCES CORP. AND DR. LAWRENCE STEINMAN
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.4</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: center">FOURTH AMENDMENT TO CONSULTING AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5pt; text-align: justify; text-indent: 35.95pt">This Fourth
Amendment to Consulting Agreement (&ldquo;<U>Amendment</U>&rdquo;), dated and effective as of the date of the last signature set forth
below (the &ldquo;<U>Effective Date</U>&rdquo;), is entered into by and between 180 Life Sciences Corp., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
and Lawrence Steinman (&ldquo;<U>Consultant</U>&rdquo;) (collectively, the Company and Consultant are the &ldquo;<U>Parties</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 5pt; text-align: justify; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5pt; text-align: justify; text-indent: 35.95pt"><B>WHEREAS,</B>
the Company and Consultant have entered into a Consulting Agreement, dated November 17, 2021, and effective November 1, 2021 (the &ldquo;<U>Initial
Agreement</U>&rdquo;), concerning the engagement of Consultant as Co-Chairman of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5pt; text-align: justify; text-indent: 35.95pt"><B>WHEREAS,</B>
the Company and Consultant have entered into a First Amendment to Consulting Agreement, dated April 27, 2022 (the &ldquo;<U>First Amendment</U>&rdquo;)
a Second Amendment to Consulting Agreement, dated May 26, 2022 (the &ldquo;<U>Second Amendment</U>&rdquo;), and a Third Amendment to Consulting
Agreement dated January 10, 2024 (the &ldquo;<U>Third Amendment</U>&rdquo;, and the Initial Agreement as amended by the First Amendment,
Second Amendment and Third Amendment, the &ldquo;<U>Agreement</U>&rdquo;), concerning the engagement of Consultant as Co-Chairman of the
Company (currently Executive Chairman of the Company);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5pt; text-align: justify; text-indent: 35.95pt"><B>WHEREAS</B>,
certain capitalized terms used below have the meanings given to such terms in the Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.3pt 0pt 5pt; text-align: justify; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5pt; text-align: justify; text-indent: 35.95pt"><B>WHEREAS</B>,
the parties wish to amend the Agreement to revise certain terms of the Agreement as set forth herein in order to reduce Company costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5pt; text-align: justify; text-indent: 35.95pt"><B>NOW, THEREFORE</B>,
in consideration of the mutual covenants and agreements hereinafter set forth, the receipt and sufficiency of which is hereby acknowledged
and confirmed, the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 5pt; text-align: justify; text-indent: 35.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>1.</B></TD><TD STYLE="text-align: justify; padding-right: 0pt">Effective as of the Effective Date, the Consultant agrees to waive and forgive
all unpaid and/or accrued amounts owed or due under the Agreement through the Effective Date (including, but not limited to the Accrued
Amount as defined in the Third Amendment)(collectively, the &ldquo;<U>Unpaid and Accrued Amounts</U>&rdquo;), and agrees that the total
compensation payable to the Consultant under the Agreement moving forward during the remaining Term of the Agreement shall be $0; provided
that as long as Consultant remains a member of the Board of Directors of the Company the Consultant shall receive the same compensation
payable to other non-executive members of the Board of Directors.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>2.</B></TD><TD STYLE="text-align: justify; padding-right: 0pt">For the sake of clarity all Unpaid and Accrued Amounts are forgiven in their entirety
by the Consultant as of the Effective Date, and Consultant hereby releases and forgives any obligation of the Company to pay the same.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>3.</B></TD><TD STYLE="text-align: justify; padding-right: 0pt">Effective on the Effective Date, <U>Section 3(a)</U> of the Agreement shall be
deemed amended and replaced in its entirety by &ldquo;[Removed]&rdquo;.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05pt 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> of 3</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05pt; text-align: center">Fourth Amendment to Consulting Agreement<BR> [Steinman and 180]</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05pt 0pt 0; text-align: center"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>4.</B></TD><TD STYLE="text-align: justify">Effective as of the Effective Date, all references in the Agreement to &ldquo;<U>Executive
Co-Chairman</U>&rdquo; and/or &ldquo;<U>Co-Chairman</U>&rdquo;, shall be amended to refer to &ldquo;<U>Director</U>&rdquo;, and Consultant
agrees that subsequent to the Effective Date, he shall only serve as a member of the Board of Directors and not as an Executive Co-Chairman
or Executive Chairman of the Company. Concurrently with his entry into this Agreement, Consultant shall be deemed to have resigned as
Executive Chairman of the Company (but not as a member of the Board of Directors) of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.35pt"></TD><TD STYLE="width: 35.3pt"><B>5.</B></TD><TD STYLE="text-align: justify">In consideration for Consultant entering into this Agreement and agreeing to the
terms hereof, Consultant shall, as a regular member of the Board of Directors of the Company, be paid such fees as regular members of
the Board of Directors receive for their services on the Board, pro-rated as of the Effective Date, the sufficiency of which consideration
is agreed to and acknowledged by the Consultant.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.4pt"></TD><TD STYLE="width: 35.25pt"><B>6.</B></TD><TD STYLE="text-align: justify">Except to the extent modified hereby, the Agreement shall remain in full force and effect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.35pt"></TD><TD STYLE="width: 35.3pt"><B>7.</B></TD><TD STYLE="text-align: justify">This Amendment shall be binding upon and inure to the benefit of the parties and
their successors and assigns.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.35pt"></TD><TD STYLE="width: 35.3pt"><B>8.</B></TD><TD STYLE="text-align: justify">This Amendment and any signed agreement or instrument entered into in connection
with this Amendment, and any amendments hereto or thereto, may be executed in one or more counterparts, all of which shall constitute
one and the same instrument. Any such counterpart, to the extent delivered by means of a facsimile machine or by .pdf, .tif, .gif, .jpeg
or similar attachment to electronic mail (any such delivery, an &ldquo;<U>Electronic Delivery</U>&rdquo;) shall be treated in all manner
and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original
signed version thereof delivered in person.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-indent: 35.95pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-indent: 35.95pt"><B></B></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05pt 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 3</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05pt; text-align: center">Fourth Amendment to Consulting Agreement<BR> [Steinman and 180]</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05pt 0pt 0; text-align: center"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-indent: 35.95pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-indent: 35.95pt"><B>IN WITNESS WHEREOF</B>, the parties
have caused the Amendment to be executed as of the date and year below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">The &ldquo;<U>Company</U>&rdquo;</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><B>180 Life Sciences Corp.</B></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 5%">Date:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">5/7/2024</TD>
  <TD STYLE="width: 20%">&nbsp;</TD>
  <TD STYLE="width: 4%">By:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/ Ozan Pamir</TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>Its:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">CFO</TD>
    </TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 60%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printed&nbsp;Name:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font-size: 10pt; width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ozan Pamir:</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">The &ldquo;<U>Consultant</U>&rdquo;</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 5%">Date:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">5/6/2024</TD>
  <TD STYLE="width: 20%">&nbsp;</TD>
  <TD STYLE="width: 4%">By:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/ Lawrence Steinman</TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>Lawrence Steinman</TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05pt 0pt 0; text-align: center">Page 3 of 3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05pt; text-align: center">Fourth Amendment to Consulting Agreement<BR>
 [Steinman
and 180]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>6
<FILENAME>ea020558901ex10-5_180lifesci.htm
<DESCRIPTION>EXECUTIVE CONSULTING AGREEMENT DATED MAY 7, 2024, BY AND BETWEEN 180 LIFE SCIENCES CORP. , BLAIR JORDAN AND BLAIR JORDAN STRATEGY AND FINANCE CONSULTING INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.5</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXECUTIVE CONSULTING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">made this 7th day of May 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMONG</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>180 LIFE SCIENCES CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BLAIR JORDAN STRATEGY AND FINANCE CONSULTING
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BLAIR JORDAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
  <TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; padding-top: 0in; padding-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal; text-transform: capitalize"><U STYLE="text-decoration: none">P</U></FONT><U STYLE="text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal; text-transform: lowercase">age</FONT></U></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in">Part 1 INTERPRETATION</TD>
    <TD STYLE="width: 10%; text-align: center; padding-top: 0in; padding-bottom: 0in">2</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Interpretation</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">2</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Engagement</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">2</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Term</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">3</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Title</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">3</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Responsibilities</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">3</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">General Responsibilities</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">3</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in">Part 2 COMPENSATION</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">4</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Fees</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">4</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Incentive Bonus</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">4</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Vesting of Options and RSUs</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">4</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Expenses and Fees</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">5</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Independent Contractor</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">5</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in">Part 3 THE CONSULTANT&rsquo;s and THE CEO&rsquo;s ADDITIONAL COVENANTS and representations</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">5</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Confidential Information</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">5</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">No Disclosure</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">6</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">No Competition &amp; Notice of Conflict</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">7</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Company&rsquo;s Proprietary Rights</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">7</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Special Remedies</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">8</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">The Consultant&rsquo;s Representations</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">8</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in">Part 4 TERMINATION</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">9</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Termination</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">9</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Payment of Amounts Due</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">9</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Termination for Just Cause and Other Events of Early Termination</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">9</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Effect on Termination under Section 4.5</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">10</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Effect on Benefits</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">10</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Return of Property</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">10</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Resignation of Director and Officer</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">10</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in">Part 5 RESOLUTION OF DISPUTES</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">11</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Mediation</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">11</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in">Part 6 GENERAL</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">11</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Further Assurances</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">11</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Assignment</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">12</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Severability</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">12</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Waiver and Consent</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">12</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Notice</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">12</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Binding Effect</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">13</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Governing Law</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">13</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Time of Essence</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">13</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Counterparts</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">13</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Entire Agreement</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">13</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: small-caps 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 12pt">Survival of Terms</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 0in">13</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXECUTIVE CONSULTING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THIS AGREEMENT</B> is dated for reference and
made effective the [__] day of May 2024 (the &ldquo;Effective Date&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AMONG:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><B>180 LIFE SCIENCES CORP.,</B> a corporation
duly incorporated under the laws of Delaware, having a place of business at 3000 El Camino Real, Bldg. 4, Suite 200 Palo Alto, CA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in">(the &ldquo;Company&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">OF THE FIRST PART</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AND:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>BLAIR
JORDAN STRATEGY AND FINANCE CONSULTING INC., </B></FONT>a corporation duly incorporated under the laws of British Columbia, having offices
at 1864 Duchess Avenue, West Vancouver, B.C., Canada, V7V 1R1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in">(the &ldquo;Consultant&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">OF THE SECOND PART</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>BLAIR
JORDAN</B></FONT>, an individual residing at 1864 Duchess Avenue, West Vancouver, B.C., Canada V7V 1R1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(the &ldquo;CEO&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: right">OF THE THIRD PART</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>WHEREAS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(A) the
Company is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases,
fibrosis and pain;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(B) the
Consultant is wholly-owned and controlled by the CEO;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(C) the
Company and the Consultant have mutually agreed to evidence the terms of the engagement of the services of the Consultant by the Company
by this Agreement which is to supersede all prior discussions and negotiation between the parties, whether written or oral; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(D) the
Consultant will direct the CEO to provide the services of Chief Executive Officer to the Company (on an interim basis) throughout the
term in order to fulfil its obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>WITNESSETH</B> that the parties mutually agree as follows:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Part
1<BR></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">INTERPRETATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Interpretation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">1.1 For
all purposes of this Agreement, except as otherwise expressly provided or unless the context otherwise requires,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a) this
&ldquo;Agreement&rdquo; means this executive consulting agreement as may from time to time be supplemented or amended by one or more agreements
entered into pursuant to the applicable provisions hereof,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b) &ldquo;Parties&rdquo;
means the Company, the Consultant and the CEO,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c) the
words &ldquo;herein&rdquo;, &ldquo;hereof&rdquo; and &ldquo;hereunder&rdquo; or similar terms refer to this Agreement as a whole and not
to any particular paragraph, subparagraph or other subdivision of this Agreement,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d) all
dollar amounts in this Agreement are expressed in American dollars,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(e) a
reference to an entity includes any entity that is a successor to such entity,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(f) the
headings of this Agreement are for convenience only and are not intended as a guide to interpretation of this Agreement or any portion
hereof,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(g) a
reference to a statute includes all regulations made pursuant thereto, all amendments to the statute or regulations in force from time
to time, and any statute or regulation which supplements or supersedes such statute or regulations, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(h) the
&ldquo;Board&rdquo; means the board of directors of the Company as from time to time constituted.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Engagement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">1.2 The
Company hereby engages the Consultant and the Consultant hereby agrees to provide consulting services to the Company upon and subject
to the terms and conditions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">1.3 Concurrently
with the Consultant&rsquo;s performance of the Services, the Company acknowledges that the CEO may have other business involvements, business
interests and sources of business income, including from parties with which the Company may or may not have a relationship. The CEO is
permitted to undertake such activities and retain all compensation received from these activities provided that such activities do not
prevent, inhibit or impair the Consultant and the CEO from meeting their obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">1.4 The
Consultant and the CEO hereby promises to perform and discharge faithfully the services which may be requested from the Consultant and
CEO from time to time by the Company and duly authorized representatives of the Company, including the Board of Directors (the &ldquo;Services&rdquo;).
The Consultant and CEO shall provide the Services required hereunder in a diligent and professional manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">1.5 All
services provided by the Consultant and CEO hereunder shall be in full compliance with all applicable laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">1.6 At
all times that the Company is subject to reporting obligations with the Securities and Exchange Commission (&ldquo;SEC&rdquo;), (a) CEO
shall use his best efforts to maintain the Company&rsquo;s compliance with all rules and regulations of the SEC and reporting requirements
for publicly traded companies under the Securities Exchange Act of 1934, as amended; and (b) CEO shall comply, and cause the Company to
comply, with the then-current good corporate governance standards and practices as prescribed by the SEC, any exchange on which the Company&rsquo;s
capital stock or other securities may be traded and any other applicable governmental entity, agency or organization.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Term</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">1.7 This
Agreement will come into effect on May __, 2024. This Agreement and the Services will continue until April 30, 2025, unless otherwise
terminated pursuant to the terms under Part 4 (the &ldquo;Term&rdquo;).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">1.8 The
CEO will act under the title of &ldquo;Interim Chief Executive Officer&rdquo; of the Company, or such other titles or position as advised
by the Board, and will report to the Board. The CEO will receive all remuneration and other benefits of such offices only through the
Consultant.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Responsibilities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">1.9 The
CEO&rsquo;s responsibilities will be those typically handled by the Chief Executive Officer of a public reporting company of similar size,
and in a similar situation to the Company.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">General Responsibilities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">1.10 During
the term of this Agreement, the CEO will</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a) diligently
perform the Services arising under this Agreement to the best of his skill and ability, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b) attend
to duties at the specific times and days as reasonably directed by the Company, excepting holidays (which will be a maximum of 20 days
on an annualized basis), absence due to sickness and other authorized absences as set out in this Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Part
2<BR>
<BR>
COMPENSATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fees</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.1 The
Company will pay the Consultant an annual consulting fee of $216,000, to be paid in twelve, equal monthly installments, with each installment
payable monthly in arrears, in respect of the Services (the &ldquo;Fee&rdquo;). No deductions from source will be made on account of income
taxes or employment insurance. All payments made pursuant to this Agreement will be made to the Consultant.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Incentive Bonus</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.2 The
Company will pay the Consultant an incentive bonus of $250,000 in recognition of the CEO&rsquo;s performance under this Agreement under
certain circumstances, as discussed below (the &ldquo;Incentive Bonus&rdquo;). The Incentive Bonus will be subject to the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">i.</TD><TD STYLE="text-align: justify">the Incentive Bonus will be payable by the Company to the Consultant upon the completion of any corporate
transaction by the Company, which occurs during the Term, including but not limited to any merger, reverse merger, acquisition, disposal,
joint-venture and/or investment involving the Company, which results in a Change of Control of the Company (each a &ldquo;Corporate Transaction&rdquo;).
For the purpose of this Agreement &ldquo;Change of Control&rdquo; means any Corporate Transaction pursuant to which the ownership of an
aggregate of 50.1% or more of the outstanding shares of the Company is held by one or more parties after completing the Corporate Transaction.
For greater certainty, the parties to this Agreement acknowledge that a Corporate Transaction may involve one or more entities, acting
separately or in concert.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.3 Subsequent
bonus payments from the Company to the Consultant under this Agreement, if any, will be based on criteria to be determined by the Compensation
Committee of the Board and communicated to the Consultant and the CEO.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vesting of Options and RSUs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.4 Any
grants of Options or RSUs will be subject to vesting terms as determined by the Board at time of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.5 In
the case of a Change of Control (as defined in Section 2.2(i)), prior to the termination of this Agreement, all Options and RSUs then
outstanding will immediately vest for the purpose of such transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.6 The
Options and RSUs will be issued subject to applicable securities laws and may be subject to hold periods and vesting, subject to Section
2.5 hereof.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Expenses and Fees</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.7 The
Company will promptly reimburse any reasonable out-of-pocket expenses of the Consultant or the CEO upon presentation of appropriate vouchers
and invoices, including but not limited to travel, lodging and business entertainment expenses, pursuant to the Company&rsquo;s reimbursement
policies in effect from time to time.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Independent Contractor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.8 The
Consultant&rsquo;s relationship with the Company shall be that of an independent contractor and not that of an employee. Accordingly,
the Consultant, as well as the CEO, will not be eligible for any employee benefits, other than as specifically provided for herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.9 It
is the express intention of the Company and Consultant and CEO that Consultant perform the Services as an independent contractor to the
Company. Nothing in this Agreement shall in any way be construed to constitute Consultant or CEO as an agent or employee of the Company.
Consultant and CEO acknowledge and agree that Consultant and CEO are obligated to report as income all compensation received by Consultant
and CEO pursuant to this Agreement. Consultant and CEO agree to and acknowledges the obligation to pay all self-employment and other taxes
on such income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.10 The
Company makes no representations or warranties with respect to the tax consequences of the payments and any other consideration provided
to Consultant under the terms of this Agreement. Consultant agrees and understands that it is responsible for payment, if any, of local,
state, and/or federal taxes on the payments and any other consideration provided hereunder by the Company and any penalties or assessments
thereon. Consultant agrees to indemnify and hold harmless the Company and its affiliates and their directors, officers and employees from
and against all taxes, losses, damages, liabilities, costs and expenses, including attorneys&rsquo; fees and other legal expenses, arising
from or in connection with (i) any obligation imposed on the Company to pay withholding taxes or similar items, or (ii) any determination
by a court or agency that the Consultant is not an independent contractor pursuant to this Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Part
3<BR>
<BR>
THE CONSULTANT&rsquo;s and THE CEO&rsquo;s ADDITIONAL COVENANTS and representations</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Confidential Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">3.1 The
Consultant and the CEO acknowledge that in the course of performing the Services the Consultant and the CEO will have access to and be
entrusted with confidential information and trade secrets of the Company (collectively the &ldquo;Confidential Information&rdquo;) relating
to the business affairs, customers, suppliers, technology, proprietary rights, patents, research, plans, research data, marketing techniques,
manufacturing methods, procedures and techniques, industrial designs, inventions, improvements, discoveries and routines concerning the
Company, its business and those of its affiliates and of its customers and their particular business requirements, and that the disclosure
of any of such Confidential Information to competitors of the Company or the general public may be highly detrimental to the interests
of the Company or its affiliates, as the case may be, and the Consultant and the CEO each agree to maintain the utmost confidentiality
respecting the Confidential Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Consultant and the CEO further acknowledge
that in the course of performing the Services they might, from time to time, be a representative of the Company in negotiations and discussions
with other parties and as such will be significantly responsible for maintaining or enhancing the goodwill of the Company and its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Consultant and the CEO further acknowledge
that the right to maintain the confidentiality of the Confidential Information and the right to preserve the Company&rsquo;s goodwill
are proprietary rights which the Company is entitled to protect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Consultant and CEO agree that it/he
shall surrender to the Company and/or destroy all documents and materials in its/his possession or control which contain Confidential
Information and which are the property of the Company upon the termination of this Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">No Disclosure</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">3.2 The
Consultant and the CEO will not, during the term of this Agreement or at any time thereafter, disclose any of the Confidential Information
to any person, nor will the Consultant and the CEO use the Confidential Information for any purpose other than to complete the Services,
nor will either disclose or use for any purpose other than in the best interests of the Company or its affiliates the private affairs
of the Company or its affiliates or any other confidential or proprietary information which it might acquire during the course of performing
the Services, except:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">(a) with
the prior written authorization of the Board,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">(b) as
required to carry out the purposes of this Agreement,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">(c) as
otherwise permitted under this Agreement, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d) where
the Confidential Information is in or comes into the public domain through no act or omission of the Consultant and/or the CEO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">3.3 Notwithstanding
any other term of this Agreement (including this Part 3, (a) the Consultant and CEO may respond to a lawful and valid subpoena or other
legal process relating to the Company or its business or operations; provided that the Consultant and/or CEO shall: (i) give the Company
the earliest possible notice thereof; (ii) as far in advance of the return date as possible, at the Company&rsquo;s sole cost and expense,
make available to the Company and its counsel the documents and other information sought; and (iii) at the Company&rsquo;s sole cost and
expense, assist such counsel in resisting or otherwise responding to such process, and (b) the Consultant&rsquo;s and CEO&rsquo;s reporting
of possible violations of federal law or regulation to any governmental agency or entity in accordance with the provisions of and rules
promulgated under Section 21F of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or any other whistleblower
protection provisions of state or federal law or regulation shall not violate or constitute a breach of this Agreement. Nothing contained
in this Agreement (or any exhibit hereto) shall be construed to prevent the Consultant or CEO from reporting any act or failure to act
to the Securities and Exchange Commission or other governmental body or prevent the Consultant from obtaining a fee as a &ldquo;whistleblower&rdquo;
under Rule 21F-17(a) under the Exchange Act or other rules or regulations implemented under the Dodd-Frank Wall Street Reform Act and
Consumer Protection Act.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">No Competition &amp; Notice of Conflict</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">3.4 Consultant
and CEO certify that neither have any outstanding agreement or obligation that conflicts with any of the provisions of this Agreement
or that would preclude Consultant and CEO from complying with the provisions of this Agreement. Consultant and CEO further certifies that
Consultant and CEO will not enter into any such conflicting agreement during the Term of this Agreement. Prompt disclosure is required
by Consultant and CEO if they undertake any activity which may conflict with any of the provisions of this Agreement, the Services, or
be adverse to the Company&rsquo;s interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">3.5 If
the Board, acting reasonably, determines that the Consultant or the CEO is engaging in an activity which it deems to be a conflicting
activity, then the Company will so advise the Consultant or the CEO, as applicable, in writing and the Consultant or the CEO, as applicable,
will, as soon as possible in order to minimize any injury to the Company and in any event no longer than 10 days, or such longer period
as the Company and the Consultant or the CEO may agree upon, after receipt of notice,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">(a) discontinue
the activity, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b) certify
in writing to the Company that it has discontinued the conflicting activity including where appropriate by sale or other disposition or
by transfer of all such interests, except a beneficial interest, into a &ldquo;blind trust&rdquo; or other fiduciary arrangement over
which the Consultant and/or the CEO has no control, direction or discretion; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">advise the Company that it disputes
the conflict and the matter will be referred to mediation or arbitration as set out under Part 5.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Company&rsquo;s Proprietary Rights</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">3.6 Notwithstanding
anything else in this Agreement, it is expressly acknowledged and understood by the Consultant and the CEO that all of the work product
of the Consultant and the CEO while performing the Services pursuant to the terms hereof will belong to the Company absolutely, and notwithstanding
the generality of the foregoing, all patents, inventions, improvements, notes, documents, correspondence, produced by the Consultant and
the CEO while performing the Services will be the exclusive property of the Company. The Consultant and the CEO further agree to execute
without delay or further consideration any patent assignments, conveyances, other documents and assurances as may be necessary to effect
this provision.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Special Remedies</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">3.7 The
Consultant and the CEO acknowledge his obligations under this Part 3 are of a special character and that in the event of any conduct by
the Consultant and the CEO in violation of this Agreement or any of these obligations, the Company may sustain irreparable injury for
which monetary damages will not provide an adequate remedy. Accordingly, the Consultant and the CEO agree that in addition to other remedies
and damages available to the Company at law or otherwise and if the Company so elects, the Company is entitled:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a) to
institute and prosecute proceedings either at law or in equity in any court of competent jurisdiction, against the Consultant and/or the
CEO: (i) to obtain damages for the conduct, (ii) to enforce specific performance, (iii) to enjoin the Consultant, the CEO, any principal,
partner, agent, servant, employer and employee of the Consultant, and any other person acting for, on behalf of or in conjunction with
the Consultant from the conduct, or (iv) to obtain any other relief or any combination of the foregoing which the Company may elect to
pursue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">3.8 If
any restriction as to time, area, capacity or activity imposed on the Consultant and the CEO by this Agreement is finally determined by
a Court of competent jurisdiction to be unenforceable (the &ldquo;Offending Restriction&rdquo;), the Consultant and the CEO agree that
upon written notice from the Company specifying for inclusion in this Agreement a lesser time or area, fewer capacities or an activity
of lesser scope than now contained in this Agreement (the &ldquo;Lesser Restriction&rdquo;), this Agreement will be deemed to be amended
by the substitution of the Lesser Restriction for the Offending Restriction insofar as is lawfully enforceable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Consultant&rsquo;s Representations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">3.9 The
Consultant and the CEO hereby confirm to the Company that the information about the Consultant and the CEO contained in the written resum&eacute;
previously provided to the Company is materially accurate and omits nothing which would render any information contained therein misleading.
The Consultant and the CEO consent to the Company making such background checks about the Consultant and the CEO as it deems necessary.
The Consultant and the CEO further represent that this Agreement does not conflict with any agreement, arrangement or other legal obligation
to any previous employer or other person to which any duty or obligation is owed.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Part
4<BR>
<BR>
TERMINATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Termination</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">4.1 Prior
to the end of the Term, subject to Section 4.2 and Section 4.3, this Agreement may be terminated on the effective termination date as
set out in any agreement between the Company and the Consultant and the CEO for voluntary termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">4.2 If
the Company completes a Corporate Transaction and pays the Incentive Bonus and any other amounts owing to the Consultant as of the date
of the completion of the Corporate Transaction, then this Agreement shall be deemed terminated at the closing of such Corporate Transaction,
unless extended by the Parties in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">4.3 The
Company shall have the right to terminate this Agreement at any time, provided that if the Company terminates by way of notice prior to
completion of a Corporate Transaction:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a) then
the Company will pay to the Consultant $75,000, as long as Consultant has served a minimum of sixty days, which the Consultant will accept
as full compensation for the termination and neither the Consultant nor the CEO need perform the Services during the notice period.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payment of Amounts Due</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">4.4 Any
amount due to Consultant hereunder under Section 4.2 or 4.3, shall be paid to Consultant within 60 days of the date of termination of
this Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Termination for Just Cause and Other Events of Early Termination</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">4.5 Despite
any other term of this Agreement to the contrary, this Agreement may be terminated by the Company without notice upon:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a) the
death or physical or mental incapacity of the CEO and as a result of which the CEO is unable to perform the Services for a period in excess
of 60 days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b) in
the event the CEO or a related party to the CEO ceases to own or control 100% of the shares of the Consultant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c) the
receipt by the Consultant and the CEO of written notice from the Board terminating this Agreement for just cause where &ldquo;just cause&rdquo;
means any of the following events:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">any material or persistent
breach by the Consultant or the CEO of the terms of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">the conviction of the
Consultant or the CEO of a felony offence, or the equivalent in a non-American jurisdiction, or of any crime involving moral turpitude,
fraud or misrepresentation, or misappropriation of money or property of the Company or any affiliate of the Company,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">a wilful failure or
refusal by the Consultant or the CEO to satisfy its respective obligations to the Company under this Agreement including without limitation,
specific lawful directives, reasonably consistent with this Agreement, or requests of the Board,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">any negligent or wilful
conduct or omissions of the Consultant or the CEO that directly results in substantial loss or injury to the Company,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">fraud or embezzlement
of funds or property, or misappropriation involving the Company&rsquo;s assets, business, customers, suppliers, or employees,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">any failure
to comply with any of the Company&rsquo;s written policies and procedures, including, but not limited to, the Company&rsquo;s Corporate
Code of Ethics and Insider Trading Policy,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">however, no termination
is deemed to be for just cause under this Agreement, except for termination for a conviction under the second subsection of Section 4.5(c),
or an act constituting just cause which has already occurred and which is ascertained to have caused the Company a financial loss or
loss of goodwill, unless the Board first gives written notice to the Consultant and the CEO, as applicable, advising of the acts or omissions
that constitute failure or refusal to perform its obligations and that failure or refusal continues after the Consultant and the CEO,
as applicable, has had thirty (30) days to correct the acts or omissions as set out in the notice.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effect on Termination under Section 4.5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">4.6 If
the Company terminates this Agreement pursuant to Section 4.5, then the Consultant is not entitled to receive and the Company will not
pay any fee, damages or other sums as a consequence of the termination (including, but not limited to any fees due pursuant to Section
2.2 or 4.3(a), except for fees and unpaid and reimbursable expenses accrued but unpaid prior to the effective termination date and the
Consultant will cause the CEO to resign from any office with the Company or an affiliate which the Company cannot by itself lawfully terminate.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effect on Benefits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">4.7 Upon
termination of this Agreement under this Part 4, the Consultant&rsquo;s vested rights and coverage, if any, and subject to the provisions
of general application, under the Company&rsquo;s group insurance will not be diminished, cancelled or prejudiced in any way by reason
thereof prior to the expiry of the relevant notice period.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Return of Property</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">4.8 On
the effective termination date, the Consultant and the CEO will deliver to the Company, in a reasonable state of repair, all property
including without limitation, all copies, extracts and summaries, whether in written, digital, magnetic or electronic form, of documents
and information of the Company in the possession or under the control or direction of the Consultant and the CEO as at the termination
date.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Resignation of Director and Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">4.9 Upon
termination hereof the CEO will immediately resign as an officer and, if applicable, director of the Company and of any subsidiaries or
affiliates, and of any other entity where he has been appointed or nominated by the Company or the Consultant.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Part
5<BR>
<BR>
RESOLUTION OF DISPUTES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mediation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">5.1 The
parties will, in good faith, use their best efforts to resolve any dispute arising under or in connection with this Agreement among themselves.
If the parties are unable to resolve such a dispute, then before recourse to arbitration, except for a matter that would justify the granting
of a preliminary injunction, the parties will jointly refer the matter to a mutually acceptable third party (&ldquo;Mediator&rdquo;) to
mediate the matter in dispute between the parties upon the following terms and otherwise upon terms in accordance with rules or procedures
and evidence then acceptable to the parties (the &ldquo;Mediation&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">(a) the
decision of the Mediator will not be binding upon the parties;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b) the
Mediation will be confidential and without prejudice to the respective rights of the parties in dispute;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c) regardless
of the outcome of the Mediation, no party will be obligated to pay more than its own cost of participation in the Mediation and one-half
of the costs of the Mediator; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d) at
any time after the appointment of the Mediator a party may, either in conjunction with or in the place of the Mediation, pursue all remedies
otherwise available to the party in law or in equity under this Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Part
6<BR>
<BR>
GENERAL</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Further Assurances</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.1 Each
party will, at its own expense and without expense to any other party, execute and deliver the further agreements and other documents
and do the further acts and things as the other party reasonably requests to evidence, carry out or give full force and effect to the
intent of this Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Assignment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.2 Neither
party may assign any right, benefit or interest in this Agreement without the prior written consent of the other party. Any purported
assignment without such consent will be void.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Severability</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.3 If
any one or more of the provisions contained in this Agreement or the application of any of them to a person or circumstance is held by
a court to be illegal, invalid or unenforceable in respect of any jurisdiction, then to the extent so held, it is separate and severable
from this Agreement but the validity, legality and enforceability of the provision will not in any way be affected or impaired in any
other jurisdiction and the remainder of this Agreement or the application of the provision to persons or circumstances other than those
to which it is held to be invalid, illegal or unenforceable is not affected unless the severing has the effect of materially changing
the economic benefit of this Agreement to the Consultant and the CEO or the Company.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Waiver and Consent</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.4 No
provision of this Agreement may be modified, waived or discharged unless the modification, waiver or discharge is agreed to in writing
and signed by the Consultant, the CEO and on behalf of the Company by an officer specifically designated by the Board. No waiver by a
party at any time or any breach by the other party of a term of this Agreement or of performance of an obligation to be performed by the
other party under this Agreement is deemed to be a waiver of similar or dissimilar terms or obligations at the same, any prior or subsequent
time.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Notice</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.5 A
notice, demand, request, statement or other evidence required or permitted to be given under this Agreement (a &ldquo;notice&rdquo;) must
be written. It will be sufficiently given if delivered to the address of a party set out on Page 1 and if</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a) delivered
in person to the Consultant or the CEO either by certified mail or courier so that a delivery receipt is obtained, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b) delivered
to the Company or the Board, as the case may be, either by certified mail or courier so that a delivery receipt is obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At any time, a party may give notice to the other
party of a change of address and after the giving of the notice, the address specified in the notice will be considered to be the address
of the party for the purpose of this paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any notice delivered or sent in accordance with
this paragraph will be deemed to have been given and received</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(a) if delivered,
then on the day of delivery,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b) if
mailed, on the earlier of the day of receipt and the 7th business day after the day of mailing, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(c) if
sent by telex, telegram, facsimile, email, on the first business day following the transmittal date; however,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(d) if
a notice is sent by mail and mail service is interrupted between the point of mailing and the destination by strike, slowdown, force majeure
or other cause within three (3) days before or after the time of mailing, the notice will not be deemed to be received until actually
received, and the party sending the notice will use any other service which has not been so interrupted or will deliver the notice in
order to ensure prompt receipt.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Binding Effect</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.6 This
Agreement will enure to the benefit of and be binding upon the parties hereto and their successors. This Agreement is non-assignable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Governing Law</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.7 This
Agreement will be interpreted under and is governed by the laws of the State of Delaware and the federal laws of the United States as
applicable and, except for matters which cannot properly or lawfully be resolved by mediation pursuant to Section 5.1, the courts of the
State of Delaware will have exclusive jurisdiction to entertain any action arising under this Agreement and the parties hereby attorn
to the jurisdiction of those courts.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Time of Essence</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.8 Time
is of the essence in the performance of each obligation under this Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Counterparts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.9 This
Agreement and any other written agreement delivered pursuant to this Agreement may be executed in any number of counterparts with the
same effect as if all parties to this Agreement or such other written agreement had signed the same document and all counterparts will
be construed together and will constitute one and the same instrument.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Entire Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.10 This
Agreement constitutes the entire agreement between the parties in respect of the Services and supersedes and replaces all prior negotiations,
written or oral understandings or agreements made between the parties.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Survival of Terms</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.11 The
provisions of Sections 2.2, 2.7, 3.1, 3.2, 3.3, 3.6, 3.7, 3.8, 4.4, 4.8, 4.9, 5.1, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, and 6.10 and
this Section 6.11, will survive the termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IN WITNESS WHEREOF</B> the parties hereto have
executed this Agreement effective as of the day and year first above-written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>180 LIFE SCIENCES CORP.</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/ Ozan Pamir</TD>
    <TD STYLE="text-align: center; width: 4%">)</TD>
    <TD STYLE="width: 56%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Signatory</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: center">)</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: center">)</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: center">)</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: center">)</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BLAIR JORDAN STRATEGY AND</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FINANCING CONSULTING INC.</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/ Blair Jordan</TD>
    <TD STYLE="text-align: center; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 56%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: center">)</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: center">)</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: center">)</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: center">)</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BLAIR JORDAN</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/ Blair Jordan</TD>
    <TD STYLE="text-align: center; width: 4%">&nbsp;</TD>
    <TD STYLE="width: 56%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: center">)</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: center">)</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: center">)</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- 14 -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>7
<FILENAME>ea020558901ex10-6_180lifesci.htm
<DESCRIPTION>FORM OF 180 LIFE SCIENCES CORP. INDEMNITY AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>FORM OF INDEMNITY AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THIS INDEMNITY AGREEMENT&nbsp;</B>(this
&ldquo;<B><I>Agreement</I></B>&rdquo;) is made as of _________, 2024, by and between 180 LIFE SCIENCES CORP., a Delaware corporation (the
&ldquo;<B><I>Company</I></B>&rdquo;), and ___________ (&ldquo;<B><I>Indemnitee</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>RECITALS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, highly competent
persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities unless they are provided
with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising
out of their service to and activities on behalf of such corporations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Board
of Directors of the Company (the &ldquo;<B><I>Board</I></B>&rdquo;) has determined that, in order to attract and retain qualified individuals,
the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company
and its subsidiaries from certain liabilities. Although the furnishing of such insurance has been a customary and widespread practice
among publicly traded corporations and other business enterprises, the Company believes that, given current market conditions and trends,
such insurance may be available to it in the future only at higher premiums and with more exclusions. At the same time, directors, officers
and other persons in service to corporations or business enterprises are being increasingly subjected to expensive and time-consuming
litigation relating to, among other things, matters that traditionally would have been brought only against the Company or business enterprise
itself. The Second Amended and Restated Certificate of Incorporation (the &ldquo;<B><I>Charter</I></B>&rdquo;) and Bylaws of the Company
require indemnification of the officers and directors of the Company. Indemnitee may also be entitled to indemnification pursuant to applicable
provisions of the Delaware General Corporation Law (&ldquo;<B><I>DGCL</I></B>&rdquo;). The Charter, Bylaws and the DGCL expressly provide
that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered into between
the Company and members of the board of directors, officers and other persons with respect to indemnification, hold harmless, exoneration,
advancement and reimbursement rights;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the uncertainties
relating to such insurance and to indemnification have increased the difficulty of attracting and retaining such persons;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Board
has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Company&rsquo;s
stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, it is reasonable,
prudent and necessary for the Company contractually to obligate itself to indemnify, hold harmless, exonerate and to advance expenses
on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company
free from undue concern that they will not be so protected against liabilities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, this Agreement
is a supplement to and in furtherance of the Charter and Bylaws of the Company and any resolutions adopted pursuant thereto, and shall
not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, Indemnitee
may not be willing to serve as an officer or director, advisor or in another capacity without adequate protection, and the Company desires
Indemnitee to serve in such capacity. Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf
of the Company on the condition that he be so indemnified; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in
consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>TERMS AND CONDITIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1. SERVICES
TO THE COMPANY</B>. Indemnitee will serve or continue to serve as an officer, director, advisor, key employee or in any other capacity
of the Company, as applicable, for so long as Indemnitee is duly elected, appointed or retained or until Indemnitee tenders his resignation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2. DEFINITIONS</B>.
As used in this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 0.5in">2.1. References
to &ldquo;<B><I>agent</I></B>&rdquo; shall mean any person who is or was a director, officer or employee of the Company or a subsidiary
of the Company or other person authorized by the Company to act for the Company, to include such person serving in such capacity as a
director, officer, employee, advisor, fiduciary or other official of another corporation, partnership, limited liability company, joint
venture, trust or other enterprise at the request of, for the convenience of, or to represent the interests of the Company or a subsidiary
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 0.5in">2.2. The
terms &ldquo;<B><I>Beneficial Owner</I></B>&rdquo; and &ldquo;<B><I>Beneficial Ownership</I></B>&rdquo; shall have the meanings set forth
in Rule&nbsp;13d-3 promulgated under the Exchange Act (as defined below) as in effect on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 0.5in">2.3. A &ldquo;<B><I>Change
in Control</I></B>&rdquo; shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following
events:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">2.3.1. <U>Acquisition
of Stock by Third Party</U>. Any Person (as defined below) is or becomes the Beneficial Owner, directly or indirectly, of securities of
the Company representing fifteen percent (15%) or more of the combined voting power of the Company&rsquo;s then outstanding securities
entitled to vote generally in the election of directors, unless (1)&nbsp;the change in the relative Beneficial Ownership of the Company&rsquo;s
securities by any Person results solely from a reduction in the aggregate number of outstanding shares of securities entitled to vote
generally in the election of directors, or (2)&nbsp;such acquisition was approved in advance by the Continuing Directors (as defined below)
and such acquisition would not constitute a Change in Control under part 2.3.3&nbsp;of this definition;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">2.3.2. <U>Change
in Board of Directors</U>. Individuals who, as of the date hereof, constitute the Board, and any new director whose election by the Board
or nomination for election by the Company&rsquo;s stockholders was approved by a vote of at least two thirds of the directors then still
in office who were directors on the date hereof or whose election for nomination for election was previously so approved (collectively,
the &ldquo;<B><I>Continuing Directors</I></B>&rdquo;), cease for any reason to constitute at least a majority of the members of the Board;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">2.3.3. <U>Corporate
Transactions</U>. The effective date of a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar
business combination, involving the Company and one or more businesses (a &ldquo;<B><I>Business Combination</I></B>&rdquo;), in each case,
unless, following such Business Combination: (1)&nbsp;all or substantially all of the individuals and entities who were the Beneficial
Owners of securities entitled to vote generally in the election of directors immediately prior to such Business Combination beneficially
own, directly or indirectly, more than 51% of the combined voting power of the then outstanding securities of the Company entitled to
vote generally in the election of directors resulting from such Business Combination (including, without limitation, a corporation which
as a result of such transaction owns the Company or all or substantially all of the Company&rsquo;s assets either directly or through
one or more Subsidiaries) in substantially the same proportions as their ownership immediately prior to such Business Combination, of
the securities entitled to vote generally in the election of directors; (2)&nbsp;no Person (excluding any corporation resulting from such
Business Combination) is the Beneficial Owner, directly or indirectly, of 15% or more of the combined voting power of the then outstanding
securities entitled to vote generally in the election of directors of the surviving corporation except to the extent that such ownership
existed prior to the Business Combination; and (3)&nbsp;at least a majority of the Board of Directors of the corporation resulting from
such Business Combination were Continuing Directors at the time of the execution of the initial agreement, or of the action of the Board
of Directors, providing for such Business Combination;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9pt"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">2.3.4. <U>Liquidation</U>.
The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement or series of agreements for the
sale or disposition by the Company of all or substantially all of the Company&rsquo;s assets, other than factoring the Company&rsquo;s
current receivables or escrows due (or, if such approval is not required, the decision by the Board to proceed with such a liquidation,
sale, or disposition in one transaction or a series of related transactions); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">2.3.5. <U>Other Events</U>.
There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule&nbsp;14A of Regulation&nbsp;14A
(or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act (as defined below), whether or
not the Company is then subject to such reporting requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 0.5in">2.4. &ldquo;<B><I>Corporate
Status</I></B>&rdquo; describes the status of a person who is or was a director, officer, trustee, general partner, managing member, fiduciary,
employee or agent of the Company or of any other Enterprise (as defined below) which such person is or was serving at the request of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 0.5in">2.5. &ldquo;<B><I>Delaware
Court</I></B>&rdquo; shall mean the Court of Chancery of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 0.5in">2.6. &ldquo;<B><I>Disinterested
Director</I></B>&rdquo; shall mean a director of the Company who is not and was not a party to the Proceeding (as defined below) in respect
of which indemnification is sought by Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 0.5in">2.7. &ldquo;<B><I>Enterprise</I></B>&rdquo;
shall mean the Company and any other corporation, constituent corporation (including any constituent of a constituent) absorbed in a consolidation
or merger to which the Company (or any of its wholly owned subsidiaries) is a party, limited liability company, partnership, joint venture,
trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, officer,
trustee, general partner, managing member, fiduciary, employee or agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 0.5in">2.8.
&ldquo;<B><I>Exchange Act</I></B>&rdquo; shall mean the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 0.5in">2.9. &ldquo;<B><I>Expenses</I></B>&rdquo;
shall include all direct and indirect costs, fees and expenses of any type or nature whatsoever, including, without limitation, all attorneys&rsquo;
fees and costs, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, fees of private investigators
and professional advisors, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, fax transmission
charges, secretarial services and all other disbursements, obligations or expenses in connection with prosecuting, defending, preparing
to prosecute or defend, investigating, being or preparing to be a witness in, settlement or appeal of, or otherwise participating in,
a Proceeding (as defined below), including reasonable compensation for time spent by the Indemnitee for which he or she is not otherwise
compensated by the Company or any third party. Expenses also shall include Expenses incurred in connection with any appeal resulting from
any Proceeding (as defined below), including without limitation the principal, premium, security for, and other costs relating to any
cost bond, supersedeas bond, or other appeal bond or its equivalent. Expenses, however, shall not include amounts paid in settlement by
Indemnitee or the amount of judgments or fines against Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 0.5in">2.10. &ldquo;<B><I>Independent
Counsel</I></B>&rdquo; shall mean a law firm or a member of a law firm with significant experience in matters of corporation law and neither
presently is, nor in the past five years has been, retained to represent: (i)&nbsp;the Company or Indemnitee in any matter material to
either such party (other than with respect to matters concerning the Indemnitee under this Agreement, or of other indemnitees under similar
indemnification agreements); or (ii)&nbsp;any other party to the Proceeding (as defined below) giving rise to a claim for indemnification
hereunder. Notwithstanding the foregoing, the term &ldquo;Independent Counsel&rdquo; shall not include any person who, under the applicable
standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee
in an action to determine Indemnitee&rsquo;s rights under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 0.5in">2.11. References
to &ldquo;<B><I>fines</I></B>&rdquo; shall include any excise tax assessed on Indemnitee with respect to any employee benefit plan; references
to &ldquo;serving at the request of the Company&rdquo; shall include any service as a director, officer, employee, agent or fiduciary
of the Company which imposes duties on, or involves services by, such director, officer, employee, agent or fiduciary with respect to
an employee benefit plan, its participants or beneficiaries; and if Indemnitee acted in good faith and in a manner Indemnitee reasonably
believed to be in the best interests of the participants and beneficiaries of an employee benefit plan, Indemnitee shall be deemed to
have acted in a manner &ldquo;not opposed to the best interests of the Company&rdquo; as referred to in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 0.5in">2.12. The term &ldquo;<B><I>Person</I></B>&rdquo;
shall have the meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act as in effect on the date hereof; provided, however,
that &ldquo;Person&rdquo; shall exclude: (i) the Company; (ii)&nbsp;any Subsidiaries (as defined below) of the Company; (iii)&nbsp;any
employment benefit plan of the Company or of a Subsidiary (as defined below) of the Company or of any corporation owned, directly or indirectly,
by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company; and (iv)&nbsp;any
trustee or other fiduciary holding securities under an employee benefit plan of the Company or of a Subsidiary (as defined below) of the
Company or of a corporation owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their
ownership of stock of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 0.5in">2.13. The term &ldquo;<B><I>Proceeding</I></B>&rdquo;
shall include any threatened, pending or completed action, suit, arbitration, mediation, alternate dispute resolution mechanism, investigation,
inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought in the right of the Company or
otherwise and whether of a civil (including intentional or unintentional tort claims), criminal, administrative, or investigative or related
nature, in which Indemnitee was, is, will or might be involved as a party or otherwise by reason of the fact that Indemnitee is or was
a director or officer of the Company, by reason of any action (or failure to act) taken by him or of any action (or failure to act) on
his part while acting as a director or officer of the Company, or by reason of the fact that he is or was serving at the request of the
Company as a director, officer, trustee, general partner, managing member, fiduciary, employee or agent of any other Enterprise, in each
case whether or not serving in such capacity at the time any liability or expense is incurred for which indemnification, reimbursement,
or advancement of expenses can be provided under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 0.5in">2.14. The term &ldquo;<B><I>Subsidiary</I></B>,&rdquo;
with respect to any Person, shall mean any corporation or other entity of which a majority of the voting power of the voting equity securities
or equity interest is owned, directly or indirectly, by that Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3. INDEMNITY
IN THIRD-PARTY PROCEEDINGS</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the fullest extent permitted
by applicable law, the Company shall indemnify, hold harmless and exonerate Indemnitee in accordance with the provisions of this&nbsp;<U>Section&nbsp;3</U>&nbsp;if
Indemnitee was, is, or is threatened to be made, a party to or a participant (as a witness or otherwise) in any Proceeding, other than
a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this&nbsp;<U>Section&nbsp;3</U>, Indemnitee
shall be indemnified, held harmless and exonerated against all Expenses, judgments, liabilities, fines, penalties and amounts paid in
settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments,
fines, penalties and amounts paid in settlement) actually and reasonably incurred by Indemnitee or on his behalf in connection with such
Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he reasonably believed to be in or
not opposed to the best interests of the Company and, in the case of a criminal Proceeding, had no reasonable cause to believe that his
conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4. INDEMNITY
IN PROCEEDINGS BY OR IN THE RIGHT OF THE COMPANY</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the fullest extent permitted
by applicable law, the Company shall indemnify, hold harmless and exonerate Indemnitee in accordance with the provisions of this&nbsp;<U>Section&nbsp;4</U>&nbsp;if
Indemnitee was, is, or is threatened to be made, a party to or a participant (as a witness or otherwise) in any Proceeding by or in the
right of the Company to procure a judgment in its favor. Pursuant to this&nbsp;<U>Section&nbsp;4</U>, Indemnitee shall be indemnified,
held harmless and exonerated against all Expenses actually and reasonably incurred by him or on his behalf in connection with such Proceeding
or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he reasonably believed to be in or not opposed
to the best interests of the Company. No indemnification, hold harmless or exoneration for Expenses shall be made under this&nbsp;<U>Section&nbsp;4</U>&nbsp;in
respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudged by a court to be liable to the Company,
unless and only to the extent that any court in which the Proceeding was brought or the Delaware Court shall determine upon application
that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled
to indemnification, to be held harmless or to exoneration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5. INDEMNIFICATION
FOR EXPENSES OF A PARTY WHO IS WHOLLY OR PARTLY SUCCESSFUL</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding any other
provisions of this Agreement, to the extent that Indemnitee is a party to (or a participant in) and is successful, on the merits or otherwise,
in any Proceeding or in defense of any claim, issue or matter therein, in whole or in part, the Company shall, to the fullest extent permitted
by applicable law, indemnify, hold harmless and exonerate Indemnitee against all Expenses actually and reasonably incurred by him in connection
therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more
but less than all claims, issues or matters in such Proceeding, the Company shall, to the fullest extent permitted by applicable law,
indemnify, hold harmless and exonerate Indemnitee against all Expenses actually and reasonably incurred by him or on his behalf in connection
with each successfully resolved claim, issue or matter. If the Indemnitee is not wholly successful in such Proceeding, the Company also
shall, to the fullest extent permitted by applicable law, indemnify, hold harmless and exonerate Indemnitee against all Expenses reasonably
incurred in connection with a claim, issue or matter related to any claim, issue, or matter on which the Indemnitee was successful. For
purposes of this&nbsp;<U>Section 5</U>&nbsp;and without limitation, the termination of any claim, issue or matter in such a Proceeding
by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6. INDEMNIFICATION
FOR EXPENSES OF A WITNESS</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding any other
provision of this Agreement except for , to the extent that Indemnitee is, by reason of his Corporate Status, a witness in any Proceeding
to which Indemnitee is not a party, he shall, to the fullest extent permitted by applicable law, be indemnified, held harmless and exonerated
against all Expenses actually and reasonably incurred by him or on his behalf in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7. ADDITIONAL
INDEMNIFICATION, HOLD HARMLESS AND EXONERATION RIGHTS</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding any limitation
in&nbsp;<U>Sections&nbsp;3</U>,&nbsp;<U>4</U>, or&nbsp;<U>5</U>, the Company shall, to the fullest extent permitted by applicable law,
indemnify, hold harmless and exonerate Indemnitee if Indemnitee is a party to or threatened to be made a party to any Proceeding (including
a Proceeding by or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments, fines, penalties and
amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of
such Expenses, judgments, fines, penalties and amounts paid in settlement) actually and reasonably incurred by Indemnitee in connection
with the Proceeding. No indemnification, hold harmless or exoneration rights shall be available under this&nbsp;<U>Section 7</U>&nbsp;on
account of Indemnitee&rsquo;s conduct which constitutes a breach of Indemnitee&rsquo;s duty of loyalty to the Company or its stockholders
or is an act or omission not in good faith or which involves intentional misconduct or a knowing violation of the law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8. CONTRIBUTION
IN THE EVENT OF JOINT LIABILITY</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.1. To the fullest
extent permissible under applicable law, if the indemnification, hold harmless and/or exoneration rights provided for in this Agreement
are unavailable to Indemnitee in whole or in part for any reason whatsoever, the Company, in lieu of indemnifying, holding harmless or
exonerating Indemnitee, shall pay, in the first instance, the entire amount incurred by Indemnitee, whether for judgments, liabilities,
fines, penalties, amounts paid or to be paid in settlement and/or for Expenses, in connection with any Proceeding without requiring Indemnitee
to contribute to such payment, and the Company hereby waives and relinquishes any right of contribution it may have at any time against
Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.2. The Company
shall not, without Indemnitee&rsquo;s consent, enter into any settlement of any Proceeding in which the Company is jointly liable with
Indemnitee (or would be if joined in such Proceeding) unless such settlement provides for a full and final release of all claims asserted
against Indemnitee and no admission of guilt by, or injunctive relief against, Indemnitee, is included.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.3. The Company
hereby agrees to fully indemnify, hold harmless and exonerate Indemnitee from any claims for contribution which may be brought by officers,
directors or employees of the Company other than Indemnitee who may be jointly liable with Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9. EXCLUSIONS</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding any provision
in this Agreement, the Company shall not be obligated under this Agreement to make any indemnification, hold harmless or exoneration payment
in connection with any claim made against Indemnitee: &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">for which payment has actually
been received by or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with respect to any excess
beyond the amount actually received under any insurance policy, contract, agreement, other indemnity provision or otherwise;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">for an accounting of profits
made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b)
of the Exchange Act or similar provisions of state statutory law or common law; or</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">except as otherwise provided
in&nbsp;<U>Sections&nbsp;14.5</U>&nbsp;and&nbsp;<U>14.6</U>&nbsp;hereof, prior to a Change in Control, in connection with any Proceeding
(or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee
against the Company or its directors, officers, employees or other indemnitees, unless (i)&nbsp;the Board authorized the Proceeding (or
any part of any Proceeding) prior to its initiation or (ii)&nbsp;the Company provides the indemnification, hold harmless or exoneration
payment, in its sole discretion, pursuant to the powers vested in the Company under applicable law.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10. ADVANCES
OF EXPENSES; DEFENSE OF CLAIM</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.1. Notwithstanding
any provision of this Agreement to the contrary, and to the fullest extent not prohibited by applicable law, the Company shall pay the
Expenses incurred by Indemnitee (or reasonably expected by Indemnitee to be incurred by Indemnitee within three months) in connection
with any Proceeding within ten (10)&nbsp;days after the receipt by the Company of a statement or statements requesting such advances from
time to time, prior to the final disposition of any Proceeding. Advances shall be unsecured and interest free. Advances shall be made
without regard to Indemnitee&rsquo;s ability to repay the Expenses and without regard to Indemnitee&rsquo;s ultimate entitlement to be
indemnified, held harmless or exonerated under the other provisions of this Agreement. Advances shall include any and all reasonable Expenses
incurred pursuing a Proceeding to enforce this right of advancement, including Expenses incurred preparing and forwarding statements to
the Company to support the advances claimed. If required by applicable law or the Charter or the Bylaws of the Company, such payments
of Expenses in advance of the final disposition of the Proceeding shall be made only upon the Company&rsquo;s receipt of an undertaking,
by or on behalf of the Indemnitee, to repay the advance to the extent that it is ultimately determined that Indemnitee is not entitled
to be indemnified by the Company under the provisions of this Agreement, the Charter, the Bylaws of the Company, applicable law or otherwise.
This&nbsp;<U>Section 10.1</U>&nbsp;shall not apply to any claim made by Indemnitee for which an indemnification, hold harmless or exoneration
payment is excluded pursuant to&nbsp;<U>Section&nbsp;9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.2. The
Company will be entitled to participate in the Proceeding at its own expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.3. The Company
shall not settle any action, claim or Proceeding (in whole or in part) which would impose any Expense, judgment, fine, penalty or limitation
on the Indemnitee without the Indemnitee&rsquo;s prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11. PROCEDURE FOR NOTIFICATION
AND APPLICATION FOR INDEMNIFICATION</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.1. Indemnitee
agrees to notify promptly the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information
or other document relating to any Proceeding or matter which may be subject to indemnification, hold harmless or exoneration rights, or
advancement of Expenses covered hereunder. The failure of Indemnitee to so notify the Company shall not relieve the Company of any obligation
which it may have to the Indemnitee under this Agreement, or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.2. Indemnitee
may deliver to the Company a written application to indemnify, hold harmless or exonerate Indemnitee in accordance with this Agreement.
Such application(s) may be delivered from time to time and at such time(s) as Indemnitee deems appropriate in his or her sole discretion.
Following such a written application for indemnification by Indemnitee, the Indemnitee&rsquo;s entitlement to indemnification shall be
determined according to&nbsp;<U>Section 12.1</U>&nbsp;of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12. PROCEDURE
UPON APPLICATION FOR INDEMNIFICATION</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.1. A determination,
if required by applicable law, with respect to Indemnitee&rsquo;s entitlement to indemnification shall be made in the specific case by
one of the following methods, which shall be at the election of Indemnitee: (i)&nbsp;by a majority vote of the Disinterested Directors,
even though less than a quorum of the Board; (ii)&nbsp;by Independent Counsel in a written opinion to the Board, a copy of which shall
be delivered to Indemnitee; or (iii) by vote of the stockholders. The Company promptly will advise Indemnitee in writing with respect
to any determination that Indemnitee is or is not entitled to indemnification, including a description of any reason or basis for which
indemnification has been denied. If it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be
made within ten (10)&nbsp;days after such determination. Indemnitee shall reasonably cooperate with the person, persons or entity making
such determination with respect to Indemnitee&rsquo;s entitlement to indemnification, including providing to such person, persons or entity
upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which
is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or Expenses (including attorneys&rsquo;
fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be
borne by the Company (irrespective of the determination as to Indemnitee&rsquo;s entitlement to indemnification) and the Company hereby
indemnifies and agrees to hold Indemnitee harmless therefrom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.2. In the event
the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to&nbsp;<U>Section 12.1</U>&nbsp;hereof,
the Independent Counsel shall be selected as provided in this&nbsp;<U>Section&nbsp;12.2</U>. The Independent Counsel shall be selected
by Indemnitee (unless Indemnitee shall request that such selection be made by the Board), and Indemnitee shall give written notice to
the Company advising it of the identity of the Independent Counsel so selected and certifying that the Independent Counsel so selected
meets the requirements of &ldquo;Independent Counsel&rdquo; as defined in&nbsp;<U>Section&nbsp;2</U>&nbsp;of this Agreement. If the Independent
Counsel is selected by the Board, the Company shall give written notice to Indemnitee advising him of the identity of the Independent
Counsel so selected and certifying that the Independent Counsel so selected meets the requirements of &ldquo;Independent Counsel&rdquo;
as defined in&nbsp;<U>Section&nbsp;2</U>&nbsp;of this Agreement. In either event, Indemnitee or the Company, as the case may be, may,
within ten (10)&nbsp;days after such written notice of selection shall have been received, deliver to the Company or to Indemnitee, as
the case may be, a written objection to such selection; provided, however, that such objection may be asserted only on the ground that
the Independent Counsel so selected does not meet the requirements of &ldquo;Independent Counsel&rdquo; as defined in&nbsp;<U>Section&nbsp;2</U>&nbsp;of
this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection,
the person so selected shall act as Independent Counsel. If such written objection is so made and substantiated, the Independent Counsel
so selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court of competent jurisdiction has
determined that such objection is without merit. If, within twenty (20) days after submission by Indemnitee of a written request for indemnification
pursuant to&nbsp;<U>Section 11.2</U>&nbsp;hereof, no Independent Counsel shall have been selected and not objected to, either the Company
or Indemnitee may petition the Delaware Court for resolution of any objection which shall have been made by the Company or Indemnitee
to the other&rsquo;s selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the Delaware
Court, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel
under&nbsp;<U>Section 12.1</U>&nbsp;hereof. Upon the due commencement of any judicial proceeding or arbitration pursuant to&nbsp;<U>Section
14.1</U>&nbsp;of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject
to the applicable standards of professional conduct then prevailing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">12.3. The Company agrees to pay the reasonable
fees and expenses of Independent Counsel and to fully indemnify and hold harmless such Independent Counsel against any and all Expenses,
claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>13. PRESUMPTIONS
AND EFFECT OF CERTAIN PROCEEDINGS</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.1. In making a
determination with respect to entitlement to indemnification hereunder, the person, persons or entity making such determination shall
presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification
in accordance with&nbsp;<U>Section 11.2</U>&nbsp;of this Agreement, and the Company shall have the burden of proof to overcome that presumption
in connection with the making by any person, persons or entity of any determination contrary to that presumption. Neither the failure
of the Company (including by its directors or Independent Counsel) to have made a determination prior to the commencement of any action
pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct,
nor an actual determination by the Company (including by its directors or Independent Counsel) that Indemnitee has not met such applicable
standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.2. If the person,
persons or entity empowered or selected under&nbsp;<U>Section&nbsp;12</U>&nbsp;of this Agreement to determine whether Indemnitee is entitled
to indemnification shall not have made a determination within thirty (30)&nbsp;days after receipt by the Company of the request therefor,
the requisite determination of entitlement to indemnification shall be deemed to have been made and Indemnitee shall be entitled to such
indemnification, absent (i)&nbsp;a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make
Indemnitee&rsquo;s statement not materially misleading, in connection with the request for indemnification, or (ii)&nbsp;a final judicial
determination that any or all such indemnification is expressly prohibited under applicable law; provided, however, that such 30-day period
may be extended for a reasonable time, not to exceed an additional fifteen (15)&nbsp;days, if the person, persons or entity making the
determination with respect to entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating
of documentation and/or information relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.3. The termination
of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere
or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee
to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he reasonably believed to be
in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause
to believe that his conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.4. For purposes
of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if Indemnitee&rsquo;s action is based on the
records or books of account of the Enterprise, including financial statements, or on information supplied to Indemnitee by the directors
or officers of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise, its Board, any committee
of the Board or any director, or on information or records given or reports made to the Enterprise, its Board, any committee of the Board
or any director, by an independent certified public accountant or by an appraiser or other expert selected by the Enterprise, its Board,
any committee of the Board or any director. The provisions of this&nbsp;<U>Section 13.4</U>&nbsp;shall not be deemed to be exclusive or
to limit in any way the other circumstances in which the Indemnitee may be deemed or found to have met the applicable standard of conduct
set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.5. The knowledge
and/or actions, or failure to act, of any other director, officer, trustee, partner, managing member, fiduciary, agent or employee of
the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>14. REMEDIES
OF INDEMNITEE</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.1. In the event
that (i)&nbsp;a determination is made pursuant to&nbsp;<U>Section&nbsp;12</U>&nbsp;of this Agreement that Indemnitee is not entitled to
indemnification under this Agreement, (ii)&nbsp;advancement of Expenses, to the fullest extent permitted by applicable law, is not timely
made pursuant to&nbsp;<U>Section 10</U>&nbsp;of this Agreement, (iii)&nbsp;no determination of entitlement to indemnification shall have
been made pursuant to&nbsp;<U>Section 12.1</U>&nbsp;of this Agreement within thirty (30)&nbsp;days after receipt by the Company of the
request for indemnification, (iv)&nbsp;payment of indemnification is not made pursuant to&nbsp;<U>Sections&nbsp;5</U>,&nbsp;<U>6</U>,&nbsp;<U>7</U>&nbsp;or
the last sentence of&nbsp;<U>Section 12.1</U>&nbsp;of this Agreement within ten (10)&nbsp;days after receipt by the Company of a written
request therefor, (v)&nbsp;a contribution payment is not made in a timely manner pursuant to&nbsp;<U>Section&nbsp;8</U>&nbsp;of this Agreement,
(vi)&nbsp;payment of indemnification pursuant to&nbsp;<U>Section 3</U>&nbsp;or&nbsp;<U>4</U>&nbsp;of this Agreement is not made within
ten (10)&nbsp;days after a determination has been made that Indemnitee is entitled to indemnification, or (vii)&nbsp;payment to Indemnitee
pursuant to any hold harmless or exoneration rights under this Agreement or otherwise is not made within ten (10)&nbsp;days after receipt
by the Company of a written request therefor, Indemnitee shall be entitled to an adjudication by the Delaware Court to such indemnification,
hold harmless, exoneration, contribution or advancement rights. Alternatively, Indemnitee, at his option, may seek an award in arbitration
to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. Except as
set forth herein, the provisions of Delaware law (without regard to its conflict of laws rules) shall apply to any such arbitration. The
Company shall not oppose Indemnitee&rsquo;s right to seek any such adjudication or award in arbitration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.2. In the event
that a determination shall have been made pursuant to&nbsp;<U>Section 12.1</U>&nbsp;of this Agreement that Indemnitee is not entitled
to indemnification, any judicial proceeding or arbitration commenced pursuant to this&nbsp;<U>Section&nbsp;14</U>&nbsp;shall be conducted
in all respects as a de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination.
In any judicial proceeding or arbitration commenced pursuant to this&nbsp;<U>Section&nbsp;14</U>, Indemnitee shall be presumed to be entitled
to be indemnified, held harmless, exonerated to receive advances of Expenses under this Agreement and the Company shall have the burden
of proving Indemnitee is not entitled to be indemnified, held harmless, exonerated and to receive advances of Expenses, as the case may
be, and the Company may not refer to or introduce into evidence any determination pursuant to&nbsp;<U>Section 12.1</U>&nbsp;of this Agreement
adverse to Indemnitee for any purpose. If Indemnitee commences a judicial proceeding or arbitration pursuant to this&nbsp;<U>Section&nbsp;14</U>,
Indemnitee shall not be required to reimburse the Company for any advances pursuant to&nbsp;<U>Section&nbsp;10</U>&nbsp;until a final
determination is made with respect to Indemnitee&rsquo;s entitlement to indemnification (as to which all rights of appeal have been exhausted
or lapsed).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.3. If a determination
shall have been made pursuant to&nbsp;<U>Section 12.1</U>&nbsp;of this Agreement that Indemnitee is entitled to indemnification, the Company
shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this&nbsp;<U>Section&nbsp;14</U>,
absent (i)&nbsp;a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&rsquo;s
statement not materially misleading, in connection with the request for indemnification, or (ii)&nbsp;a prohibition of such indemnification
under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.4. The Company
shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this&nbsp;<U>Section&nbsp;14</U>&nbsp;that
the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before
any such arbitrator that the Company is bound by all the provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.5. The Company
shall indemnify and hold harmless Indemnitee to the fullest extent permitted by law against all Expenses and, if requested by Indemnitee,
shall (within ten (10)&nbsp;days after the Company&rsquo;s receipt of such written request) pay to Indemnitee, to the fullest extent permitted
by applicable law, such Expenses which are incurred by Indemnitee in connection with any judicial proceeding or arbitration brought by
Indemnitee (i)&nbsp;to enforce his rights under, or to recover damages for breach of, this Agreement or any other indemnification, hold
harmless, exoneration, advancement or contribution agreement or provision of the Charter, or the Company&rsquo;s Bylaws now or hereafter
in effect; or (ii)&nbsp;for recovery or advances under any insurance policy maintained by any person for the benefit of Indemnitee, regardless
of the outcome and whether Indemnitee ultimately is determined to be entitled to such indemnification, hold harmless or exoneration right,
advancement, contribution or insurance recovery, as the case may be (unless such judicial proceeding or arbitration was not brought by
Indemnitee in good faith).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.6. Interest shall
be paid by the Company to Indemnitee at the legal rate under Delaware law for amounts which the Company indemnifies, holds harmless or
exonerates, or is obliged to indemnify, hold harmless or exonerate for the period commencing with the date on which Indemnitee requests
indemnification, to be held harmless, exonerated, contribution, reimbursement or advancement of any Expenses and ending with the date
on which such payment is made to Indemnitee by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>15. SECURITY</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything herein
to the contrary, to the extent requested by the Indemnitee, the Company may at any time and from time to time provide security to the
Indemnitee for the Company&rsquo;s obligations hereunder through an irrevocable bank line of credit, funded trust or other collateral.
Any such security, once provided to the Indemnitee, may not be revoked or released without the prior written consent of the Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>16. NON-EXCLUSIVITY;
SURVIVAL OF RIGHTS; INSURANCE; SUBROGATION</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.1. The rights
of Indemnitee as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled
under applicable law, the Charter, the Company&rsquo;s Bylaws, any agreement, a vote of stockholders or a resolution of directors, or
otherwise. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee
under this Agreement in respect of any Proceeding (regardless of when such Proceeding is first threatened, commenced or completed) arising
out of, or related to, any action taken or omitted by such Indemnitee in his Corporate Status prior to such amendment, alteration or repeal.
To the extent that a change in applicable law, whether by statute or judicial decision, permits greater indemnification, hold harmless
or exoneration rights or advancement of Expenses than would be afforded currently under the Charter, the Company&rsquo;s Bylaws or this
Agreement, then this Agreement (without any further action by the parties hereto) shall automatically be deemed to be amended to require
that the Company indemnify Indemnitee to the fullest extent permitted by law. No right or remedy herein conferred is intended to be exclusive
of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given
hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder,
or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.2. The DGCL, the
Charter and the Company&rsquo;s Bylaws permit the Company to purchase and maintain insurance or furnish similar protection or make other
arrangements including, but not limited to, providing a trust fund, letter of credit, or surety bond (&ldquo;<B><I>Indemnification Arrangements</I></B>&rdquo;)
on behalf of Indemnitee against any liability asserted against him or incurred by or on behalf of him or in such capacity as a director,
officer, employee or agent of the Company, or arising out of his status as such, whether or not the Company would have the power to indemnify
him against such liability under the provisions of this Agreement or under the DGCL, as it may then be in effect. The purchase, establishment,
and maintenance of any such Indemnification Arrangement shall not in any way limit or affect the rights and obligations of the Company
or of the Indemnitee under this Agreement except as expressly provided herein, and the execution and delivery of this Agreement by the
Company and the Indemnitee shall not in any way limit or affect the rights and obligations of the Company or the other party or parties
thereto under any such Indemnification Arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.3. To the extent
that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, trustees, partners,
managing members, fiduciaries, employees, or agents of the Company or of any other Enterprise which such person serves at the request
of the Company, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of
the coverage available for any such director, officer, trustee, partner, managing member, fiduciary, employee or agent under such policy
or policies. If, at the time the Company receives notice from any source of a Proceeding as to which Indemnitee is a party or a participant
(as a witness or otherwise), the Company has director and officer liability insurance in effect, the Company shall give prompt notice
of such Proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter
take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of
such Proceeding in accordance with the terms of such policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.4. In the event
of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of
Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents
as are necessary to enable the Company to bring suit to enforce such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.5. The Company&rsquo;s
obligation to indemnify, hold harmless, exonerate or advance Expenses hereunder to Indemnitee who is or was serving at the request of
the Company as a director, officer, trustee, partner, managing member, fiduciary, employee or agent of any other Enterprise shall be reduced
by any amount Indemnitee has actually received as indemnification, hold harmless or exoneration payments or advancement of expenses from
such Enterprise. Notwithstanding any other provision of this Agreement to the contrary, (i)&nbsp;Indemnitee shall have no obligation to
reduce, offset, allocate, pursue or apportion any indemnification, hold harmless, exoneration, advancement, contribution or insurance
coverage among multiple parties possessing such duties to Indemnitee prior to the Company&rsquo;s satisfaction and performance of all
its obligations under this Agreement, and (ii)&nbsp;the Company shall perform fully its obligations under this Agreement without regard
to whether Indemnitee holds, may pursue or has pursued any indemnification, advancement, hold harmless, exoneration, contribution or insurance
coverage rights against any person or entity other than the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>17. DURATION
OF AGREEMENT</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All agreements and obligations
of the Company contained herein shall continue during the period Indemnitee serves as a director or officer of the Company or as a director,
officer, trustee, partner, managing member, fiduciary, employee or agent of any other corporation, partnership, joint venture, trust,
employee benefit plan or other Enterprise which Indemnitee serves at the request of the Company and shall continue thereafter so long
as Indemnitee shall be subject to any possible Proceeding (including any rights of appeal thereto and any Proceeding commenced by Indemnitee
pursuant to&nbsp;<U>Section&nbsp;14</U>&nbsp;of this Agreement) by reason of his Corporate Status, whether or not he is acting in any
such capacity at the time any liability or expense is incurred for which indemnification can be provided under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>18. SEVERABILITY</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any provision or provisions
of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a)&nbsp;the validity, legality and
enforceability of the remaining provisions of this Agreement (including, without limitation, each portion of any Section, paragraph or
sentence of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal
or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by
law; (b)&nbsp;such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the
maximum effect to the intent of the parties hereto; and (c)&nbsp;to the fullest extent possible, the provisions of this Agreement (including,
without limitation, each portion of any Section, paragraph or sentence of this Agreement containing any such provision held to be invalid,
illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent
manifested thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>19. ENFORCEMENT
AND BINDING EFFECT</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.1. The Company
expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce
Indemnitee to serve as a director, officer or key employee of the Company, and the Company acknowledges that Indemnitee is relying upon
this Agreement in serving as a director, officer or key employee of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.2. Without limiting
any of the rights of Indemnitee under the Charter or Bylaws of the Company as they may be amended from time to time, this Agreement constitutes
the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings,
oral, written and implied, between the parties hereto with respect to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.3. The indemnification,
hold harmless, exoneration and advancement of expenses rights provided by or granted pursuant to this Agreement shall be binding upon
and be enforceable by the parties hereto and their respective successors and assigns (including any direct or indirect successor by purchase,
merger, consolidation or otherwise to all or substantially all of the business or assets of the Company), shall continue as to an Indemnitee
who has ceased to be a director, officer, employee or agent of the Company or of any other Enterprise at the Company&rsquo;s request,
and shall inure to the benefit of Indemnitee and his or her spouse, assigns, heirs, devisees, executors and administrators and other legal
representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.4.&nbsp;The Company shall
require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all, substantially all
or a substantial part, of the business and/or assets of the Company, by written agreement in form and substance satisfactory to the Indemnitee,
expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to
perform if no such succession had taken place.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.5. The Company
and Indemnitee agree herein that a monetary remedy for breach of this Agreement, at some later date, may be inadequate, impracticable
and difficult of proof, and further agree that such breach may cause Indemnitee irreparable harm. Accordingly, the parties hereto agree
that Indemnitee may enforce this Agreement by seeking, among other things, injunctive relief and/or specific performance hereof, without
any necessity of showing actual damage or irreparable harm and that by seeking injunctive relief and/or specific performance, Indemnitee
shall not be precluded from seeking or obtaining any other relief to which he may be entitled. The Company and Indemnitee further agree
that Indemnitee shall be entitled to such specific performance and injunctive relief, including temporary restraining orders, preliminary
injunctions and permanent injunctions, without the necessity of posting bonds or other undertaking in connection therewith. The Company
acknowledges that in the absence of a waiver, a bond or undertaking may be required of Indemnitee by a Court of competent jurisdiction
and the Company hereby waives any such requirement of such a bond or undertaking.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>20. MODIFICATION
AND WAIVER</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No supplement, modification
or amendment of this Agreement shall be binding unless executed in writing by the parties hereto. No waiver of any of the provisions of
this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute
a continuing waiver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>21. NOTICES</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All notices, requests, demands
and other communications under this Agreement shall be in writing and shall be deemed to have been duly given (i)&nbsp;if delivered by
hand and receipted for by the party to whom said notice or other communication shall have been directed, or (ii)&nbsp;mailed by certified
or registered mail with postage prepaid, on the third (3rd) business day after the date on which it is so mailed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">If to Indemnitee, at the address indicated on the signature page of this Agreement, or such other address as Indemnitee shall provide in writing to the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">If to the Company, to:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">180 Life Sciences Corp.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3000 El Camino Real, Bldg. 4, Suite 200<BR>
Palo Alto, CA 94306</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Attn: Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">With a copy, which shall not constitute notice, to:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Loev Law Firm, PC</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attn: David M. Loev</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">6300 West Loop South, Suite 280</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bellaire, Texas 77401</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fax: (713) 524-4122</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: dloev@loevlaw.com</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">or to any other address as may have been furnished to Indemnitee in writing by the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>22. APPLICABLE
LAW AND CONSENT TO JURISDICTION</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement and the legal
relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without
regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to&nbsp;<U>Section 14.1</U>&nbsp;of
this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally: (a)&nbsp;agree that any action or proceeding arising
out of or in connection with this Agreement shall be brought only in the Delaware Court and not in any other state or federal court in
the United States of America or any court in any other country; (b) consent to submit to the exclusive jurisdiction of the Delaware Court
for purposes of any action or proceeding arising out of or in connection with this Agreement; (c)&nbsp;waive any objection to the laying
of venue of any such action or proceeding in the Delaware Court; and (d)&nbsp;waive, and agree not to plead or to make, any claim that
any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum, or is subject (in whole
or in part) to a jury trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>23. IDENTICAL
COUNTERPARTS</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement may be executed
in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute
one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to
evidence the existence of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>24. MISCELLANEOUS</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Use of the masculine pronoun
shall be deemed to include usage of the feminine pronoun where appropriate. The headings of the paragraphs of this Agreement are inserted
for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>25. PERIOD
OF LIMITATIONS</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No legal action shall be brought
and no cause of action shall be asserted by or in the right of the Company against Indemnitee, Indemnitee&rsquo;s spouse, heirs, executors
or personal or legal representatives after the expiration of two years from the date of accrual of such cause of action, and any claim
or cause of action of the Company shall be extinguished and deemed released unless asserted by the timely filing of a legal action within
such two-year period; provided, however, that if any shorter period of limitations is otherwise applicable to any such cause of action
such shorter period shall govern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>26. ADDITIONAL
ACTS</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If for the validation of any
of the provisions in this Agreement any act, resolution, approval or other procedure is required, the Company undertakes to cause such
act, resolution, approval or other procedure to be affected or adopted in a manner that will enable the Company to fulfill its obligations
under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[SIGNATURE PAGE FOLLOWS]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the parties hereto have
caused this Indemnity Agreement to be signed as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt"><B>180 LIFE SCIENCES CORP.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%"></TD>
    <TD STYLE="width: 5%">

    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name:</P></TD>
    <TD STYLE="width: 31%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 7%; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 33%; border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Address:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page 14 of 14</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>atnf-20240507.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +K4ps7xRiXgOn8uBan0sSaSHOcP9wZ1yyZkxvW99bdk6fysiel35yCoJfUuWwesP -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ATNF="http://180lifesciences.com/20240507" elementFormDefault="qualified" targetNamespace="http://180lifesciences.com/20240507">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://180lifesciences.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="atnf-20240507_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="atnf-20240507_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="atnf-20240507_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="ATNF_CommonStockParValue0.0001PerShareMember" name="CommonStockParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ATNF_WarrantsToPurchaseSharesOfCommonStockMember" name="WarrantsToPurchaseSharesOfCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>atnf-20240507_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://180lifesciences.com/role/Cover" xlink:href="atnf-20240507.xsd#Cover" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://180lifesciences.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnf-20240507.xsd#ATNF_CommonStockParValue0.0001PerShareMember" xlink:label="loc_ATNFCommonStockParValue0.0001PerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFCommonStockParValue0.0001PerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="atnf-20240507.xsd#ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="57" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>atnf-20240507_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnf-20240507.xsd#ATNF_CommonStockParValue0.0001PerShareMember" xlink:label="ATNF_CommonStockParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ATNF_CommonStockParValue0.0001PerShareMember" xlink:to="ATNF_CommonStockParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ATNF_CommonStockParValue0.0001PerShareMember_lbl" xml:lang="en-US">Common Stock, par value $0.0001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="atnf-20240507.xsd#ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="ATNF_WarrantsToPurchaseSharesOfCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:to="ATNF_WarrantsToPurchaseSharesOfCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ATNF_WarrantsToPurchaseSharesOfCommonStockMember_lbl" xml:lang="en-US">Warrants to purchase shares of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>atnf-20240507_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://180lifesciences.com/role/Cover" xlink:href="atnf-20240507.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://180lifesciences.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnf-20240507.xsd#ATNF_CommonStockParValue0.0001PerShareMember" xlink:label="loc_ATNFCommonStockParValue0.0001PerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFCommonStockParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnf-20240507.xsd#ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140394980963392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 07, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  07,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">180 LIFE SCIENCES
CORP.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001690080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">90-1890354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3000 El Camino Real<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">&#160;Bldg. 4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">&#160;Suite
    200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Palo
    Alto<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">507-0669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNF<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants to purchase shares of Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNFW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    (  U J5@'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  -0*E8B!H66NX    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M3L,P#(9?!>7>.LT B:C+!<0))"0F@;A%CK=%:]HH,6KW]K1EZX3@ 3C&_O/Y
ML^0:H\8NT4OJ(B7VE*^&T+198UR+/7/4 !GW%&PNQT0[-K=="I;'9]I!M'BP
M.P(EY2T$8NLL6YB 15R(PM0.-2:RW*43WN&"CY^IF6$.@1H*U'*&JJQ F&EB
M/ Y-#1? !&-*(7\7R"W$N?HG=NZ ."6'[)=4W_=EOYISXPX5O#\_O<[K%K[-
M;%ND\5?VFH^1UN(\^6UU_[!Y%$9)=5W(FT+>;2JEI=1*?DRN/_PNPJ%S?NO_
ML?%9T-3PZR[,%U!+ P04    "  -0*E8F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M  U J5C\\ *4QP0  + 4   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MG9A=<^HV$(;OSZ_0N)U..Y,$V7P$4F"&$-(R)Q\TILU,[X0M0!/;<B4YA'_?
ME2$V2<V:Y@9L8[T\WEWM*ZN_D>I%KSDWY"V.$CUPUL:D5XV&#M8\9OI"ICR!
M7Y92Q<S J5HU=*HX"_-!<=3P*.TT8B829]C/K\W4L"\S$XF$SQ3161PSM;WF
MD=P,'-=YO_ D5FMC+S2&_92MN,_-G^E,P5FC4 E%S!,M9$(47PZ<D7MUW:1V
M0'['7X)O],$QL8^RD/+%GDS#@4,M$8]X8*P$@Z]7/N919)6 XY^]J%/\IQUX
M>/RN?IL_/#S,@FD^EM&S",UZX'0=$O(ERR+S)#>_\_T#M:U>(".=?Y+-[MY6
MRR%!IHV,]X.!(!;)[IN][0-QR@!O/\#+N7=_E%/>,,.&?24W1-F[0<T>Y(^:
MCP8XD=BL^$;!KP+&F>%8OG+5;QB0LA<:P7[8]6Z8=V38/=L2>GE&/.JU/HYN
M $!!X1447B[7/")W(X,,4FW(?)OR*AI\>/?\.P+1+"":J,H(",*<XC9BJRH*
M?/R219HC'*V"HW5:,&9<"1F221(2R&UE7' EFZ4\375Y:A=H;51PDAAAMN16
M1)P\9/&BNG1P#4K=\V;7I6V$IU/P=$[A>>(KH8UB$+,'%E<&"M=QNY3<36\G
MQ!]/)P_CB?]M_/@TNT (+PO"RU,(QY!/Q2(R34+^1K[S;14CKD0A<)T>I5V*
M8'4+K.XI6'/V1J8AL(FE"%C>)H^G%5?LT7.WVZ/--E9GO0*O=PK>- FD2J7*
MR<Z(;V 6$*G(6&803HBJ#"N3C8O?3!!"EY:-DY[". I#Q;4^>S\@=W ?>4PJ
MP6HDFY!C,HG(F$&GEU#6+,)0#WJ\^W74^496HJ*2=K%PI5,6\($#JP'-U2MW
MAC_]X';HK]=1N+H@6!FXI2^X>&?'R=>*5X<9%<78_4P8_HT0VS&Q>>:6IN+B
MKO#Y"<;V#&IX+C=))3LN-V.1S/E&D9$88.DV+FX2GP&+6393\E4D076$<<WQ
M"$,KW<8]R6X*M)G4!IKHWR(].O5K%'NM)NU@;*7SN+AEY'D<P4+X. HNT&FC
M!58:C(O[PIT,(":SM4PP3ZX1:=/+<]KI]#"BTEM<W J>E3"&)Q"8.,Z2O;'H
M2BI<J&Y%Y99^XN(]WY>1"(01R8K<0WDK\;FS[GEPE3H>KS0/#^_T,\7/ P@/
MA_FU6_C"VI,K\KA<5N>O1J^6K/0*#_>*_Y!-M<Z K!80EZT%/'A5.,D2)C%7
M*YO/WT#!K&VQI2RI7%?5"-:BE;W>PYNS+7A80OE&!B]G)&6*O+(HX^1'>F%7
M;R2% .HU4]6O.*@V9EH8>VD#'MZRY\+ HEXNB>O]O/B%^#S(8!I7Q[.F^7\M
M"A^Y2X_P\(X^5RRT9>!OXX6LG-0U J/YPRU&4CJ"AS?T]Y"1R5NP9LF*'WT9
MJ1%Z&/DWHS\PIM(</+RO/S-E7XLT,9*DF0(NS7?!US;7AZFJ!$75OUJ3I9%X
M>/__/S598TE?C<-'\M)O/-PI3JA*7,!6Y3.VJ5%:31.WAM/+LD;H>%DV#O:?
M[%[>/;.M69.(+T&)7ES"#%2[[;'=B9%IOB6UD,;(.#]<<P;^8F^ WY=2FO<3
MN\M5;%(._P502P,$%     @ #4"I6.#T.HFJ @  , P   T   !X;"]S='EL
M97,N>&UL[5?;BMLP$/T5H0^HD[@U<4D";2!0:,O"[D-?E5AV!+JXLIPZ^_75
M6+9S6<WV\ECJD'AFCF;FC&9DDU7CSI(_'CEWI%-2-VMZ=*Y^GR3-X<@5:]Z8
MFFN/E,8JYKQJJZ2I+6=% TY*)HO9+$L4$YIN5KI5.^4:<C"M=FLZH\EF51I]
ML:0T&/Q2IC@Y,;FF6R;%WHI^+5-"GH-Y 8:#D<82YZGP-9V#I7D.\#QHP'*(
MHX0V%HQ)R!!^]\/R.V#4&J\**2>""QH,FU7-G.-6[[S2+^Z-+R RR$_GVC.L
M+#O/%^_HQ:&_^21[8PMNIS1S.IHV*\E+H&-%=82[,W4"H'-&>:$0K#*:]1Q&
MCT'P80]<RD=HX;?R)G97DM"+3P6T@4"IH^@)#6(($Q2(?QTMQ+X*^_:OPI):
MG(S[V/IJ=*]_;XWC#Y:7HNOUKISR8]'G>'16U_+\08I**QYJ_^V$FQ4;_<C1
M6/'LL\&D'+R!6TI.W#IQN+;\L*Q^XIT;IZDK<<Z+_YQ_P;GBFELFKTG[T8\S
M3H99O!KXFW&?K 0>*VOZ%9Y6\L*![%LAG="#=A1%P?6+J??A'=O[Q^%-?+^^
MX"5KI7N:P#6]R%]X(5J53ZL>8%^&51?Y,YSN>38]TWPNH0O>\6([J+;:]R+Q
M@L\Z7.!PC^SZ*XY@/@&+(X!A>3 &F$_PPO+\2_4LT7H"AG%;1I$EZK-$?8)7
M#-GV'RQ/W"?W5[S2/$_3+,-V=+N-,MAB^Y9E\(U'P[B!!Y8',OW97N/=QB?D
M]3G >OK:A&"5XI.(58KO-2#Q?0.//(]W&\L#'E@7L-F!_/$\,%-QGS2%KF+<
ML!.,(WF.(3"+\1G-,F1W,OC$^X.=DC3-\S@"6)Q!FF((G$8<P1@ !PQ)T_X]
M>/<^2L;W5'+YC[#Y"5!+ P04    "  -0*E8EXJ[',     3 @  "P   %]R
M96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:
MI7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$
MVV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_
M,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH
M^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    (  U J5BJQ"(6,P$  "("
M   /    >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5*A^P%K0A#5%>0-N0I@V-
MB??0NM0BB2O'A8VOG]NJ&M)>]I3<V;K<7187XM.!Z)1\>1=B;FJ19IZFL:C!
MVWA'#02=5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y&+6VG-X"$B@$*2C9$7N$
M2_R==S Y8\0#.I3OW/1W!R;Q&-#C%<K<9":)-5U>B/%*0:S;%4S.Y68R#/;
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M>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ #4"I6&60>9(9 0  SP,  !,
M  !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !
M8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB
M'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G
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M+GAM;%!+ 0(4 Q0    (  U J5B(&A9:[@   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (  U J5B97)PC$ 8
M )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ #4"I6/SP I3'!   L!0  !@              ("!#0@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (  U J5C@]#J)J@(
M # ,   -              "  0H-  !X;"]S='EL97,N>&UL4$L! A0#%
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K  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  %<4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0205589-8k_180lifesci.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://180lifesciences.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>atnf-20240507.xsd</File>
    <File>atnf-20240507_def.xml</File>
    <File>atnf-20240507_lab.xml</File>
    <File>atnf-20240507_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0205589-8k_180lifesci.htm">ea0205589-8k_180lifesci.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="27">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0205589-8k_180lifesci.htm": {
   "nsprefix": "ATNF",
   "nsuri": "http://180lifesciences.com/20240507",
   "dts": {
    "schema": {
     "local": [
      "atnf-20240507.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "atnf-20240507_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "atnf-20240507_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "atnf-20240507_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0205589-8k_180lifesci.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 2,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 65,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 27
   },
   "report": {
    "R1": {
     "role": "http://180lifesciences.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-05-07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205589-8k_180lifesci.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-05-07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205589-8k_180lifesci.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "auth_ref": []
    },
    "ATNF_CommonStockParValue0.0001PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://180lifesciences.com/20240507",
     "localname": "CommonStockParValue0.0001PerShareMember",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, par value $0.0001 per share"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ATNF_WarrantsToPurchaseSharesOfCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://180lifesciences.com/20240507",
     "localname": "WarrantsToPurchaseSharesOfCommonStockMember",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase shares of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>21
<FILENAME>0001213900-24-041030-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-041030-xbrl.zip
M4$L#!!0    (  U J5B ^93+T ,  .H.   1    871N9BTR,#(T,#4P-RYX
M<V2]5VUSVC@0_MZ9^P\Z?^WX!6C:XD([;3+I<9<T3$B:3K]TA+T&#;;D2G*
M?W\KOP4P4. NY9.\>IY]D7972^_#(HG)(TC%!.];+<>S"/! A(Q/^M;]R/XX
M.A\,+/+A_1\O"/YZ?]HVN600ASZY$($]X)%X1[[0!'SR&3A(JH5\1[[2.#,2
M<<EBD.1<)&D,&G"CL.23,Z?=IL2V#]#[%7@HY/WMH-8[U3I5ONO.YW.'BT<Z
M%W*FG$ DARD<::HS56OS%E[Y.XQ^S510DU_^\RI5;Q:W[-ODAK_-/E'NJ1$=
M_743#+OS[ZWE\OML\?C0[8[#V>MHJ5!CYVQY+OZ.[K.'.:AA8;*G@BDDE.!E
M<-6W3'QE>/..(^3$;7M>R_UV?37*<58!]!<QX[-M\%:WVW7SW0K:0"[&,JY4
M=URS/:8*:LVXR_;@&5>:\F -'^J:L H^<XO--2C;"GU=0%D%#6$#IR!P)N+1
MQ0W$MSL5,%/VA-*T!D=4C7.EY<8:6$G=!*)P$V3K90IJ*[386B.$6FX0UDX-
MMUVS;3AMV^O8G5;%_'CWY;(FM=YZ,8M !0S+$/*D-I17WIGW!DLSA@2XOA0R
MN8"(9C%&\C.CR& 06D13.0%MLE2E-(##E%893SD76!A8G:7$R-*48>;7 A29
M3/&EB.$.HR%F@96YUY+!N.<"FXQ%6-BWBN6*SDIK"!'C+/>@+,@6L4WY929H
M7.;,GKL);FK*%(0W_'V^3B4HI.>17:&@Y)>0_=R QD$6GT1]\F\?LY17Y]DX
MZ*HN;R$B>3W[)HGZEF*FHUJE;"HAZEM4\\BNKO4'ANU@?E408V%//>=WM'E2
MI>%*!95!0TNCWZ 2D8+4#,MCI:D4KC-MZ,,5,\38419Q_\?(8SH^-G*D0/R,
M(5\9_<\1*V;9L;&N)^8S!7Q1&VE&W7/7VPI^;[:>'@8NI":\T<KV/47%(WHE
M@ES5'HKYLBN>;41VJXT=V5FH\,G38YQX.H;CG*AX)SBQXT'<9E_M@IN%2:;.
MH49W/*Q[C6[EN!!K54E.=F'U&?X//N1JCG+BUV_[+G=^Q<R_U4E)$(B,:[D\
M)A%6*=7':;?Q-$ ==A$5OK@$,U.=:O:$+&@:WYD"Y<B53RYF4ON!?V82P4=:
M!+,AE?G? ,\QL\H0Y&A*)5Q#,C:SCO':3#N'PEF,SY!IGEIFII^:$=S'/LM$
M>)<_!V$F\ZAPT"N^JY'3#T5"&1]H2 P23R$;*^S$F4%_EB+#R;A0QQ"R+[@'
M*B7E6MV)82:#*7:FW$=U$ZW$L1[@<93?&V3/+?(!E_\"4$L#!!0    (  U
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MTGY?4E(2'2[9XVA.8@V)^+!C0_SGZSL6;13-HD2C0LW=+CB 3,G6-_=Y;W/
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MZAEXG3TD+$4Q)X1 I:I8FE#KG'<XBJTD!L=.60Y)^/7O7DE>XVP4VS0UIZ<
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MZ&0"(#,[KM**A325%@-N;?^$3LA6AN <,W7<:V,+$!=)XJC993#=<44^9)=
M%^9BMF1M/\D+FXH79/CN@G5-CMD4#R.GZ:PP^=+]WG2O/QPYU_?>O8K%Z=!A
M?.ZU_>)V@7QJ'C5(J]YLG-8;+;"(+LYS,ZG^S!O<>F,,BQ,19RFB_FHTRDEK
MP'3T^@UBVJ0.O@R,M?$"&-6C;8M!'\L"[.F8-UT#(<2_!]0P_+]7AB_BE<R$
M)/!"X*%%!QQ\#?\WX;7N><I]V_.,A%/C.PMMZ;?D*J'G<LM<S]2IY:,#W(P
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M5H.Z!B>B( ;'3XV/EM=I/#X:U2ZY7Q24@*T>DG\>F".>]8*;R 4VJ1?<1"[
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M:K"$:BCK,QU5WSG#UD\@!ZPS38(J"A8#CXL/V^A8H:=!P+N0)9$V\,\D@2J
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M6I^67%]H3H=+?$7RM'2B$A/8?1MC!@'#<_^0E+VR5ZQ&ZZAOFLQ,\DF!%+,
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M;]2G3F[)3V8685$*/:&)C-,_S#= =PKW_6CF87@ULLCDRI4][!<RZ]$O9"X
M"6V?_UWY:\A+?A<JO+#$S\DPBE^WK&SO%(IL7"QDBU-YE?G@+KSUTQ!65BQ
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M)MHA MO>ZE&8\+D?U!-<TI^J&O<;SFWH5*)+W%TYT!*%64$$L:]"#TYA697
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MLJ4L?F]@H)DK1M[;BPRP"?/'.!C_75&U\SZQ!_.%3\?!<(?[;BRD652M5GB
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M7/W%^J,''R=YEB8581[KNQ1BIV=WBS)FR4PB89*2@&'[%C0)%]QGS M]&B>
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MFT4TSY:UNZ59$*=& Z?-F[AH!M#T(]"HP#HF=YQF.DA TD4>)UI#)'C#L:B
MY'Y(LD8<^TG59BQ.R,G,M?FDOH/ESSD&'?O%=@SE+H^4>",SKZS7"3^W;?N(
M22"F=F*Z7N9@KW9J[+\L9_7#1S7U,RFU$S:24%!HNC&FP[4?-E#>:U.:U6LK
M3+S2"T+O2%!F)I*[Y;-:LO^0U_<O!0J\)D,0,C_;"ZLD,1=_)VRDM72HU7*)
MUGFM?^89V?;@0.E5C*!]:N>:@GO0VLIG+)YN*TTD2<JE@)W8Y'0>$5T:</M;
M&''2@M J:KAE[B/JK$51I2#V;I?$I7#P;<X2*"M5>E(PJ' 3@N(<ZW?'4N_K
MQ3.Y=A\CT%5%')+63B&LU&L8CUP*;1O"T&2+3S'T/Y4"KL<G.3^,85 OK,]&
MN"Y/1Z!G1!?S^EUN*';:XS(D+Z;$\4'C(8CAV12<B($F@9GV6LQX51$*16HE
M?&8]2W9,T"4O#3;+J"6D*ZTH_*[T@\BG5%)64(=XBQNJ:H_4S))NB@>#22U,
M\U?VC:/Y*RQJY5HX!T"IWG[VSMFS8BT8"Z+:8%Q[:D0%E3I6S0K]L_QC_$68
M^;<-&#C[6'7II* B89+ [WQX6@\'GKVSQWC4EZ!.@WTPK\@#B&H!=P/N'$!9
M.6J(=HA(X*@#'<H.W]6:9(3IM?D#T3'6,",\+F(H(;':X2E98/-0>G#OGA)*
M"&V(P ?X<+WD 9*/Q?GF?8.3,5R,C2$OV37H/])YP-+Y0CH:O VZ\&[PG K0
MX15W0/9C>\MM2%9K_\UU:[4I!LQN1E*HVKAB6^4YML\)LPE.Z[3L?B(X$2@J
M,".)^UDB #C<Z?>"-U:F:$A:)$:!L.[84^IW6G!-.^>9>!/.N$FTB-R:^L1W
M) &=!.&;BA4@Z PS4]*V@2PEX<S9HTC6*:/W>AN&_<*5 8-Y"$0WJ4ILV>/7
MFNFV>MMF@6#6[!M-U3)K-N8KD[9<U$];M'+XK%?,?\U&DH8B.]DY)W]1,O6K
M-OAS\];OHB)V?]]IQ4?DNB+$@Y?:66Y[Z]P%P0?2&Q@Z]XKNW'/1,9*24UZ-
M-.X,03TH 0!SH T#^N+AJ$=>_;PV39-\:T:U6ZH%E<1\='"C6Y4Q^P(#2?2I
M;O4E^730IX+9#55<U+:3.1$5#4B94!KO<I8E^<CL^*CSI-([U:]4%^#S; %:
M<*V= 4.&1!19MLUN.=U=EL!)&@>9DG&;UQ#\'I><MN1V\]2?M:Q3^FZ[W(9N
MG]WOMI_YE>^[3F["O1^Y";W<A'L_<A.^'A5_#,L^\!-\;7T"(8:>!)GB1!6O
M,OU=M*<^ ^RG;VE;9C.+'1/NF:.6P3&H*6F:94XH/YK3S?ZL,(%=?/><3"\0
ME!;P0/L&:([8FNQ/M*TX<L@6)X?]\?N,N]8!-S1A6(_CH[XW&L.8G"P*T[*F
MXN;<5>Q/Z:\2-9D1V8 VV5YDFG+X[2U)UPQ:CXSX%,K*YN>YN 49VO6E(/*5
MU%I!9"10THSZ_1E-J>;PH42C1CV7C9XCF@_=M9=>6T:[?$*YP1':G,Q7.H+K
M@Q?XGMF0T(@*I1N\RP1Q94:NY-/&9U'"JTPC?9!7&:JI"DP3%#IM3#]NJK:9
MDS8R8D.<7 H4V>=2#E(ST,]K06_F8?&NG ;V@>BX'-:#MDZ,@^T*&\G[A14]
MC!C,[7'WO=<_IWLP##QD X<N+B2]CFQF"N4R^QMLTY^]R5L0)*O(2(2P"UX[
MH-A85<8;S_ET7)HS'>JB++STS=@II7[FZ1!9? D=YB]E]'=\CS7?>=K=4S7G
MU'4=:IH)0]MT+N;OY20B7QQ5B7*99,@6A6-85#Q)=F?J<>V%N@E95/VW(O$S
M1(&5/W-KB-8#"$@N3:D3!OG*N)C? NS#75_&JZOT)5D<)V(.>#XL2I2S-S3F
M.!"UP+#/KNDJQ=V>1L[&&+2/UJ)QW;AS\;K'_TIN'BEGO1K66?"(:JD"1U>X
MRWZ9^IXHJ1JUC:[4GX2-S @2DW"ZBQFG=[K.8LJT4>G@,(6F]2^KS"6":I*_
M"R[B^_PH(H=/O6(7[L=]\T[;0_(^<@$$5SUWG:#AHV@G%@]P42J^FVBSK80&
M^BU> M*Q=9G4PL!5)MGH >G;ZP=X'.U,;/N:33#)7,7D@U6)<P5YR12SE$G
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MZ5# +^E:Z3_<,$,[F :HL-Q $7BDDP8D]R)#*U# QF5C006MX"VD0<U^B"/
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M1HNS@2 ,C1?C/H?I"RZNPZV1<A N &=-=!V*INQF9)F=XP7P><9Z[ %Z"7V
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MXCE&4Z';6>?^<&@$LT\-!L$H9',3%C32MD-)LF[S<ED6A7.F2EISL0H'J44
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M?YZGFR!\ _I)"ZGE$V"T0SN 3*TE3@YFR3CYPES069E;N"/DF(]](9/(S(Q
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MO@.+TM97EK?M9\#L,<M+;.2UQ(V[,"G"$"5-V1J]8-P/]MBX1Q;:8]$>D;(
MP\)J_Y+LOI1[S:*Z>DO%"<YA$0N,JL9947D, ZLCV9LZ-;44PLH7#97<H#L(
M8MTII]+&?I'(DG=UXN@.,\*PE.0AHP# $'!91]:[V+3R:&>W(LA4 K/<Q<R#
M/5<5Q6DQ0ZN1V4L)*5+NHL@NNM6""-BEN*Y9DRDI+H6EB$4!&HI7*-4SEK=R
MU^!J!7UBN>E0DT)D5Z+AK*I%5]?2#2!29('CS-=X(758TDNMIF;1&*M2M@T3
M64>K>&ZX820T6D&Z*E?2W]$"L=%KKJJ:J6S!10\M<$D8=C?MH$],@Z%;@#&X
M TB< HC7T-0Y#Y04A#Z]^5L3W9_!C:*(XC,ZFYP8_IP-!7=UT[$M1\E<:>2+
M,S)P%.R]<W*R?7-)R24U:8)T$AWJ'%28)))SM>U8?@WVMI7A&B:5,O:*1B14
MSG3EU&&BUTIS;:S("B9ZX=^L"4P6-]%4#W$>^NIYV!]?5\D=TATT*=T9D%G+
MRMT91=YBNAWS,O>%X4R^M:S8H:]CUYI8#S,-KP/AW%Q7RX%B2U.J%2 8$HY
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M!<4*I'D-D3U'^+X]B;^L&TW$#(S,JUT$Q<I+<D.EYDQEZ35WA2"+B">!Z'E
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M1N1 U%!)GJ<*D^FWFA_]_2WZ^LD6-=J'^B0I9E)_A1#/ Z5E9*YRS\CM(Y'
MMKC5BBFH=(YL/:5+DUOI(PJ;._"?=5#5$M%D1XQV'" "ADOFPKQ@$R%?Q(^R
MQ7.:)"P2,55HKF$OE((!2Q\ZF]GF2OPFZ>$1(Y-<4I+U0@!SF0_92=JD@@\L
M3>JBQ*..XG/N,Q#7F7$K'RQIAB[DZ":H%7Y/S>\_0C8U1:G9 $F5:@U[DMJ>
MX41;BH [0(K[9(\F8L6\EZBX; NPVM"/5^1>#$K]44,O&BL0[P!, R;M R,H
M5$.@HN)"6D@.Z*3^2ND9E=A'4@G1)!%GJMY4N4D \-D4:9GHC1RX1\#Q%RQ^
M#RGA5JW$ (,C*&Z+!:QQ,DH'T4/X4 1?*PD4'EZ5/0%,PD?9VXA?CVN.WSTS
MIO:/<5*W_6.<]/<8)WUO3GHUA#IA/!S<W1'S/L;HTKP@D"UPJA43(QUJWH Q
MY6\6)]E$5WB]%?&Q9) OS&LS7_'EBD<-[>) @4]B::@ E,F_'C/"RTS^;)ES
M7R&41Y_//%TSB,.BYF*$,@[?U-I8Q-S_LJW)(/'&5 6K6SE:^+2^_&7?M*:*
M08\9:5<G6!?J(3D+'^] GGPY>0SVP<[\-"=!'@H;<T9JYT,D<]QZU<+W!<LH
MQ>O:"(>2$^=7'<&B\^472G0"1%JJ14:?(1+?T#F7W]2HW2NMGG2B6O?B<E0B
M^BYKI,R@<!4JLJ&A&#H>S2[W)&!CA$GT^U#79+_(TL^*T5#\,[.RI-Q.2M"V
MU<:#-FSL7(Z&X]Q*#U#D+T\?.FN!*I0]$AHHYEI)3&F3"(4LNN6R%7 Q64?Z
M)NG;KW<J_<J!3K,"QS@T@-PE$O\9J:OD"Q^/REX_\M-3\M/),\Q/:]\,^K9I
MJN36-A*F,>#YO1G\_ ENUS<?IJWN[IA^>;L+,$@;7CMY2CK>75<FF>;S-O)9
M(VE -XU"-DQE"P$^NSN;^C(C$T.MI"Y+4( -<OP[VR#GA/PZP&OA5W;M=WCQ
MJ[[_!U!+ P04    "  -0*E8FI65I9@W   [DP$ (    &5A,#(P-34X.3 Q
M97@Q,"TU7S$X,&QI9F5S8VDN:'1M[7UK;]O&UNYW _X/?(.W10+(CJ])FF0'
MD&TE]89K&[;2GHV#@XT1.9+8\*)R2#GJKS_K,C,<4I3CM))J6=K8=6R)EYDU
M:]:LZ[/>_]S]Y>+#]M;[GSOM,_C7P_^][YYW+SH?WK_D?^';E_KK]R=79__Q
M;KO_N>C\ZUD_3?*WWO[>*/>Z82R5=RGOO)LT%DF+/VAYMS(+^\_@1KCUVMR7
MRZ_YCHC"0?+6R\+!,'_GQ2(;A/#GWK,/[T\^=+X.PUZ8PZ-WC]^_/(&!7-<>
M4;W^QZ2G1N^:KWSH()TQP*5[[SQWE+Y,<IGQV/Y/Y_1S]_S7CG=Z=7G[^:)[
M?OG):W^ZZ71^Z5QVES &,]F%OB06@?3R8:B\U_G0"\3$2_O>+_#/P=[!T>*)
MO,P%;?]R=?EI.:]:YK3VW^QY%^<?.][MZ7GG\K1S"_QZ<[W[]";:OCQ[>I,Z
MN6B?WWC_OKHY:U_".V[:W<ZG_W@P5>_C^64;EM.1/MM;YY>GFX5=C4FY"SO7
M-\[]8'A6CNU_=G:\CZ&,@K?>M1C(=W#]'X5,? F/]79VM-KP_NS\U^KYO).G
M([CD8&1/^)U>FN=I_-9[A9_UTBR0F?WL)!+^%V]_]QA>K](H#& (TR?^*'>G
M^OXEO+5A +U,BB\[/=E/,QCEB$;M#NI5PYAPH-_[2H<T+Y$V3(Y'M9X\X;V&
M"=-G,QBUVSZYZ'A7'U'0=$&SN5W@_B EL#YA>@^/XK1S<7'=/CL#8?>O9WO/
MZ._;Z_:I^5N/Y2X,\B$.9N^'9[0^[[LW33IG)/LP[[',\M 7D?F4B?+.XQGU
MTBAXT+3HP7DF$@6L!C0M1B.9^4(!O_6 G0=96B3!CI]&:?;6^VT8YO*9X9WN
MV>S1C400A,E KUV8E)_8Q7,_Q)OHHY**W;/I]WQKPS5QPP/' DSS$3C%Y8N=
MOHC#:/+V6R2D:U7XIV1&,A_DDP@^28"J(M*?W4GDE/+#.O%],0IS&/V?0.3W
MGRO4#:2?9B(/TP1O3^""Z_<O/P-'XZB_??$CF%R4WC%G/?L @L8,G.8 :PT_
M;AXGTV>#WO.#O:/6P>&;UL'Q\8L&_M<[]Z>]'ZH<^'?WPK7(P(KTSD&"W5S?
M=+KM[OG59?/6L,+CA[^U"0[FMA@*F"#: 8Y6#UJ2I0L;/BW/D3JC3.:T6YI)
M^S3(^0 VGBME.\D MGD,]'K*5%T*DW9E%L^=B(>/AXC+9LUNF$?R*1-T*5QY
M(]4H3538"Z,P#Z5ZR@1=-H=^DHG,1.2M$(U7U^(@+>L #,5?KCN7M_?H6'^#
MSD?KR\L?Y0+X]A'1<TEZ*A(H'$OO)$V*)TW/9?/GKU+E\!E&B*Y&: 4H3R2!
M=W/[^4F3>2ELV_DZDHF23-&%"(+CQT/193/N>1)((&\ !/-.80J9\/,T>\04
M7G$5X=#K_FP#5^W+[H^9^J-(WS%STU>=*_L9NGM1DVA?P!V_=B[A^ENZ,).C
M3"I8 O(X;#;$'#<$;()^B-LA!-7Y/$'>68Q;YQ'1>"EB_#+USD+E1ZDJLOD;
MSJ\>#S67S;% V-,T'LD\1#[U?A3QZ)UWF<(4)>HCR-!1Z,_?@_;Z\9!\*0R,
M1!;)Q$KGZRP=9:',13;Q;C!L,7\Y_(A(O&RNOAU)/R3O12R#17@MWCP>VB['
M 3R4* M4$>4BR2T7WRQ8E9@?F?^QR-S<E< CK]NY^>7\<C%NHI_6C;%E%H?)
M8I2T1T3+90O@:S'!P!NJ$.T8!I(K[ZR8O^+VB"B\;&Z%<6?>OPL%EK<HE"3+
M[BH?RLSKC"72&TC?$5DT\38LOAC/4K\O?>#PQ"6P!P.");B%;_"OH]WCN9-\
M?^_QT'PY+CQ+Z!.9R'ZX %7Y,=%TV7Q\(_,B2U!<H$T"<YL\:?(N*S(-#V*)
M (0]"S.)GE$6TOT^&-?S]Y+.D<A/1UD^]FXZMU<7GU%7QES<L_/;Z\_=SNW\
MJ;^_9BS^"QC6B]$IYDC*I\/(K[Q/G<O.3?OB,9-[-3CW8Y&1GMQ6JH 5]Q?@
M'GI,-%VV/@%DA0<M).UR?]WR+F\ES$)0[M4"M+)'1,UE,^EO(H09D3Z&;LT-
ML\XEE(11HR=-QV6SZ4F8X&<>F\#S)^TC2G!="HM^2F$6"5+T0MP]:7(N/Z,]
MIH!Q1RFL:WW2M%U2P+B@RB!0_A>@GSXB:BZ_+"@/,^FU!YE<3''08R+N<K34
M(AN'8Q'A_D=?^*+Y%?[!JN8/CZI(_.WW%/T?+*OHOXGF#RAJ?_9AIU*9;T;^
MSNM.1C#^"ZRD)6*\\RY%+'F&ERE.*ZR4])L[\1MO9P,[\!2 E'XO5![V)\N!
M_G!?UOWY_+8Z0R]47B!R&5 X-)-]F1&W@6&WO4483))49ZQ;R(?2^[___>__
MJZ,Q><_QFQ^C '-:.O;R,WCLCQE]^&)WGO)A(40KD9C>SO.Y^RB2E[CV^K][
M7SL#F*E%_" \/\U&&GM@>RLHHHD7)N8SX!,.T.**1^*.HN1G$GX3F6QY0S%&
MVT!X(Y"II,[V"A4F4BE/Y-[AWMZ>UXF\4Q&'2>K=2!&U0/H&@UWO"&93P$D+
M_+0'HC!*O7:4IRWOM#W'A9BW9*%'NKQO<Q29Z9>)5;*8=UQ]I*SXC^<WMUWO
MNGW379%M?'FVK$WL@G+,C(%,358#9RQMS_]5Z)#[9T1(4MM;#\,(\Q BK.4Y
M\Z](&N\A@N8D"_-0#;W3-"KB7BBLP$DI)*RVMT#*[+]Y=>2=%?X0I4Y[+),"
M!--O4N7>KP(>7X#! %)G%P=S*A(1P%-^??VKMW^SOUJBILPE?6+2YK8#7',V
M5W&S/X4.M-9[U9E8"S0]#YVDXS HP +-I K)8_I7=M*\-]+>HK;3WHQ-A=5?
M<]Y-S<N]F%UU[[OT[@(3X&:^FVNQ9_EO/W=N.NW;N9[GLRRDA0HY^Y;G[1=X
MJFUO:74133 X"Z,P(3^6RM&:[H5I+OUADD;I8 (')5_93_U"P=$(YR6R;2#'
M,DI')E$X2>%/+\B*@8*O80/WBZ@?1A&<I+',O43*0,%>A__W(Q''(D^SB1>$
M2H*04*WMK7[8RU(5<C7D2  ?/1&"GUB"FT,3:7XW3*-HLI/>)4!1G+*/%;CP
M&?S9FQ"!02 \%1J<UI@.)YQ7BE)0F9)>7.1P#H N)M"_"]>DGAQC2:;/#H <
M_9/(;?B'M A1YA,ELS&J8N9OY_&&ICR [2WZ&];!.I)A14)_B$L#+U4%'%_
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MK3+'A#C50["OG$)_41$0SN#$?$9V-7E'5>'[0-<T8]>0/]27K#M)^UK\#*7
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M)7N(",B4)//,%5A1ECSVVNB*LCQDCT7+!E/+4)*8%Z0GR4@L] $<A:2PD")
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MP?E.28- !J<Y,;^Z'P8%W Q;E++[!UHK&*,9[$:F9_@"B2)):B*G+9U%KNU
M)%5&$#SOENB^77[\NB*"JQR#2PMFO])@ ^9 -Q(K1J#7S&:&4+=1'1Y@" !-
M29&!J6\ T$OP5 ? _WA%K,VZXG'M1-=N*"-BO272X>ZK1O<R>X9DI.1T45E+
M5[?H KBHTIXP<.MAL&U*<YLALZ$9FJC,,+I+LR^H;R)6H1-);8YV#\-(SDS
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ML^^-P.O+@&JDW:L_)P1Y0#<IZA12%L5QG9R3=,]9ZTI+00T'P/6G$3DX+"
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M&RIC,%G_=(/)E4'.B1BUA7UY<G7V'V3,ES]W?[GX\/\!4$L#!!0    (  U
MJ5C9-&)H]T@  '6+ 0 @    96$P,C U-3@Y,#%E>#$P+39?,3@P;&EF97-C
M:2YH=&WM?>EOV]:V[W<#_A]X _3 !AC'0Y*V24[P%%MI=>'8ANVTMWAXN*!$
MRF)#D3H<[.C\]6]->R*W9#FQ&Y\J_= D$K6YA[77O'[KS:^7'X[?;FZ\^;7?
M.X(_ _SOS>7@\KC_]LTS_A.^?29?OWEW>O1'<''YQW'_GT_&15Z_"O9V9W5P
MF4Z3*CA);H+S8AKE(7\0!A=)F8Z?P _AIV=W_=WK8!J55VG^*L!'=U\'=?*Y
M?AIEZ15\5*97D_K)VS?OWO8_3])A6L. .R_?/'L'TSY[B!>.DKQ.RB=O_Y$/
MJ]GK!WX)+.O-Q[?O3\\_!*?O@\')4?_#R>#RCZ#WRWF__Z%_<OGFV<>W#[C8
M/YNJ3L=S^3#-XP0'W=UYD>8/O -+WPS;<OGKX,*W(6I2[]YNU9.TVMSX1Q;_
MJRE>XTX.WO:NRB29PE!OG@UHW_Y1TK?;05K!;.(DB*J@& ?_J_X+@_W=_>=A
M,)P'41X'PZ2^29(\V/MI-S@>O.\'%X>#_LEA_R(X/#T_VPF#*#A*LN@F*I-@
M5)2SHHSJM,@#F$O2FLIA,9U%^;P]D9#>\[_FOV#+^=D =F*:IW62M'^Y\[>C
M ?<6G/</!Y>]XXNU)?G??^V?]WL7N/8PF #?R^9 9--94L.#FQNSI*R*O HF
MT74"A K?),&T $(LDZP9U5%>!W415$D)7\^:89:.LOG329+%-J56> 'BM$Q&
M=5'"K(OQ.!W!P$%1!FD>%$#'93"*9M$HK5-89Y-G254%\#%<$'C7K"RNTSB)
M-S=NTGH2P(WZ5Q/5]'D-8^)=J"=ET5Q-8+BJ*:-\E.#8^L&4Z1O>RC<GNHK@
MP1H^+\HXS?&1,JT^T2T=95$ZK>C"1".9O3P.$YK"A-(JS:\V-XJFQN?AP[2D
M'8 UX6:H7U[S8N!UPV0296-\N&I&$V=GOLFQ/QZ"@\T+WA51"4<+NW.D2$3V
M-1!V1IPN<#@6_:C#;R=(9T"YY33-DQB&B.J0**R,@<+P;.JZA+.A,RJ3&HXU
M  K)@#+@<9@K'%H,_Z["S0W[_3=IEN%OD^F,Z'T*/Z0?(RWA_Z\*((E@&%4I
M[%$$A%57055D29!\GB5YE81!ED;#-$OKN46B,)*0<*#N&=$1#&6]?7,#9TLC
M-L,JC5.@0#B;<5E,@9F5- \U.GRQ$_2R>D*7 0<9-V6>5A,<4]&?F0#NUQ!%
M3Q2,X-C@I$L623=PW:I9F40QS!")>022)IK"0O4M#V GX4ZV[CG\EJ_SL(%;
M@K>8V.T,+@V2C[VIPR1+D^NDDF.Z2J]A(J.F+.$72&"?DAH&AS,Q0]?P78R'
MTUK'-,+A@N@Z2K-HF-'.IGB]90OJ!KA(D<.DX6R0R<$$8773M)&;3GR%^%KR
M>93!U.&-L)%TY8,J J97 _V'/B;&Q\.+5J<(+[88@K-#A7]KB,\-$SRF-!_!
MQB./@?G"D?\);T1B+H288)]X,V!&3V&#JF9*_ B/_XKY&S!G^ N240'D2,?&
M$ZR1$&#R4R3FDK>>#I(V.<K@C3=% ]Q;^#V<R) 8:RW;9SBA/D?_BC8W@&*3
M;+P37,*S%PF>9- #+0EI!J=_GE1UA L[!!IFUIP@B0[RMH[CWOS#253"2SIW
M'\=\-P<UJ<T]-C=*$ -P<!TQ(,]I<81#Q MXT$Y@E"2B-^ 2!1(=+#FM,SZ@
M]@MF35DU(B.CV0SN#5(G2%44:!73 []%*WB_)'E21AF\UFS"<7334MB.?CD\
M[JAJM-.R/:':"Z(4? '\ @FHA&."@Q21BFPNXN/LS-W,L8*;."[*FCA*"41*
MU)H7M;HMUTFH7E0F0U0@<N25&1XIO0 _0#Y2J:M*A$(\MRZ4 NSR7!QOFDR'
MB3F*(3)]_(=/E^C>0KK4L-X9,MCNZ8"Z4Q"EEU-4-T)83(%[3]_!K8ZOD;>@
M7B_B(IT.X3SY$[(0OTOO!'0UD4$H>_"J:<[3%C9$(-T[0IQ&>%["M!JG>*A-
M!L(2#EMD-@YJQ#;^B\:7P_Y^$DJ/\NA <K_5%EO;BU=YE>U%2Q8&+5,D?N!.
M<(YT(1-2HO$J5W6;8_ZCK) O 5& 9C'ZA)=-W5,]*779JPE)G8@O:E15*+"=
M":B?P.>DC0WM%2D2G&L=QS(-'"U@S>D$E:(JP%T#:0^B*$19U,2*Q^7)"#@A
M*H' [IT#4@R\(1T!SJ@ +?"*;"L2\_;-GB_DK)H)"'-5ZC'0B&TFA:VC+^0
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M:^6.KVWO&>K3_CT+25O55HDHD3H=#MU>G"23.D :T4A";5=%$8.-Q]J\>-^
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MALE3\3*RYZPJ;O&8+9VA<A&Y51J&"1,9W^:<YUXO]I[M=$>S @NCHIBQE#0
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ML)@.^^>7/;<;QSHF4!QP H7R3D9&._;[J6]Q7^E$@O#KO*&())I4S32Y8U3
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M5.\Y!.5!G6#$7)9_@$GA$;RX-. @Z-'#_GVM (Y_D@QLX)]E>XM8D-S>!C3
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M373K24%5. (Z@L:A+A6N"/%*5P-8I<]B(/IV2.;1&E?0!\GR7;-[A7SFY4Z
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M?_;KY8?CM_\?4$L! A0#%     @ #4"I6(#YE,O0 P  Z@X  !$
M     ( !     &%T;F8M,C R-# U,#<N>'-D4$L! A0#%     @ #4"I6$\L
M6>H""0  E6@  !4              ( !_P,  &%T;F8M,C R-# U,#=?9&5F
M+GAM;%!+ 0(4 Q0    (  U J5CNXJY=\@L  !20   5              "
M 30-  !A=&YF+3(P,C0P-3 W7VQA8BYX;6Q02P$"% ,4    "  -0*E86+"9
MD4D(   O8P  %0              @ %9&0  871N9BTR,#(T,#4P-U]P<F4N
M>&UL4$L! A0#%     @ #4"I6.JW12M')@  _](  !L              ( !
MU2$  &5A,#(P-34X.2TX:U\Q.#!L:69E<V-I+FAT;5!+ 0(4 Q0    (  U
MJ5@7'1^ZVSH  /$& 0 @              "  55(  !E83 R,#4U.#DP,65X
M,3 M,5\Q.#!L:69E<V-I+FAT;5!+ 0(4 Q0    (  U J5BS(T#?83D  (P$
M 0 @              "  6Z#  !E83 R,#4U.#DP,65X,3 M,E\Q.#!L:69E
M<V-I+FAT;5!+ 0(4 Q0    (  U J5C1$./Z8"T  %#C   @
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:+FAT;5!+!08     "P + "4#  !4=P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>ea0205589-8k_180lifesci_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ATNF="http://180lifesciences.com/20240507"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="atnf-20240507.xsd" xlink:type="simple"/>
    <context id="AsOf2024-05-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
        </entity>
        <period>
            <startDate>2024-05-07</startDate>
            <endDate>2024-05-07</endDate>
        </period>
    </context>
    <context id="From2024-05-072024-05-07_custom_CommonStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-07</startDate>
            <endDate>2024-05-07</endDate>
        </period>
    </context>
    <context id="From2024-05-072024-05-07_custom_WarrantsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-07</startDate>
            <endDate>2024-05-07</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-05-07" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-05-07" id="Fact000004">0001690080</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-05-07" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-05-07" id="Fact000010">2024-05-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-05-07" id="Fact000011">180 LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-05-07" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-05-07" id="Fact000013">001-38105</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-05-07" id="Fact000014">90-1890354</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-05-07" id="Fact000015">3000 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-05-07" id="Fact000016">&#160;Bldg. 4</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="AsOf2024-05-07" id="Fact000017">&#160;Suite     200</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-05-07" id="Fact000018">Palo     Alto</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-05-07" id="Fact000019">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-05-07" id="Fact000020">94306</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-05-07" id="Fact000021">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-05-07" id="Fact000022">507-0669</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-05-07" id="Fact000023">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-05-07" id="Fact000024">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-05-07" id="Fact000025">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-05-07" id="Fact000026">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="From2024-05-072024-05-07_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000027">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2024-05-072024-05-07_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000028">ATNF</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2024-05-072024-05-07_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000029">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="From2024-05-072024-05-07_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      id="Fact000030">Warrants to purchase shares of Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2024-05-072024-05-07_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      id="Fact000031">ATNFW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2024-05-072024-05-07_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      id="Fact000032">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-05-07" id="Fact000033">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
